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Abstract 
 
Reversible histone acetylation on lysine residues has been intensively studied as an 
epigenetic mark for gene activation in a variety of eukaryotes. Histone deacetylases 
(HDACs) act to repress gene expression by removing acetyl groups from histones and 
possibly other proteins. Based on their expression pattern, distribution and biochemical 
activity, HDAC1 and 2 have been considered to be the major HDACs to regulate gene 
expression in a wide range of tissues in mammals. Experiments using transformed cells 
and HDAC inhibitors suggest that HDACs are important for cell cycle progression, 
apoptosis regulation and induction of differentiation; however their in vivo roles in a 
higher organism as well as their molecular mechanism of actions remain largely 
unexplored. 
I have generated mice conditionally targeted at the HDAC1 or HDAC2 locus and crossed 
these to different deleter mice in order to dissect the function of these enzymes in vivo; I 
focused on B cell specific inactivation in the first part of the thesis and on hematopoietic-
lineage specific inactivation in the second part. Mice completely lacking HDAC1 die 
during embryogenesis while animals lacking HDAC2 show partial perinatal mortality. In 
contrast, ablation of HDAC1 or 2 in the B cell lineage led to no obvious developmental 
defect. Simultaneous deletion of both HDAC1 and 2 in the B cell lineage causes a very 
severe blockade in the early B cell development accompanied by severe defects in cell 
cycle progression, apoptosis regulation and recombination of immunoglobulin heavy 
chain (IgH) variable (VH) segments. Using three-dimensional DNA fluorescence in situ 
hybridization, we show that pre-BI cells lacking HDAC1 and 2 are severely impaired in 
the contraction of the IgH locus, a mechanism whereby distantly located variable genes 
are brought in close proximity to the rest of the locus. Analysis of histone modifications 
revealed that these pre-BI cells lshow global histone hyperacetylation as well as increased 
histone lysine 9 methylation. Taken together, we conclude that HDAC1 and 2 are crucial 
factors for B cell development, survival and IgH recombination by modulating histone 
modifications which may affect gene expression and the higher order of chromatin 
structure.  
In the second part I have analyzed the roles of HDAC1 in the hematopoietic lineage. Loss 
of HDAC1 in the hematopoietic lineage has only minor impacts on the myeloid lineage 
development, but impaired IgG secretion and reduced germinal center formation were 
observed upon induction of a T cell dependent immune response. Using transcriptome 
analysis, we found that these germinal center B cells lacking HDAC1 exhibit higher 
expression of genes involved in cell cycle regulation as well as apoptosis. These results 
suggest that HDAC1 has important roles to regulate the adaptive immune response by 
controlling the expansion of B cells upon antigen stimulation. 
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1. Introduction 
1.1 Basics of transcription 
1.1.1 Basal transcriptional machinery 
 
Genome is often referred as the “blueprint of life” since it contains almost the 
complete, if not all, set of hereditary information needed for the next generation. The 
life of a living organism starts by following the plan encoded in its own genome. 
In order to extract the genetic information from the genome, the DNA has to be 
transcribed to generate RNA that is processed and translated into proteins. In humans, 
there are 20,000-25,000 genes encoding proteins (2004). Despite such a large number 
of genes, there are only three types of RNA polymerases (RNAPs) to transcribe genes 
in eukaryotic nucleus and each of them has specific targets for transcription. RNAP I 
is responsible for synthesizing most of ribosomal RNAs, RNAP II is for messenger 
RNAs, most of small nuclear RNAs and micro RNAs, and RNAP III is for a variety 
of small stable RNAs including transfer RNA, 5S ribosomal RNA and U6 small 
nuclear RNA. Since protein-cording transcripts are synthesized by RNAP II, I will 
focus here on reviewing what is currently known about transcriptional control by this 
enzyme. 
RNAP II is the holoezyme having 12 subunits with a total mass of about 500 kDa 
(Davey et al. 2002). Two major types of core DNA promoters are known for 
transcription initiation by RNAP II; focused and dispersed promoters. Focused 
promoters are composed of a single transcriptional start site. On the other hand, 
dispersed promoters contain multiple start sites over 50-100 nucleotides under the 
control of same regulatory mechanisms, which are often found in CpG islands in 
vertebrates (Juven-Gershon et al. 2008). Despite the fact that majority of core 
promoters in simple eukaryotes are focused promoters, more than two-third of core 
promoters in vertebrates are dispersed promoters. To date, major efforts to understand 
the mechanisms of core promoter transcription have been dedicated to the study of 
focused core promoters. Therefore our current knowledge about core promoters is 
mainly obtained from focused promoters, which I discuss here. 
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There are at least 7 conserved 
motifs found in focused core 
promoters (Fig. 1). The TATA box 
is a most conserved and utilized 
element in the core promoter with 
the sequence 5'-TATAa/tAAa/g-3', 
where the capital letters represent 
the most conserved and the small 
letters represent less conserved 
bases. The TATA box is located 
28-33 bp upstream of the 
transcription start site in at least 
half of all RNAP II promoters 
(Carninci et al. 2006). The initiator 
(Inr) is usually found at the 
transcription start site and its 
sequence contains preferentially 
pyrimidines. Both a TATA and Inr 
sequences are recognized and 
bound by TFIID that contains TBP 
(TATA-binding protein) (discussed later). Most of RNAP II promoters contain a 
TATA box, an initiator or both thereby ensure efficient RNAP II recruitment and 
binding of TFIID, leading to accurate initiation and transcription. The BRE was first 
identified as a TFIIB-binding sequence that is located in upstream of a TATA box 
(Lagrange et al. 1998) and later on it has been shown that there are two BRE sites 
both upstream and downstream of a TATA (BREu and BREd). The DPE (downstream 
core promoter element) and MTE (motif ten element) sequences synergistically 
enhance basal transcriptional activity with the Inr and TATA box. The DPE is 
recognized by TFIID and the MTE appears to affect the interaction of TFIID with the 
core promoter (Burke and Kadonaga 1996; Lim et al. 2004). The DCE (downstream 
core element) frequently overlaps with the TATA sequences, spreads into three 
segments and is recognized by TAF1/TAF(II)250 of TFIID components (Lewis et al. 
2000; Lee et al. 2005). The XCPE1 (X core promoter element 1) motif is often found 
in a few bases upstream of the initiation site (Tokusumi et al. 2007). XCPE1 alone 
Figure 1. Transcriptional initiation at focused and 
dispersed promoters and core promoter elements (taken 
from (Juven-Gershon et al. 2008)). Focused promoters 
have a single initiation site whereas dispersed promoters 
contain multiple sites (the upper drawing). The known 
core promoter elements for transcription by RNAPII (the 
bottom diagram). Each of these elements is estimated to 
be found in 1 - 50% of core promoters, depending on the 
motif.  
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can potent transcription weakly however 
it can enhance transcription robustly in 
concert with sequence specific 
transcription factors such as NF-1 and 
Sp1. 
A large body of biochemical studies has 
identified essential protein complexes to 
initiate transcription in vitro using 
focused promoters containing core 
promoter elements. RNAP II itself is not 
enough to recognize the transcription 
start site and initiate transcription but it 
requires assembly of additional factors to 
form a preinitiation complex (PIC). The 
PIC is composed of RNAP II and five 
general transcription factors  (GTFs) that 
are TFIIB, TFIID, TFIIE, TFIIF and 
TFIIH (Woychik and Hampsey 2002). 
TFIID consists of the TBP and 8-14 
TBP-associated factors (TAFs) (Liu et al. 
2008). The TBP in a TFIID complex 
binds to the TATA box, TFIID binds to 
core promoter elements such as the DPE and DCE, and thereafter induces a sharp 
bend in the DNA. Such binding of TFIID is the first step to initiate the subsequent 
binding of the PIC. TFIIA, a member of GTFs, binds directly to the TBP and 
stabilizes an association of the TFIID and the TATA box. This binding is especially 
important for the promoter which contains a non-consensus TATA box even though 
TFIIA is dispensable in a highly purified in vitro transcription system. TFIIB enters 
the PIC after the binding of the TEIID on the TATA box, by which a novel nucleo-
protein structure provides a binding site for TFIIB. TFIIB binds both side of the 
promoter DNA including the BREu and BREd; in the major groove of DNA at 
upstream and in the minor groove of DNA at downstream of the TATA box. Such an 
asymmetric contact encompasses the unidirectional recruitment of RNAP II which 
requires TFIIB as its binding platform. TFIIF is tightly associated with RNAP II, even 
Figure 2. Ordered assembly of general 
transcription factors and RNAP II. Recognition 
of a promoter is achieved by the binding of TBP 
on the TATA sequence. After stepwise 
recruitment of factors, RNAP II gets 
phosphorylated in the C-terminus domain (P), 
which allows the initiation of the RNA synthesis 
using nucleoside triphosphates (NTPs). 
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in the absence of DNA. Both TFIIF and RNAP II can bind to TFIIB so that TFIIF 
association with RNAP II enhances the binding affinity to TFIIB on the promoter 
DNA. Two more basal factors are assembled before the initiation of transcription; 
TFIIE and TFIIH. TFIIE comes to bind to RNAP II and increase the binding capacity 
of the following factor, TFIIH, to RNAP II. TFIIH is the largest and most complicated 
complex in the PIC. TFIIH contains subunits harboring several distinct enzymatic 
activities. Subunits called XPB and XPD are ATP-dependent DNA helicases which 
function to unwind the DNA duplex during transcription. Cyclin H and cyclin-
dependent protein kinase (cdk) 7 are also part of TFIIH and are important for the 
phosphorylation of the C-terminus domain of RNAP II (Fig. 2). 
Once the PIC is assembled, transcription can begin with 3 modes of action as follows. 
First, TFIIE activates the kinase activity of TFIIH at the same time inhibits the 
helicase activity. Activated kinase activity of TFIIH leads to the phosphorylation of 
RNAP II C-terminal domain, which causes the dissociation of TFIIE from the PIC. 
Second, release of TFIIE let helicase subunits of TFIIH function to unwind the DNA 
duplex, which results in the initiation of RNA synthesis. Third, TFIIB and TFIIH are 
released from RNAP II by which RNAP II can be physically separated from TFIID at 
the TATA box and continue to transcribe through whole body of gene.  
 
 
1.1.2 Activator, repressor, coactivator and corepressor 
 
RNAP II and GTFs are enough to initiate transcription in in vitro highly purified 
system; however transcriptional initiation in vivo is regulated by far more 
sophisticated and complex manners. Higher eukaryotes often have additional 
regulatory elements rather than simple core promoters such as a promoter and an 
enhancer element. The promoter sequences are typically found within 1,000 bases 
upstream of the transcription start site, whereas the enhancers can be found many kilo 
bases away. These regulatory elements are recognized and occupied by sequence 
specific transcription factors (TFs), which can influence transcription positively 
(activators) or negatively (repressors). TFs contain typically 2 domains; one is a DNA 
binding domain and the other is a activator/represssor domain. TFs bind to a specific 
DNA sequence on the promoter or the enhancer element via DNA binding domain 
and modulate transcription by many different ways. The best-characterized 
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mechanism to enhance transcription by the activator is the recruitment of GTFs and 
coactivators. The activator domain of the protein is often able to interact directly with 
TFIID and then recruits and/or stabilizes its binding to the TATA box. In addition, the 
activator also can associate with and recruite a coactivator to the promoter region. The 
coactivator lacks a DNA binding capacity but can enhance a transcriptional activity. 
In the case of a repressor, it binds to the regulatory sequences and recruits a 
corepressor, which results in the suppression of gene expression. A corepressor as 
well unable to bind to DNA but has the capacity to repress gene expression, thereby it 
requires specific TFs for its recruitment to the promoter/enhancer element.  
Both coactivators and corepressors often harbor an enzymatic activity to modulate 
histone posttranslational modifications, which I will intensively discuss later. In 
summary, an additional layer of mechanism, which is governed by sequence specific 
TFs and coregulatory factors, regulates eukaryotic gene expression with more 
sophisticated and complex manners (Fig. 3). 
 
 
1.2 Epigenetic regulation of gene expression 
1.2.1 Chromatin 
 
The human genome, comprising of over three billion base pairs in haploid, would 
span about 2 meters if it was laid end to end (2004). This large amount of DNA must 
fit in a cellular nucleus whose diameter is about 10-20 μm. In eukaryotes, DNA is 
packaged into a highly compacted and organized structure called chromatin. Three 
billion base pairs of the human haploid genome are organized into 22 pairs of 
autosomes and a pair of sex chromosomes. Eukaryotic chromosomes have been 
historically defined in two forms; euchromatin and heterochromatin. Euchromatin is 
Figure 3. Transcriptional activation 
by sequence specific transcription factors 
(TFs) and coactivators/corepressor.  
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the chromatin region mainly containing transcriptionally active genes and its structure 
is more relaxed or decondensed. On the other hand, heterochromatin is more 
condensed and tightly packed structure, which is able to prevent a transcriptional 
activation. Originally these structures are described based on the cytological staining. 
Heterochromatin regions are able to be visualized easily under the microscope, 
however molecular mechanisms affecting for these two distinct chromatin structures 
were not explored until recently. 
The nucleosome is the fundamental unit of the chromatin structure; it contains a 
histone octamer complex, including two dimers of H2A/H2B and a tetramer of H3/H4, 
wrapped around 146 bp of DNA (Luger et al. 1997; Davey et al. 2002) (Fig. 4). 
Histone molecules are some of the most conserved proteins in evolution, with a 
molecular mass 10-14 kDa. Histone comprises a globular domain and a flexible tail, 
which is relatively unstructured; however the amino acid sequences are very well 
conserved, suggesting a crucial function throughout evolution. Details about functions 
of histone tails will be discussed in the later topic. Adjacent nucleosomes are 
connected via linker DNA and form an 11 nm fibre conformation called “beads on a 
string” which is believed to represent the active and relaxed interphase euchromatin. 
This 11 nm fibre can be organized in a further compacted form, the 30 nm fibre, via 
association with Histone H1. This 30 nm fibre structure is considered as a 
conformation for a transcriptionally repressive or silenced state of chromatin. In 
mitotic and meiotic cells, chromatin structure becomes the most condensed formation 
and a whole chromosome gets compacted to a length of a few μm. In summary, 
chromatin structure changes dynamically during cell cycle progression and distinct 
structural organization of chromatin is well correlated with transcriptional activity, 
suggesting that this conformational change may influence gene expression or may be 
the reflection of on going transcription.  
 
 
Figure 4. Crystal structure of the 
nucleosome core particle (Luger et al. 1997). 
Ribbon traces for the 146 bp DNA 
phosphodiester backbones (brown and turquoise) 
and eight histone protein main chains (blue: H3; 
green: H4; yellow: H2A; red: H2B. The views 
are down the DNA superhelix axis for the left 
particle and perpendicular to it for the right 
particle. For both particles, the pseudo-twofold 
axis is aligned vertically with the DNA centre at 
the top. 
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1.2.2 Nucleosome remodeling 
 
Alteration of the chromatin structure is a significant step in transcriptional regulation 
of many eukaryotic genes, by which ATP-dependent nucleosome remodeling 
complexes are responsible for the process. The action of ATP-dependent nucleosome 
remodelling machineries influence for a variety of biological process, from the 
complete clearance of nucleosomes at regulatory sites to shifting nucleosome positions, 
increasing the accessibility of DNA on the surface of positioned nucleosomes and 
exchange of H2A variants (Eberharter and Becker 2004). This remodeling of 
nucleosomes increases the accessibility of DNA sequence elements to regulatory 
proteins that scan the genome for target sites, which results in the dynamic changes of 
transcription. A number of nucleosome remodeling complexes have been identified 
that modulate the arrangement and stability of nucleosomes without inducing covalent 
modifications. Generally, these ATP-dependent remodeling machines are divided into 
four major subfamilies including SWI/SNF, ISWI, NuRD and INO80, characterized 
by the identity of their central catalytic subunit comprising BRG1 (or hBrm), ISWI, 
Mi-2 and Ino80, respectively (Eberharter and Becker 2004). These nucleosome 
remodeling complexes can alter the chromatin structure and influence gene expression. 
 
 
1.2.3 Histone post-translational modifications and modifiers 
 
As discussed in the previous topic, dynamic alterations in chromatin structure are well 
associated with many aspects of biological processes. What makes chromatin 
structure so dynamic and what is the effect for transcription? One of the most 
important mechanisms is histone post-translational modifications (Fig. 5). Histone 
acetylation and methylation on H3 and H4 were identified in 1964, since then it was 
proposed that these covalent modifications correlate with transcriptional activity 
(Allfrey et al. 1964). Several decades later, the "histone code" hypothesis was 
proposed which postulates that different combinations of modifications in histones 
could be translated into functionally distinct effects on nuclear processes such as 
transcription, DNA repair and DNA replication (Strahl and Allis 2000; Jenuwein and 
Allis 2001). Recent accelerated progresses in the field brought us many evidences 
supporting this hypothesis and, in turn, the fact that the situation could be much more 
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complex than a simple “code”. At the moment, we know the following types of 
posttranslational modifications on core histones; acetylation, methylation, 
phosphorylation, ubiquitination, sumoylation, ADP ribosylation, biotinylation and 
proline isomerization. These modifications take place at specific residues of each 
histone and the specific patterns of them are very well correlated with distinct 
biological processes. In the following section, I will summarize the function of several 
modifications and enzymes responsible for modifications focusing on the aspect of 
transcriptional regulation.  
In general, two ways of action are believed to alter the transcriptional activity through 
histone modifications. First histone modifications may directly affect for the higher 
order of the chromatin structure through the conformational changes in each 
nucleosome and controlling the association of the nucleosome arrays. Second histone 
Figure 5. Chromosome organization and post-translational modifications (Sparmann and van 
Lohuizen 2006). Eukaryotic DNA is organized into a chromosome structure composed of 
nuclesomes. Highly condensed mitotic chromosome is shown in the top-left. A chromatid is one of 
two identical copies of DNA making up a chromosome. A centromere is the region where two of 
chromatids fuse together and a telomere is the each end of chromosome. Both centromere and 
telomere contain repetitive sequences. Histone tails are able to be modified by different types of 
post-translational modifications: Ac, acetylation; Me, methylation; P, phosphorylation; Ub, 
Ubiquitination; respectively. Many of them are known to be catalyzed reversibly.    
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modifications may provide the binding sites for proteins harboring an activity altering 
gene expression; at the same time these histone modifications are also able to function 
to prevent proteins from binding.  
 
 
1.2.4 Histone methylation and modifying enzymes 
1.2.4.1 Histone methylation 
 
Lysine and arginine residues on histone H3 and H4 can be methylated to different 
degrees: mono-, di- and, in some cases, tri-methylations are possible. Each type of 
modification could have different biological outcomes. In several cases, differences in 
outcome are very well characterized. For example, methylation at lysine 4 in histone 
H3 is well correlated with gene active regions. However distributions of mono-, di-, 
and tri-methylated H3K4 in the active gene loci are totally different, which may 
indicate their differential implication in transcription. Tri-methylation of H3K4 occurs 
at the 5' ends of ORFs as genes become induced, whereas di-methyl modification of 
H3K4 is peaked at the middle part of transcribing gene. In addition, mono-methylated 
H3K4 is enriched at the termination site of gene (Ruthenburg et al. 2007). Similar 
observations have been made in the case of H3K9 methylation. H3K9 methylation is 
the best characterized modification associated to the gene silencing and repression. In 
higher eukaryotes, tri-methylated H3K9 is typically connected to constitutive 
heterochromatin, while mono- and di-methylated H3K9 are mainly located in 
euchromatin and generally linked to repressed promoter regions (Berger 2007).  
H3K27 tri-methylation at transcriptional start sites is generally correlated with the 
repression of gene expression. This repression is mediated by the protein complex 
called Polycomb repressive complex (PRC). H3K27 trimethylation contributes to the 
recruitment and/or stabilization of PRC on chromatin, which in turn mediates gene 
repression (Schuettengruber et al. 2007). Recent genome wide analyses identified 
chromatin regions containing both H3K4 and H3K27 tri-methylation, termed 
“bivalent domains”, which are enriched in embryonic stem (ES) cells at promoters of 
genes encoding key developmental TFs and components of critical signaling 
pathways (Bernstein et al. 2006). This enrichment of tri-methylation at both active 
(H3K4) and repressive (H3K27) position is interpreted as repression of gene 
expression by recruitment of PRC. Upon ES cell differentiation, many bivalent 
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domains, in turn, resolve into transcriptionally active H3K4 tri-methyl or 
transcriptionally silent H3K27 tri-methyl chromatin regions, depending on the 
specific cell fate and the lineage commitment, and some remain bivalent in terminally 
differentiated cells (Mikkelsen et al. 2007). 
 
 
1.2.4.2 Histone methyltransferases 
 
To date, it has been demonstrated that histone methylation can be reversibly catalyzed 
by site specific histone methyltransferases and histone demethylases. During the past 
few years, remarkable progresses have been made in the identification of the 
enzymatic machineries involved in histone methylation. These enzymes have been 
grouped into several classes, including the lysine-specific SET domain-containing 
histone methyltransferases involved in methylation of lysines 4, 9, 27, and 36 of 
histone H3 and lysine 20 of histone H4; non-SET domain-containing lysine 
methyltransferases involved in methylating lysine 79 of histone H3; and arginine 
methyltransferases involved in methylating arginine 2, 17, and 26 of histone H3 as 
well as arginine 3 of histone H4 (Shilatifard 2006) (Fig. 6).  
The conserved lysine methyltransferases motif, SET domain, is named from the 
Drosophila proteins Su(var)3–9, Enhancer of zeste [E(z)], and Trithorax. All proteins 
are conserved in mammals and human homologous proteins are SUV39, EZH2, and 
MLL family, respectively. H3K4 methylation has been shown to be catalyzed by 
more than 10 methyltransferases. Drosophila trithorax-related proteins, Mixed 
Lineage Leukemia (MLL) protein family, are the main member of H3K4 
methyltransferases, which consist of MLL1, MLL2, MLL3, MLL4, MLL5, SET1A 
and SET1B in human (Emerling et al. 2002; Ruthenburg et al. 2007). This multiplicity 
of H3K4 methyltransferase activity provides a wide range of functional diversities 
based on their tissue and temporal restricted expression patterns and target-
specificities (Yu et al. 1995; Glaser et al. 2006; Lee et al. 2006). 
H3K9 is known to be methylated by several enzymes, however three enzymes are the 
best characterized: G9a, SUV39h1 and SUV39h2. Mouse mutagenesis experiment 
revealed that in vivo G9a dominantly regulates H3K9 mono- and di-methylation at 
euchromatic regions, whereas both Suv39 proteins contribute to H3K9 tri-methylation 
on pericentric heterochromatin (Peters et al. 2003). Combined loss of Suv39h1 and 
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Suv39h2 impairs heterochromatin formation and genome stability, which results in 
the embryonic lethality around E12.5 (Peters et al. 2001). 
H3K27 methylation is governed by mainly EZH2 protein in vivo. EZH2 is responsible 
for the key enzymatic activity of the Polycomb repressive complex PRC2. Polycomb 
group proteins were genetically identified in Drosophila as factors required for 
maintaining the lineage specifications during embryogenesis by repressing Hox genes 
in a body-segment-specific manner (Kanno et al. 2008). Therefore mouse Ezh2 also 
has been reported to contribute to regulate development in various biological systems 
(O'Carroll et al. 2001; Su et al. 2003; Puschendorf et al. 2008). 
 
 
1.2.4.3 Histone demethylases 
 
Until recently, it was assumed that histone methylation is an irreversible modification 
and that removal of methyl groups can only be achieved by turn-over and/or exchange 
of histones. However, in 2004, Shi and colleagues made a break through and 
identified the factor, Lysine Specific Demethylase 1 (LSD1) (Shi et al. 2004). LSD1 
is also called BHC110, a nuclear amine oxidase homologue previously found in 
several histone deacetylase corepressor complexes (You et al. 2001; Hakimi et al. 
2002; Shi et al. 2003). LSD1 homologs are well conserved in eukaryotes except for S. 
cerevisiae. LSD1 demethylase activity is restricted toward H3K4me1/2 both in vitro 
and in vivo, and presence of the CoREST complex is required for the demethylase 
activity towards in vitro nucleosome substrates (Shi et al. 2004; Lee et al. 2005). 
The discovery of LSD1 raised the question whether are there any other demethylases? 
A novel JmjC domain-containing protein, JHDM1 (JmjC domain-containing histone 
demethylase 1), was identified as a histone demethylase by biochemical purification 
in 2006 (Tsukada et al. 2006). The JmjC domain was originally found in the jumonji 
(jmj) protein which was identified to be essential in the mouse for the development of 
multiple tissues by a forward genetic approach (Takeuchi et al. 1995). Many jumonji 
family proteins have domains responsible for DNA and chromatin association and 
some of them have been shown to repress gene expression, however the molecular 
mechanisms underlying had not been explored until the discovery of their 
demethylase activity (Toyoda et al. 2003; Kim et al. 2004; Kim et al. 2005). JHDM1 
preferentially demethylates H3K36me2 and to a lesser extent H3K36me1, which are 
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usually enriched in actively trnanscribed loci (Tsukada et al. 2006). In the mammalian 
genome, over 100 jmjC domain-containing genes are encoded; thereby these enzymes 
may have diverse- and specific- roles in different tissues during the mammalian 
development, which is largely unexplored yet. 
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Figure 6. Human and yeast histone modifying enzymes. Currently known enzymes are 
drawn in the Figure. HDACs are not indicated since their specificity in higher eukaryotes 
has not been clear yet. S.c indicates Saccaromyses Saccharomyces cerevisiae and S.p 
represents Schizosaccharomyces pombe. The figure is taken from Abcam web site. 
(http://www.abcam.co.jp/ps/pdf/chromatin/a4_chip_card.pdf) 
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1.2.5 Histone acetylation and modifying enzymes 
1.2.5.1 Histone acetylation 
 
Histone acetylation is one of the best characterized modifications which positively 
correlate with gene transcription. A large number of genome-wide studies has shown 
that the bulk of histone H3 and H4 acetylation is enriched in gene active loci such as 
euchromatic regions, whereas hypo-acetylation is detected at inactive loci and in 
heterochromatic regions. Histone acetylation occurs reversively at the ε-amino group 
of lysine residues in all of the core histones, mainly at the tails but also at a few 
positions in the globular domain. Histone acetylation is proposed to regulate gene 
expression by making the chromatin structure “open” or “accessible”, so that GTFs 
and RNAP II can bind onto DNA to initiate transcription. Originally the open 
structure of chromatin has been identified by the DNase I hyper sensitivity since 
DNase I is able to digest DNA if it is free from the nucleosome structure. These 
traditionally defined hyper sensitive sites are, in tern, shown to be associated with 
histone hyper acetylation, proving that open conformation of chromatin contains 
histone hyper acetylation. In addition, in vitro studies have proven that acetylation of 
H4K16 could inhibit an association of nucleosome arrays which are likely a 
luminescent situation of 30 nm fibre chromatin conformation in vivo (Dorigo et al. 
2003; Shogren-Knaak et al. 2006). Taken together, histone acetylation can be a causal 
Figure 7. Histone 
acetylation and chromatin 
structure. Histone acetylation on a 
lysine residue is catalyzed by 
HAT and deacetylation by 
HDAC. Acetylated nucleosomes 
form more relaxed structure, 
which is transcriptionally active, 
whereas hypo-acetylated 
nucleosomes are condensed, 
which prevent the gene 
expression.  
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effect of opening up chromatin and has strong positive correlation with open 
conformation of chromatin (Fig. 7).  
Another mechanism by which histone acetylation affects for gene expression is that 
acetyl-lysine can be recognized by proteins containing a bromodomain motif. 
Bromodomain motifs are often found in proteins acting as a transcriptional machinery 
(TAF1/TAFII250; a subunit of TFIID), coactivetors (p300, CBP, GCN5 and PCAF) 
and nucleosome remodeling proteins (BRG1 and SWI/SNF). In details of these 
bromodomain containing proteins are discussed in later. Thus histone acetylation 
facilitates the binding of these factors and promotes gene expression in a positive 
manner.  
 
 
1.2.5.2 Histone acetyltransferases 
 
This reversible acetylation on lysine residues is mediated by two opposing enzymatic 
activities; Histone acetyltransferases (HATs) and Histone deacetylases (HDACs). 
HATs are enzymes that acetylate lysine residues by transferring an acetyl group from 
acetyl-CoA to lysine to form ε-acetylated lysine. On the other hand, HDACs remove 
acetyl groups from ε-acetylated lysines by hydrolysis. HATs are classified into five 
families including the Gcn5-related acetyltransferases (GNATs); the MYST-related 
HATs (for MOZ, Ybf2/Sas3, Sas2 and Tip60 named from yeast genes); p300/CBP 
HATs; the general TF HATs, TAF1/TAFII250; and the nuclear hormone-related 
HATs SRC1 and ACTR (SRC3) (Carrozza et al. 2003).  
 
The GNAT superfamily in human includes GCN5 and PCAF, which are known to be 
a major source of nuclear type HATs. Both proteins share 73% identical amino acids 
and possess similar domains (Nagy and Tora 2007). In the N terminus, they contain a 
catalytically essential domain called the PCAF homology domain and a bromodomain 
in the C terminus. Similar to other superfamilies of HATs, they are found in several 
large protein complexes with a total mass of either 2 MDa or 700 kDa. In yeast, the 
SAGA and the ADA complexes have been identified to contain the Gcn5 protein 
(Baker and Grant 2007). In human, there are 3 large complexes; TFTC, STAGA and 
PCAF complexes and 1 small complex; ATAC. All of them catalyze acetylation 
preferentially on histone H3, in which they may have an additional preference for 
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specific lysines based on the results observed with complexes. All three large 
complexes contain several ADA proteins involved in the nucleosomal HAT activity, 
SPT proteins and TAFs for the interaction with TBP and GTFs. Yeast SAGA complex 
is known to contain Ubp8 protein which is the enzyme that deubiquitylate histone 
H2B at Lys 123. H2B ubiquitylation is transient, increasing early during gene 
activation, and then decreasing coincident with significant RNA accumulation. It 
might well be that H2B monoubiquitination is important for the initiation of 
transcription and/or association with the transcriptional machinery, however it will be 
deubiquitinated by SAGA complex during the transcriptional process. Based on these 
facts that coactivator HAT complexes might enhance transcription by following 
mechanisms;,(1) binding to the acetylated histone in the promoter regions via its own 
bromodomain, (2) directly catalyzing acetylation on histone, (3) stabilizing the 
binding to GTFs via its complex components, and (4) deubiquitination of H2B. 
 
The MYST family currently comprises five human HATs: Tip60, MOZ, MORF, 
HBO1 and MOF. Their defining feature is the presence of the highly conserved 
MYST domain composed of an acetyl-CoA binding motif and a zinc finger. Some 
family members also have in common additional structural features such as 
chromodomains, plant homeodomain-linked (PHD) zinc fingers, and others 
(Avvakumov and Cote 2007). Tip60 is the catalytic subunit of the coactivator 
complex called NuA4 (Nucleosome acetyltransferase of histone H4), which can 
catalyze the acetyltransferase activity toward hisotne H4 and H2A. The function of 
Tip60 in transcription is well described. One example is that human NuA4 was linked 
to the function of transcription activators required for cell-cycle progression by which 
c-Myc recruits NuA4 to its target genes (McMahon et al. 1998). Another member of 
the MYST family, MOF was identified by Drosophila genetic screening to search for 
genes involved in dosage compensation of male X chromosome. MOF stands for 
males-absent-on-the-first. MOF is a HAT that specifically acetylates lysine 16 of 
histone H4 (H4K16ac), a modification found highly enriched on the male X 
chromosome in Drosophila. Recent genome-wide study has shown that Drosophila 
MOF complex is not only critical for the dosage compensation but also regulating 
gene expression in autosomes by affecting the level of H4K16 acetylation (Kind et al. 
2008). The MOF complex is also highly conserved in human as well as its substrate 
specificity. Two studies have discribed that depletion of human MOF in cell lines and 
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the targeted inactivation of mouse MOF lead to genomic instability, spontaneous 
chromosomal aberrations, cell cycle defects, altered nuclear morphology, and reduced 
transcription of certain genes (Gupta et al. 2005; Gupta et al. 2008). Taken together, 
MOF functions are conserved in evolution and regulate essential gene expression as 
well as H4K16 acetylation in the whole genome. 
Importantly, the MYST family of HATs is involved in the process of DNA repair 
(Avvakumov and Cote 2007). This effect may be partly due to acetyltransferase 
activity toward histones, however Tip60 and MOF are also shown to acetylate p53 
directly on lysine 120 (Sykes et al. 2006; Tang et al. 2006). As a result of this 
acetylation on DNA binding module, acetylated p53 appears to bind preferentially to 
the promoter of pro-apoptotic genes. Acetylation of p53 is the important switch to 
decide the cell fate toward either cell cycle arrest or apoptosis. 
 
Another family of HATs comprises the cAMP response element-binding protein-
binding protein (CBP) and p300 which were originally identified as factors binding to 
the cAMP response element-binding protein (CREB) and the adenoviral E1A 
transcription factor, respectively (Karamouzis et al. 2007). The preferred in vitro sites 
of acetylation on the N-terminal histone tails are K12 and K15 in histone H2B, K14 
and K18 in histone H3 and K5 and K8 in histone H4 (Schiltz et al. 1999). Importantly 
both p300 and CBP are the acetyltransferases not only for core histones but also a 
number of non-histone proteins such as p53, FoxO1, STAT1, NF-κB and type I 
interferon (IFN) receptor 2 (Goodman and Smolik 2000; Chen et al. 2001; Motta et al. 
2004; Matsuzaki et al. 2005; Kramer et al. 2006). Following DNA damage, p53 is 
activated by kinase-mediated phosphorylation as well as by acetylation at specific 
residues by CBP/p300, resulting in increased stability of the p53-CBP/p300-DNA 
complex. Furthermore, CBP/p300 is required for p53-mediated transactivation of 
target genes through their co-activator function and through local histone acetylation. 
Interestingly, CBP and p300 also control p53 stability by regulating its ubiquitination 
and degradation, through both Mdm2-dependent and independent mechanisms. 
Degradation of p53 has been shown to be mediated by a complex comprising p53, 
Mdm2 and CBP/p300 (Grossman et al. 1998). Recently, the CH1 domain of 
CBP/p300 was found to exhibit ubiquitin ligase activity towards p53; this indicates 
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that CBP/p300 can play a direct role in regulating the level of p53 protein (Grossman 
et al. 2003). 
 
In summary, HATs family proteins are the catalytic core of various large protein 
coactivator complexes, which function to acetylate lysine residues of core histones at 
the promoter regions of genes. As a result of this, HATs are able to activate gene 
expression. Each HAT displays preferred lysine sites on core histones, which 
determines their in vivo specific roles. In addition, an increasing number of non-
histone proteins are found to be a substrate of “histone acetyltransferases”, by which 
HATs can modulate various properties of the target protein such as protein stability, 
intra-cellular localization or DNA binding capacity. 
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1.2.6 Histone deacetylases 
1.2.6.1 Yeast HDACs 
 
Yeast, S. cerevisiae, Rpd3 was the first HDAC gene identified genetically as a factor 
that represses the expression of potassium transporters in yeast (S. cerevisia) (Vidal et 
al. 1990; Vidal and Gaber 1991), subsequently, later on it was found that it has an 
activity to deacetylate histones and repress gene expression (Rundlett et al.). Since 
then, using genetic, biochemical and bioinfomatic approaches, many HDAC genes 
have been identified from yeast to human. So far 10 yeast genes are known to encode 
proteins harboring the deacetylase activity: Rpd3, Hda1, Hos1, Hos2, Hos3, Sir2, 
Hst1, Hst2, Hst3 and Hst4 (Brachmann et al. 1995; Kurdistani and Grunstein 2003). 
According to the sequence and functional similarity, they are grouped into 3 classes. 
Rpd3, Hos1 and Hos2 are the members of class I HDACs. Rpd3 and Hos1 are 
necessary for the deacetylation of H4K5, 8 and 12, and only Hos2 is required for 
H4K16 (Wang et al. 2002). Rpd3 forms two distinct large protein complexes; Rpd3L 
and Rpd3S which are apparent mass of 1.3 MDa and 0.8 MDa respectively (Carrozza 
et al. 2005). Both protein complexes share the core subunits including Rpd3, Sin3 and 
Ume1. In addition, the Rpd3L complex contains different proteins such as Ume6, 
Sds3, Sap30 and others, whereas Rpd3S contains Rco1 and Eaf3. The mechanisms 
targeting these distinct complexes to specific genomic loci appears to be different. 
Genome-wide studies have shown that Rpd3 proteins are predominantly recruited to 
promoter regions of genes via sequence specific DNA binding factors, and at the same 
time a significant amount of proteins is detected globally on the genome (Kurdistani 
et al. 2002). Altough many publications described the correlation between gene 
expression and promoter histone acetylation, recent reports suggested that 
recruitments of Rpd3S complexes to gene cording regions are also an important 
function of HDACs acting to repress the aberrant transcription initiation from cryptic 
start sites (Carrozza et al. 2005; Keogh et al. 2005).  
Hos3 belongs to class II HDACs, whereas Sir2 (Silent information regulator) and its 
homologous genes Hst1, Hst2, Hst3 and Hst4 belong to class III. Sir2 gene was first 
identified as a yeast mutation required for repressing the expression of mating type 
genes (Buck et al. 2004). Class III HDACs need a nicotinamide adenine dinucleotide+ 
(NAD+) for their enzymatic activity and their protein structures are unrelated to any of 
class I and II enzymes.  
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1.2.6.2 Mammalian HDACs 
 
In mouse and human, 18 HDACs have been identified that can be grouped into four 
classes based on their protein homology to yeast HDACs (Fig. 8). Class I enzymes 
comprise HDAC1, 2, 3 and 8, class II includes HDAC4, 5, 6, 7 and 9, class IV 
contains only HDAC11, and class III, NAD+ dependent-Sir2 homolog, contains 
SIRT1-7 (Yang and Seto 2008). To date, a tremendous amount of researches has been 
carried out to understand the function of these enzymes since it has became clear that 
HDACs are intimately involved in many different types of diseases, and that HDACs 
might be potential targets of drug therapies. It has been known for long time that 
HDAC inibitors (HDACis), such as trichostatin A (TSA) and suberoylanilide 
hydroxamic acid (SAHA), function as anti-cancer drugs, which can inhibit cell cycle 
progression and/or induce apoptosis and differentiation in a cell type- and context-
dependent manner (Yoshida et al. 1987; Richon et al. 1996; Richon et al. 1998; 
Minucci and Pelicci 2006). Recent progresses in the field have pointed out that the 
targeting of HDACs could potentially be applied for very diverse diseases including 
inflammatory diseases, heart diseases, neurodegenerative diseases, and others (Saha 
and Pahan 2006; Adcock 2007; Berry et al. 2008). Inhibition of HDACs has such a 
great impact on a diverse set of diseases that it is not surprising that functions of 
HDACs are not only restricted to the regulation of gene expression through 
modulating histone acetylation but also controlling the many aspect of biological 
processes such as a protein stability, protein translocation, enzymatic activity, and 
DNA binding affinity via acetylation of non-histone proteins (Minucci and Pelicci 
2006). 
To date, at least ten different HDACis are currently under c.a. 80 clinical trials as anti-
cancer drugs, tested in everything from rare leukemias and lymphomas to breast, 
prostate and ovarian cancer either alone or in combination with other drugs.  
Importantly SAHA, also called Vorinostat (Zolinza™, Merck & Co., Whitehouse 
Station, NJ, USA), has been approved by the U.S. Food and Drug Administration for 
treatment of cutaneous T-cell lymphoma (CTCL) (Duvic and Vu 2007; Mottet and 
Castronovo 2008). However there are several hurdles to overcome in the future of the 
HDACi field. First many of the HDACis work very well in vitro in tumor cell lines 
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including hematological and solid tumors, but in animal trials the anti-cancer effects 
are not as striking as seen in in vitro experiments, especially on solid tumors, although 
most trials are in early stages. In addition, there are several cases reported that 
HDACis show heart-related side effects. Most of these effects are thought to be 
medically insignificant; yet one HDACi, depsipeptide, was dropped from the trial 
because of that (Garber 2007). Why HDACis is not working well on solid tumors in 
vivo and how do HDACis affect the heart? Answers for these questions have not been 
addressed yet mainly due to the lack of knowledge showing molecular mechanisms of 
HDAC function in vivo, key targets of HDACs, and subtype-specific functions of 
HDACs. Given the complexity of mammalian HDACs (18 homologs), non-selective 
inhibitory activity of HDACis (the majority of HDACis inhibits both class I and II 
HDACs), and a growing number of non-histone substrates for HDACs, evaluating the 
effects by HDACis has been facing a huge problem. Therefore, research to dissect the 
role of specific HDACs in vivo using a genetic approach will help to understand how 
Figure 8. Schematic representation of mammalian HDACs. HDACs are grouped into 4 
subfamily based on their amino acids homology. Blue or green boxes represent a conserved HDAC 
domain for class I, II and IV enzymes, and Sir2 homologs. Numbers of amino acids in each protein 
are shown in the right side. P in each HDAC indicates the identified phosphorylation site. 
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individual HDAC functions and which HDAC is implicated in specific biological 
processes. Here I summarize reports describing the in vivo functions of the class I and 
II HDACs, which are the main targets of HDACis, as revealed by genetic approaches 
to remove specifically individual enzymes. 
 
 
1.2.6.3 Class I HDACs in matazoans 
 
As mentioned above, mammalian class I HDACs (HDAC1, 2, 3 and 8) are closely 
related to yeast Rpd3, which is predominantly found on the promoter region of genes 
as well as globally on the genome (Kurdistani et al. 2002). Thus class I HDACs in 
mammals are also thought to be regulating gene expression by removing the acetyl 
group from core histones in the promoter regions, however this remain to be 
demonstrated experimantaly in higher eukaryotes by the genome-wide manner. There 
are at least 4 protein complexes identified in mammals containing at least one of class 
I HDACs; Sin3, Mi-2b/NuRD, CoREST, and N-CoR/SMRT. The Sin3, Mi-2b/NuRD 
and CoREST complexes include HDAC1 and 2 as catalytically core enzymes, 
whereas N-CoR/SMRT harbors HDAC3 in the complex (Karagianni and Wong 2007; 
Yang and Seto 2008) (Fig. 9). All complexes are known to function as a co-repressor 
to shut down gene expression, by which sequence specific TFs recruit them on the 
promoter regions. In other metazoans such as C. elegans (worm), D. melanogaster 
(fly), and D. rerio (zebrafish), orthologs of mammalian HDAC1 and 3 are found, and, 
Figure 9. HDAC1 and 2 containing co-
repressor complexes.  
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in addition, the zebrafish genome encodes an ortholog of HDAC8. Several members 
of three co-repressor complexes containing HDAC1 and 2 are encoded in the genome 
of C. elegans, D. melanogaster, and D. rerio, whereas N-CoR/SMRT are not found in 
C. elegans, although it has HDAC3 homolog as a functional protein (Shi and Mello 
1998; Yang and Seto 2008). 
Since all of HDAC1/2 complexes lack the ability to bind to DNA, their target genes 
are determined by interaction partners having a sequence specific DNA binding 
capacity. To date a number of proteins has been identified to associate directly with 
HDAC1 and/or 2 or co-repressor complexes in different types of transformed cells as 
well as primary cells. One of the first identified interaction partner in mammalian 
cells is Retinoblastoma (Rb) protein which represses specific genes that are active in 
the S phase of the cell cycle. The Rb protein masks the trans-activation domain of 
E2F transcription factor and, at the same time, brings HDAC1 and/or 2 to the 
promoter region of genes involved in proper control of the G1/S transition, which 
results in repression of genes inhibiting this step (Brehm et al. 1998; Ferreira et al. 
1998; Luo et al. 1998; Magnaghi-Jaulin et al. 1998).  
The multisubunit transcription factor NF-κB plays an essential role in the regulation 
of gene expression involved in immune and inflammatory responses and cell survival. 
The most abundant form of NF-κB is a heterodimer of p50 and p65 (RelA). The 
subunit p65 is shown to associate with both HDAC1/2 and repress the interleukin-8 
(Il8) gene induced by the TNF-dependent manner (Ashburner et al. 2001).  
In addition to these factors, HDAC1/2 interaction was confirmed with other TFs such 
as Blimp-1 (Yu et al. 2000), YY1 (Coull et al. 2000; Yang et al. 2001), Sp1 and Sp3 
(Choi et al. 2002; Won et al. 2002), BCL6 (Bereshchenko et al. 2002), Nanog and 
Oct4 (Liang et al. 2008).  
It is worthy to note again in this chapter that an increasing number of reports have 
demonstrated that acetylation of lysine residues on non-histone proteins are also 
important to regulate biological features. Acetylation of proteins can modulate their 
function at multiple levels such as: the transcriptional activity, DNA binding affinity, 
protein stability, protein localization and protein-protein interaction (Glozak et al. 
2005). 
Among the large number of proteins identified, p53 is one of the most and best 
characterized proteins for the impact of acetyl modification. The activity of the p53 
tumor suppressor is modulated by protein stability and post-translational 
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modifications in the response to various forms of cellular stress (Gu and Roeder 1997; 
Lavin and Gueven 2006). Acetyl modification of p53 at lysine 120 and 164 within the 
DNA binding domain and 6 additional sites in the C-terminus of p53 occurs following 
genotoxic stress and enhances its transcriptional activity towards p21 gene expression, 
which leads to a blockade of the cell cycle and promotes the DNA repair pathway. 
This acetylation also stabilizes p53 itself, preventing the binding to Mdm2 which 
ubiquitinates p53 for degradation. It has been confirmed that the HDAC1/2 complex 
is responsible to deacetylate several sites, therefore HDAC1/2 complex is crucial to 
reduce the activity of p53 via deacetylation, which results in repression of genes 
inhibiting the cell cycle progression (Luo et al. 2000; Ito et al. 2002; Tang et al. 2008). 
 
 
1.2.6.4 Developmental roles of class I HDACs in organisms 
 
With the exception of HDAC8, all class I HDACs and several subunits of HDAC 
complexes have been inactivated either in the entire mouse or in a tissue-specific 
manner (Table 1). HDAC1 knock out mice were the first reported HDAC deficient 
mice, which results in embryonic lethality before E9.5 (Lagger et al. 2002; 
Montgomery et al. 2007). HDAC1-/- ES cells show  proliferation defects associated 
with upregulation of cyclin-dependent kinase inhibitors; p21 and p27, later on it was 
shown that acetylation of the p21 promoter is directly regulated by HDAC1 in these 
cells (Lagger et al. 2003). A tissue-specific role of HDAC1 was reported together in a 
comparison with the effect of HDAC2 inactivation (Montgomery et al. 2007). 
HDAC2-/- mice show the complete lethality within 24 hours after birth, although they 
are born at near expected Mendelian ratios. Histological analysis of HDAC2-/- 
neonates revealed unusual morphological abnormalities of the right ventricular 
chamber in the heart.  In sharp contrast to the lethality in the absence of HDAC1 or 2, 
tissue specific abrogation of one of both enzymes in the neural crest, skeletal muscle, 
central nervous system, endothelium, smooth muscle, secondary heart field and B 
lymphocytes does not have apparent defects (Montgomery et al. 2007; Yamaguchi et 
al. submitted). Combined cardiac inactivation of both HDAC1 and 2 leads to postnatal 
death with severe cardiac defects by day 14 accompanied by misregulation of genes 
encoding skeletal muscle-specific contractile proteins and calcium channels 
(Montgomery et al. 2007). These results have demonstrated that essential functions 
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for both proteins during embryogenesis and dispensable functions in the adult mice. It 
is worth mentioning that other modified alleles of HDAC2 mutant mice generated by 
either a gene-trap method or removal of exon 6 show only partial perinatal lethality 
(Trivedi et al. 2007; Ymaguchi et al. submitted). In these mutant mice, about 50% of 
them die within a month, and the rest has a smaller body size as well as cardiac 
defects. The heart of these mutant mice are protected from cardiac hypertrophy by 
upregulating the gene encoding inositol polyphosphate-5-phosphatase f (Inpp5f), 
which results in constitutive activation of glycogen synthase kinase 3β (Gsk3β). 
HDAC3-/- mice were recently reported to show embryonic lethality prior to E9.5 
(Bhaskara et al. 2008). Further analysis was conducted using mouse embryonic 
fibroblasts (MEFs) to investigate the requirement of HDAC3 for the cell-cycle 
progression, which had previously been observced in cancer cell lines (Li et al. 2006). 
Although primary MEFs lacking HDAC3 show a delay in cell-cycle progression, they 
do not exhibit decreased H3S10 phosphorylation, which leads to the dissociation of 
the heterochromatin protein 1 (HP1) from chromatin during mitosis, whereas cancer 
cell lines as well as immortalized MEFs show mitotic catastrophe accompanied with 
reduced H3S10 phosphorylation. In addition, an accumulation of DNA damage was 
observed in HDAC3-/- interphase MEF cells, which appears to be associated with a 
defective DNA double-strand break repair. However HDAC3-/- MEFs were protected 
from DNA damage when they are not cycling or quiescent. These results might 
partially explain the observation that HDACi affects selectivity to the cancer cells or 
highly proliferating cells rather than primary or quiescent cells. 
 
 
 
1.2.6.5 Class II HDACs in matazoans 
 
HDAC4, 5, 6, 7, 9, and 10 belong to the class II family, and they are further divided 
into 2 subfamilies based on their sequence homology; class IIa as HDAC4, 5, 7 and 9, 
and class IIb as HDAC6 and 10. Interestingly C. elegans, D. melanogaster, and D. 
rerio encode only one gene in each subfamily, so that only mammalians show 
multiple enzymes in both class II families. The class IIa enzymes consist of a large N-
terminal extension and a conserved HDAC domain in the C-terminus; this structure is 
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conserved in other metazoans. The N-terminal domain contains multiple 
phosphorylation sites as well as a binding site for myocyte enhancer factor-2 (MEF2). 
Phosphorylation on the conserved serine residues by calcium/calmodulin-dependent 
kinase (CaMK) and other kinases in response to specific stimuli creates binding sites 
for the 14-3-3 proteins which can mediate shuttling of proteins from the nucleus to the 
cytoplasm. In fact all class IIa enzymes are found in both the cytoplasm and the 
nucleus, and mutations in these phosphorylation sites prevent binding of 14-3-3 
proteins, which results in the lack of nuclear export (Kao et al. 2001). Class IIb 
enzymes, HDAC6 and 10, are able to be clustered from class IIa because of a longer 
C-terminal extension; furthermore HDAC6 is unique in that it contains two HDAC 
domains. The subcellular localization of class IIb enzymes is predominantly, if not 
exclusive, cytosolic, and no shuttling activity has been detected. 
Whereas class I HDACs are detected in a wide range of culture cell line, tissues and 
organs, class IIa HDACs are expressed in a more restricted type of cells. The highest 
expression of HDAC4, 5 and 9, is detected in heart, skeletal muscle and brain, and 
HDAC7 expression is found predominantly in thymocytes, heart and lung (Fischle et 
al. 1999; Grozinger et al. 1999; Miska et al. 1999; Verdel and Khochbin 1999; Wang 
et al. 1999; Dequiedt et al. 2003). Class IIb family enzymes are also abundant in many 
cells and tissues however HDAC6 expression is the highest in testis and HDAC10 has 
the highest level in liver, kidney and spleen (Verdel and Khochbin 1999; Seigneurin-
Berny et al. 2001; Fischer et al. 2002; Guardiola and Yao 2002; Kao et al. 2002; Tong 
et al. 2002; Zhang et al. 2008). 
 
 
 
 
1.2.6.6 Developmental roles of class II HDACs in organisms 
 
Class II HDACs have also been genetically ablated in mice, and their contributions to 
mouse development were definitely more restricted than those of class I enzymes, in 
agreement with their more limited expression patterns (Table 1). In sharp contrast to 
the early embryonic death of HDAC1 and 3 mutant mice, many of class II HDAC 
mutants reported to date show tissue-specific defects, which implies that class I 
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HDACs function as a general HDACs to regulate expression of key and essential 
genes whereas class II enzymes have selected targets in specific tissues and situations. 
 
The HDAC9 locus was the first genetically modified class II HDAC gene in a mouse 
(Zhang et al. 2002). HDAC9 locus encodes two forms of proteins which are a full 
length HDAC9 protein and MEF2-interacting transcriptional repressor (MITR), a 
splice variant of HDAC9 lacking a HDAC domain and expressed predominantly in 
the heart (Sparrow et al. 1999). Both forms of HDAC9 gene products can bind to the 
MEF2 transcription factor and inactivate its transcriptional activity (McKinsey et al. 
2002). This association of HDAC9 in the nucleus can be revoked by phosphorylation 
in the N-terminus, which results in the export of HDAC9 by 14-3-3 proteins (Kao et 
al. 2001). The upstream kinase CaMK is activated by cardiac hypertrophic stimuli and 
induces dissociation of HDAC9 and MEF2, which results in the de-repression of 
genes involved in the prevention of hypertrophy. HDAC9 mutant mice appear to be 
viable and show a morphologically and functionally normal heart at young age, 
however at old age or under stress conditions by overloaded pressure or calcineurin 
activation, they show severe cardiomyocyte hypertrophy (Zhang et al. 2002).  
 
HDAC5, another class IIa HDAC highly expressed in the heart, mutant mice show 
age- and stress-dependent cardiac hypertrophy which is similar defects observed in 
the heart of HDAC9 mutant (Chang et al. 2004). Combined loss of both HDAC5 and 
9 leads to a propensity for lethal ventricular septal defects and thin-walled 
myocardium, which suggest redundant functions in the control of cardiac 
development. In addition to the response to cardio-hypertrophic stress, chronic 
cocaine and stress exposure in brain was also examined in HDAC5 mutant mice 
(Renthal et al. 2007). Chronic exposure to cocaine or stress enhances the nuclear 
export of HDAC5 in the nucleus accumbens (NAc), a set of neurons within the 
forebrain thought to be a major brain reward region. Reduction of HDAC5 activity in 
the nucleus of NAc causes hypersensitive responses to chronic cocaine or stress. 
 
Mice lacking HDAC7 appear to have the most severe phenotype among reported class 
II HDAC mutants, as they die during embryogenesis,; this lethality is solely due to a 
failure in endothelial cell-cell adhesion and consequent dilatation and rupture of blood 
vessels since HDAC7 specific deletion in endothelial cells recapitulates this defect 
  28
(Chang et al. 2006). Phosphorylation of HDAC7 in endothelial cells is regulated by 
protein kinase D under the control of VEGF signaling, which disrupts the binding of 
HDAC7 and MEF2 and de-represses expression of genes involved in endothelial cell 
proliferation and migration (Wang et al. 2008).  
 
Inactivation of HDAC4 in mice shows chondrocyte hypertrophy, which results in 
ectopic bone formation leading to complete lethality by the time of weaning (Vega et 
al. 2004). Defects observed in HDAC4-/- mice resemble the phenotype of mice 
continuously expressing Runx2 (Takeda et al. 2001; Ueta et al. 2001). In fact, 
HDAC4 can bind to Runx2 and function to repress the target genes. Loss of HDAC4 
is partially rescued by the reduced amount of MEF2C transcription factor (Arnold et 
al. 2007). Chondrocyte hypertrophy in HDAC4-/- mice can be diminished by a 
heterozygous MEF2C mutation, which clearly demonstrated that HDAC4 is 
genetically upstream of MEF2C and inhibiting the expression of genes normally 
activated by MEF2C depend on the stimuli. 
 
Genetic analysis of class IIa HDACs revealed that the functional importance of each 
HDAC activity in different tissues was all associated, at least to a certain degree, with 
the binding to MEF2 transcription factor, which is regulated by the sub-cellular 
localization of HDAC. Export of class IIa HDACs is mediated not only by 
phosphorylation but also the redox status in the cells that is involved in the 
pathogenesis of cardiac hypertrophy and heart failure (Ago et al. 2008). Therefore 
extensive extracellular stimulation such as VEGF signaling as well as stressed 
conditions such as cardiac hypertrophic stimuli and the redox status may dominantly 
determine the export of class IIa HDACs and the dissociation from MEF2 
transcription factor, which results in misregulation of gene expression and provokes 
the abnormal development observed in each HDAC mutant mouse. Thus class IIa 
HDACs are integrated in a cellular signaling cascade as a both mediator (transduces 
cytosolic signaling to nucleus) and director of gene expression (represses gene 
expression directly). 
 
The class IIb family of HDAC6 has unique features distinguished from other HDACs 
in the protein structure and in its function. HDAC6 is composed of two catalytic 
domains and a C-terminal zinc finger domain (ZnF-UBP) binding with very high-
  29
affinity free ubiquitin as well as mono- and polyubiquitinated proteins (Seigneurin-
Berny et al. 2001; Hook et al. 2002; Boyault et al. 2006). The double catalytic 
domains are conserved during evolution, which strongly suggests a critical and 
possibly unique role for this domain duplication in HDAC6 functions. An obvious 
question is whether both catalytic domains are required for the intact deacetylase 
activity. An unambiguous answer is so far not avairable since there are steep 
discrepancies in three independent reports which have shown that (1) each domain 
functions independently, (2) both domains are required for the catalytic activity, and 
(3) the catalytic activity resides in the C-terminal second domain (Grozinger et al. 
1999; Zhang et al. 2006; Zou et al. 2006). 
Another remarkable feature of HDAC6 is its function in the cytoplasm. Despite the 
fact that the roles of class IIa HDACs in cytoplasm remain obscure, a growing 
number of evidences have demonstrated the functional importance of HDAC6 in the 
cytoplasm. The first important achievement uncovering the cytosolic functions of 
HDAC6 was the identification of α-tublin as a substrate of deacetylase activity 
(Hubbert et al. 2002; Matsuyama et al. 2002; Zhang et al. 2003). In addition, the 
chaperone HSP90 was found to be a substrate of HDAC6, which regulates its activity 
(Bali et al. 2005; Kovacs et al. 2005). 
In addition to its deacetylase activity, the C-terminal ZnF-UBP domain has critical 
roles in the fate of ubiquitinated proteins. HDAC6 interacts with the chaperone-like 
AAA ATPase p97/VCP, a protein that is critical for proteasomal degradation of 
misfolded proteins, and this association controls the levels of polyubiquitinated 
cellular proteins, mostly consisting of misfolded proteins (Boyault et al. 2006). 
HDAC6 also facilitates the clearance of misfolded ubiquitinated proteins by 
promoting their accumulation in an aggresome, thereby HDAC6 protects cells from 
apoptosis following stress induced by misfolded proteins (Kawaguchi et al. 2003). 
HDAC6 senses ubiquitinated cellular aggregates comprising polyubiquitinated 
proteins and consequently induces the expression of major cellular chaperones by 
triggering the dissociation of a repressive HDAC6/HSF1 (heat-shock factor 1)/HSP90 
complex and a subsequent HSF1 activation, which leads to the activation of the heat-
shock protein-encoding genes (Boyault et al. 2007). Such an implication of HDAC6 
in the ubiquitin-proteasome system was examined in Drosophila neurodegenerative 
disease model, which showed crucial functions of HDAC6 to remove misfolded 
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proteins that is an early onset of neurodegenerative diseases (Pandey et al. 2007). 
HDAC6 is also essential for formation of stress granules which are dynamic 
cytoplasmic structures containing mRNAs prevented from translation reversiblely 
(Kwon et al. 2007). 
HDAC6 deficient mice appear to be viable and no obvious defects in most of tissue 
examined, despite they show hyperacetylated tubulin (Zhang et al. 2008). There is a 
minor effect in the adaptive immune response as well as a small increase in cancellous 
bone mineral density. 
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Table 1. Summary of HDAC mutant mice. Exons represents the number of 
exons encoding mRNAs, which is taken from the UCSC Genome Browser 
(http://genome.ucsc.edu/)
 Class Mutant viability Exons Modified allele Phenotypes 
HDAC1 I Embryonic lethal by E9.5 15 
lacZ/neo replaces exon 5-7 
(Lagger et al. 2002) 
Exon 5-7 is floxed 
(Montgomery et al. 2007) 
Exon 6 is floxed 
(Zhang et al. unpublished) 
Proliferation defect in ES cells 
and primary MEF cells 
Dispensable in the brain, liver, 
lung, heart or skeletal muscle 
Slight reduction of splenic 
myeloid cells and impaired 
adaptive immune reaction 
HDAC2 I 
Complete (Montgomery et al. 
2007) or partial (Trivedi et al. 
2007; Zimmermann et al. 2007) 
perinatal lethality 
14 
Exon 2-4 is floxed 
(Montgomery et al. 2007) 
Insertion of lacZ after exon 8 
(Trivedi et al. 2007; 
Zimmermann et al. 2007) 
Exon 6 is floxed 
(Yamaguchi et al. submitted) 
Cardiac defects (complete 
KO) 
Dispensable in the brain, liver, 
lung, heart or skeletal muscle 
HDAC3 I Embryonic lethal by E9.5 15 
Exon 7 is floxed (Bhaskara et al. 
2008) 
Proliferation defect, apoptosis 
induction and DNA damage 
sensitivity in MEF cells 
Defects in G2/M transition in 
immortalized and transformed 
cells 
HDAC4 IIa Postnatal lethality by weaning 26 
lacZ/neo replaces exon 6 (Vega 
et al. 2004) 
Chondrocyte hypertrophy 
HDAC5 IIa Viable and fertile 26 
lacZ/neo replaces exon 3-7 
(Chang et al. 2004) 
Age- and stress-dependent 
cardiac hypertrophy 
Hypersensitive responses to 
chronic cocaine or stress 
HDAC6 IIb Viable and fertile 28 
Exon 8-10 is floxed (Zhang et 
al. 2008) 
Increased acetylation of α-
tublin and HSP90 
Modest impairment in the 
immune response 
HDAC7 IIa Embryonic lethal around E12.5 24 
lacZ/neo replaces exon 2-5 
(Chang et al. 2006) 
Failure in the formation of 
blood vessels 
HDAC8 I N.D. 11   
HDAC9 IIa Viable and fertile 12 
lacZ/neo replaces exon 4 and 5 
(Zhang et al. 2002) 
Age- and stress-dependent 
cardiac hypertrophy 
HDAC10 IIb N.D. 20   
HDAC11 IV N.D. 10   
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Figure 10. Cellular differentiation. A stem 
cell loses its potency and gains a lineage/cell-type 
specificity  
1.3. Differentiation 
 
Differentiation is the process which cells become specialized to a particular cell lineage 
and execute specific functions. The cells capable to self-renew and also to generate 
progenitors of differented cells are defined stem cells, which are further separated based 
on their differentiation potential (Table 2). In mammals, all terminally differentiated cells 
such as red blood cells, fibroblasts and neurons are originated from one totipotent stem 
cell, the zygote. During the differentiation process, a totipotent stem cell loses its 
“potency” or “plasticity” to generate all kinds of lineages and is restricted into one 
lineage (Fig. 10). This lineage restriction process is tightly controlled by the specific 
pattern of gene expression, which decides 
the cellular fate toward terminal 
differentiation. Specific patterns of gene 
expression are governed by mainly two 
mechanisms; lineage- and temporally-
restricted expression of sequence specific 
TFs, and epigenetic regulation of gene 
expression. 
 
 
Table 2. Classification of different stem cells (modified from (Jaenisch and Young 
2008; Roobrouck et al. 2008)) 
 
 Developmental potency Example 
Totipotent stem cell All lineages of organisms Zygote Cells in the morula at the early stage 
Pluripotent stem cell 
All lineages of body (the three germ 
layers: endoderm, mesoderm and 
ectoderm but not for the 
extraembryonic trophoblast) 
Embryonic stem cells (ES cells) 
induced pluripotent stem cells (iPS cells) 
the embryonic inner cell mass 
Multipotent stem cell Multiple cell types 
Hematopoietic stem cells (HSCs) 
Neural stem cells 
Mesenchymal stem cells 
Unipotent stem cell One cell type 
Spermatogonial stem cells 
Epithelial stem cells 
Corneal stem cells 
 
Potency Specification
Stem cells 
Differentiated cells 
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1.3.1 Hematopoietic cell development 
 
Hematopoietic cell development (i.e. hematopoiesis) takes place in different manners and 
places during the entire life of higher eukaryotes. During embryogenesis, multipotent 
stem cells, hematopoietic stem cells (HSCs), are generated from ventral mesoderm and  
the yolk sac in mammals becomes the source of hematopoiesis around embryonic day (E) 
7.5-9, which is mainly providing red blood cells allowing embryos to grow rapidly 
without suffering from low oxygen availability. Hematopoiesis in mammals occurs 
subsequently in the aorta-gonad-mesonephros (E9.5-11.5), the fetal liver (E10.5- birth) 
and the bone marrow (E15.5-). In an adult mouse, HSCs reside in the bone marrow, 
where hematopoiesis continues throughout life (Fig. 11). HSCs can be isolated 
exclusively within the lineage marker negative (Lin−) Sca-1+ c-kithi (LSK), which are all 
cell surface molecules, population that constitutes ca. 0.1% of bone marrow cells in the 
adult mouse (Morrison and Weissman 1994). The lineage marker is the mixture of the 
antibodies and can identify T lymphocytes, B lymphocytes, monocytes/macrophages, NK 
cells, erythrocytes, and granulocytes. Based on the length of its life span and expression 
Figure 11. A pathway for adult 
hematopoiesis (Modified from (Johnson et al. 
2004; Nagasawa 2006; Dakic et al. 2007; 
Iwasaki and Akashi 2007; Nutt and Kee 
2007)). Red arrows show the alternative 
model of T cell development recently 
proposed.
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of cell surface molecules, the LSK population can be divided into long-term HSCs (LT-
HSCs), short-term HSCs (ST-HSCs), multipotential progenitors (MPPs) and lymphoid-
primed multipotent progenitors (LMPPs). The cell-cell adhesion factor CD34 and the 
tyrosine kinase receptor Flt3 are used to distinguish these four populations as follows: 
LT-HSCs are Flt3- CD34-, ST-HSCs/MPPs are Flt3- CD34+, and LMPPs are Flt3+ CD34+ 
(Nagasawa 2006; Dakic et al. 2007; Iwasaki and Akashi 2007; Nutt and Kee 2007). In 
cell transfer experiments into leathaly irradiated mice, LT-HSCs give rise to a long-term 
reconstitution, while ST-HSCs only allow a short-term reconstitution. This reflects the 
different self-renewal capacity of LT-HSCs and ST-HSCs. MPPs lack the self-renewal 
ability although they are able to give rise to all hematopoietic lineages (Morrison and 
Weissman 1994). It has not been identified yet that a cell surface molecule can 
distinguish clearly the populations between ST-HSCs and MPPs. LMPPs have been 
recently proposed as a first step towards commitment to the lymphoid-myeloid lineages 
since these cells do not have the capacity to self-renew and give rise to the erythrocyte 
and megakaryocyte lineages (Adolfsson et al. 2001; Adolfsson et al. 2005). This result 
indicates that the first lineage restriction from the multipotent state is the separation of the 
erythrocyte and megakaryocyte lineages from the other hematopoietic lineages. This 
finding proposed a new view on the lineage restriction of myeloid lineage development. 
In the old model, all cells of myeloid lineages including granulocytes, macrophages, 
erythrocytes and megakaryocytes are thought to be generated from a common myeloid 
progenitor (CMP), and then further restricted to a megakaryocyte-erythrocyte progenitor 
(MEP) and a granulocyte-macrophage progenitor (GMP). It implies the additional or 
alternative pathway for the myeloid lineage commitment that LMPP unable to produce 
megakaryocytes and erythrocytes. 
The first and major branch to separate the lymphoid lineage from the myeloid lineage is 
the step giving rise to a common lymphoid progenitor (CLP) which gives rise to the B, T, 
NK and lymphoid dendritic cell lineages. Several publications have shown that there are 
also other pathways leading to the T cell lineage, originating from an early T lineage 
progenitor (ETP), early lymphoid progenitor (ELP) or from a LSK CD62L+ population 
(Medina et al. 2001; Allman et al. 2003; Perry et al. 2004). All these populations were 
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found within the LSK population, suggesting that the branch between the B and T cell 
lineages could be a very early step in hematopoiesis (Fig. 11; red arrows). 
The intrinsic determination of cellular fate during hematopoietic cell development is 
controlled by the sequential expression of genes that is conducted by coordinated 
regulation by TFs and epigenetic modifications. Studies describing the fundamental 
requirement of TFs as well as an increasing number of epigenetic modifiers have been 
intensively done by using mouse genetic approachs to inactivate or enforce expression of 
molecules in hematopoietic cells and identify affected subpopulations. This allowed 
establishing a very complex hierarchy and ordered expression of these factors during 
hematopoiesis have been defined.  
The transcription factor stem cell leukaemia SCL/tal-1 gene product was identified as 
essential for the HSC generation and proper development of the erythrocyte and 
megakaryocytic lineages, however dispensable for the maintenance of HSC function in 
long term (Mikkola et al. 2003). The Lim-domain containing protein LMO2, an 
interaction partner of SCL, is also critical for the yolk sac hematopoiesis (Warren et al. 
1994). Runx1 (previously known as AML-1) is also not required for adult HSC function, 
but critical for the fetal liver HSC generation as well as for megakaryocytic maturation 
and lymphocytic differentiation in adult hematopoiesis (Okuda et al. 1996; Ichikawa et al. 
2004). With the importance of epigenetic regulation for the cellular differentiation, it is 
not surprising that epigenetic modifiers are essential for the hematopoiesis. A recent 
study has shown that the SNF2-like ATPase Mi-2β of the NuRD complex is required for 
maintenance of and multi-lineage hematopoietic differentiation (Yoshida et al. 2008). The 
Mi-2β/NuRD complex is implicated in the regulation of gene repression through its 
activity to remodel nucleosomes and deacetylate core histones. In addition, Mi-2β is 
highly expressed in HSCs and can physically associate with TFs required for early stages 
of hematopoiesis such as Ikaros and GATA-1 (Kim et al. 1999; O'Neill et al. 2000; 
Rodriguez et al. 2005; Sridharan and Smale 2007). Loss of Mi-2 β increases activity of 
cell cycling in HSCs and expression of genes crucial for commitment to the different 
lineages; however, the committed cells toward each lineage are severely blocked during 
their development at early progenitor stages. 
 
  36
Figure 12. Scheme of early B cell differentiation, depicting the different developmental 
stages and the expression of markers used to discriminate them (marker expression is indicated by 
+, lack of expression by -). Curved arrows indicate relative cellular proliferation activities: very 
high in large pre-BII, intermediate in pro- and pre-BI, low or absent in small pre-BII, immature and 
mature B cells. V(D)J shows the rearrangement status of the different Ig gene alleles during B cell 
differentiation. The kind of immunoglobulin present at the membrane is also indicated at the 
bottom. 
 
1.3.2 B lymphocyte development 
 
The development of B lymphocytes from multipotent progenitor cells is a tightly 
controlled, yet flexible, process under the control of a number of lineage-specific or 
ubiquitous transcription factors which initiate, maintain and restrict specific sets of gene 
expression patterns required for B cell identity (Busslinger 2004; Matthias and Rolink 
2005; Cobaleda et al. 2007; Nutt and Kee 2007). Recent development of gene targeting 
studies in mice enabled to identify intrinsically required factors in B lymphocyte 
development and loss of these essential factors has uncovered several checkpoints for B 
cell development which are associated with key biological events. Distinct B cell 
subpopulations have been identified by the expression of cell surface molecules, the state 
of immunoglobulin recombination, cell size, and proliferation ability as shown in Fig 12. 
Several TFs are identified as essential components to commit progenitor cells to the B 
cell lineage: PU.1, E2A, EBF and Pax5. The regulatory network exerted by these TFs is 
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controlling the early stage of B cell development (Busslinger 2004; Matthias and Rolink 
2005; Cobaleda et al. 2007; Nutt and Kee 2007). 
 
PU.1 
PU.1 is an Ets family transcription factor which is essential for both myeloid and 
lymphoid progenitors (Scott et al. 1994; McKercher et al. 1996). PU.1-/- MPPs, which are 
reduced in mutant mice, show reduced expression of Flt3 and Il7ra (encodes the IL-7 
receptor α-chain) genes, both of which encode cell surface cytokine receptors required 
for B cell differentiation and survival (DeKoter et al. 2002). In fact, PU.1-/- MPPs fail to 
respond to IL-7 and enforced expression of Il7ra can partially rescue the blockade of 
PU.1-/- cells (DeKoter et al. 2002). Thus PU.1 is one of the earliest TF required for B cell 
fate determination. 
 
E2A 
The E2A gene encodes the E12 and E47 proteins which are two helix-loop-helix 
transcription factors generated by alternative splicing. Loss of E2A shows marked defects 
in B cell differentiation at the pro-B cell stage (Bain et al. 1994; Sun 1994; Zhuang et al. 
1994). In E2A inactivated pro-B cells, expression of genes encoding EBF, Pax5, Igα and 
germline transcription from the IgH locus, which are all discussed later, is absent and no 
IgH recombination takes place. Over-expression of EBF1 in E2A deficient HSCs can 
rescue B cell differentiation in vitro, although these pro B cells fail to proliferate in 
response to IL-7 (Bain et al. 1994; Seet et al. 2004). 
 
EBF1 
EBF1 is a TF that binds DNA through an N-terminal domain containing a novel zinc-
coordination motif (Hagman et al. 1995). EBF1 contains a putative helix-loop-helix 
domain which is required for its homodimerization and functions (Hagman and Lukin 
2005). Ablation of EBF1 in mice blocks B cell differentiation at the pro-B cell stage, 
similar to the defect in E2A mutant mice; EBF1-/- pro-B cells fail to express genes 
essential for the B cell commitment including mb-1 (encoding Igα), B29 (Igβ), Igll1 (λ5), 
VpreB1 and Pax5 although E2a is normally expressed (Lin and Grosschedl 1995). 
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Importantly, enforced expression of neither the upstream factor E2A nor the downstream 
target Pax5 (discussed later) can restore the defects in EBF1-/- pro-B cells; this indicates 
that EBF1 is essential to activate the B cell gene program independently of Pax5 (Seet et 
al. 2004). Similar to the defect observed in E2A mutant mice, Ebf1-/- pro-B cells lack IgH 
recombination (Lin and Grosschedl 1995). Ectopic expression of either EBF1 or E2A 
together with RAG1 or RAG2 in non-lymphoid cells can induce D-J rearrangement of the 
IgH gene but no V-DJ recombination (Romanow et al. 2000).  
 
Pax5 
Pax5 is a paired homeodomain protein that is expressed throughout B cell differentiation 
(Fuxa et al. 2004). Pax5 was first identified as a transcription factor binding to the IgH 
and Igk gene loci (Weaver and Baltimore 1987). Independently, the B cell–specific 
activator protein (BSAP), which turned out to be encoded by Pax5, was shown to activate 
the expression of CD19, an absolutely required factor to commit and maintain the B cell 
identity (Kozmik et al. 1992; Liao et al. 1994). Pax5 expression is under the control of 
EBF1, observed throughout B cell development and repressed when B cells terminally 
differentiate to plasma cells (Cobaleda et al. 2007). Loss of Pax5 completely blocks B 
cell development at the pro-B cell stage (B220+ c-kit+), when B cells are not yet fully 
committed; thereby Pax5-/- pro-B cells maintain multipotency and can give rise to several 
other lineages such as T, NK and myeloid cells (Nutt et al. 1999; Rolink et al. 1999). 
Moreover, conditional Pax5 deletion in mature B cells allows committed B cells to 
dedifferentiate in vivo back to early uncommitted progenitors, which can give rise to T 
cells in the thymus (Cobaleda et al. 2007). These results indicate that, although PU.1, 
E2A and EBF1 are crucial for the formation of pro-B cells and their specification, Pax5 is 
essential to fully commit to the B cell lineage and maintain cellular identity throughout 
B-cell ontogeny. 
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1.3.2.1 Mechanisms to create an antibody 
repertoire 
 
The principal role of B cell in the immune 
system is to generate antibodies against a 
wide range of pathogens encountered during 
the lifetime of the organism (Fig. 13). In order 
to achieve this goal, B cells must undergo the 
process rearranging the large parts of 
chromosome encoding the immunoglobulin 
heavy and light chain genes (IgH and IgL, 
respectively), whose translated products 
associate and function as an antibody. This 
assembly of gene segments in IgH and IgL 
includes the cleavage of specific DNA 
sequences by Recombination Activating Gene 
1 and 2 (RAG1/2), which introduces DNA double-strand breaks (DSBs) and re-ligation 
of breaks by the DNA DSBs repair, which is mainly done by non-homologous end 
joining pathway (NHEJ). IgH and IgL recombination takes place independently and 
sequentially, allowing a combinational assembly of antibodies. Mature B cells harboring 
successfully recombined IgH and IgL express IgM, a tetramer structure of two heavy 
chain and two light chain molecules, and its splice variant IgD on their cell surface. 
Together with their associated partners, two heterodimers of Igα and Igβ, these cell 
surface antibodies form the B cell receptor (BCR).  
Once B cells encounter a foreign antigen, they expand their antibody repertoire by two 
processes called Class Switch Recombination (CSR) and Somatic Hyper-Mutation 
(SHM). CSR is a secondary DNA rearrangement in the constant region of the IgH locus 
whereby the μ constant region can be replaced by other C regions with other effector 
functions. SHM is the process by which mutations are introduced in the DNA both in the 
IgH and IgL variable regions allowing the generation of higher affinity antibodies. 
Figure 13. A schematic representation 
of an immunoglobulin molecule. The constant 
regions are depicted in blue, and the variable 
regions are shown in red. The two antigen 
binding sites are at the top of the variable 
regions. Two of heavy chains and light chains 
are connected disulfide bonds. 
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The adaptive immunity using diverse specificity of antibodies is extremely important and 
efficient in vertebrates to fight infections; yet, at the same time, the process of 
reassembling chromosome segments and mutating the DNA can potentially be very 
harmful to cells if it eacapes the proper control. In fact, c.a. 95% of lymphomas are of B 
cell origin and a majority of them contain reciprocal chromosomal translocations 
involving one of the Ig loci and a proto-oncogene such as BCL6 and ABL.  
 
 
1.3.2.2. Check points of Ig recombination during B cell maturation 
 
The murine IgH locus spans approximately 3 Mb and comprises 150 or more variable 
(VH), 12 diversity (DH) and 4 joining (JH) gene segments followed by 8 genes encoding 
the different constant (CH) regions (Fig. 14) (Jung and Alt 2004; Jung et al. 2006). The 
first recombination event in immunoglobulin genes takes place in the IgH locus from the 
CLP cell up to the pro-B cell stage before full commitment to the B cell lineage (these 
cells do not yet express the transcription factor Pax5, which ensures and maintains the B 
cell identity (Cobaleda et al. 2007)), and starts with DH to JH (DJ) rearrangement. At the 
subsequent pre-BI developmental stage, the locus undergoes VH to DJH rearrangement. 
While DJH recombination takes place on both alleles concomitantly, VH to DJH 
recombination occurs on one allele at a time with the second allele not being processed 
once a locus has been successfully rearranged. B cells harboring a rearranged allele start 
to express the IgH gene at the large pre-BII cell stage, whose translated product is called 
μ heavy chain. μ heavy chain forms the protein complex, pre-BCR, on a cell surface that 
contains two of μ heavy chains, surrogate light chains and two heterodimers of Igα and β 
proteins. A surrogate light chain comprises a pair of VpreB and λ5 proteins that are close 
similarity to IgL protein. Once large pre-BII cells expose pre-BCR on their cell surface, it 
receive signal that leads to enforce cessation of further recombination of the second IgH 
allele, which is the process called allelic exclusion, enhance proliferation of cells, repress 
gene expression of surrogate light chains and RAG1/2, and move to next developmental 
stage small pre-BII where the IgL rearrangement takes place. Two gene loci encode the 
immunoglobulin light chain; κ and λ genes. The murine Igκ locus spans over 3 Mb 
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including about 120 Vκ gene segments and five Jκ gene segments, one of which is a 
pseudogene, whereas the Vλ and Jλ segments of the λ gene are spread over approximately 
230 kb. The rearrangement of light chain loci takes place only between V to J segments; 
therefore it is referred as VJL recombination. In human and mouse, one allele of κ gene 
tends to be rearranged prior to λ gene rearrangement. As is the case for IgH 
recombination, a further rearrangement is prevented once B cell completes the IgL 
rearrangement and generates a functional light chain. After successful recombination on 
IgH and IgL loci, B cell starts to express IgM on their cell surface. Since each B cell 
contains and expresses only one allele of rearranged IgH and IgL, each B cell produces 
one form of IgM and exposed on a cell surface. This B cell clonal specificity of antibody 
production ensures that all the antibodies secreted by the activated B cells are specific for 
the antigen that stimulates its activation. This is a cardinal feature of adaptive immunity 
by B cells that prevents secretion of non-specific antibodies, which might potentially be 
harmful to the organism.  
The completion of Ig recombination in the bone marrow allows B cells to further develop 
to the immature B cell stage where they face to an additional challenge to pass the quality 
control of antibodies. Immature B cells express IgM on their cell surface and these 
antibodies are tested whether they can recognize self-cell surface molecules and soluble 
self molecules. When developing immature B cells express IgM that recognize self-cell 
surface molecules such as those of MHC molecules, they are deleted by apoptosis 
through BCR stimulation, a process called clonal deletion. On the other hand, when cells 
Figure 14. Genomic organization of the IgH locus (not drawn to scale) (taken from (Jung et 
al. 2006)). The VH81X, DFL16.1, and DQ52 gene segments are highlighted in yellow. 15 V gene 
families are depicted in blue. The most distal VH genes are the VHJ558 gene family, whereas the 
most proximal is the VH7183 family. D, J and C indicate each gene segments. iEμ is the intronic 
enhancer and 3’RR is the 3’ regulatory region. Distances shown are from the murine 129 strain and 
vary between strains 
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encounter and bind to soluble self antigens, they are rendered unresponsive to the antigen 
(anergic), move to the periphery, and express more IgD molecules than IgM on their cell 
surface. Since these cells are not able to respond to the antigens, in the periphery they can 
not proliferate following BCR stimulation, therefore this anegic B cell population is 
rapidly lost after its maturation. Once B cells pass through this quality control process at 
the immature B cell stage in the bone marrow, they move to a peripheral lymphoid organ, 
spleen, to further maturate, and then they start to express IgD on their cell surface. There 
is the process called the receptor editing that occurs after generation of both an 
unproductive rearrangement during V(D)J recombination and self-reactive IgM. These 
non-functional or self-reactive Ig genes can be further rearranged using a different V 
gene segments. In this way, B cells can change their antibodiy specificities wich are 
functional/productive and non-self reavctive. 
The last step of immunoglobulin gene rearrangement, the CSR and the SHM, takes place 
in cells that meet the specific foreign antigen recognized by their own cell surface 
antibodies (Fig. 15). These two processes are linked to the formation of specialized 
microenvironment, the germinal center (GC), in secondary lymphoid organs. B cells 
encountering antigens are activated in the GC as a result of their interaction with CD4+ T 
cells and antigen-presenting cells (MacLennan 1994). Activated B cells undergo the 
clonal expansion step which is one of the fastest cell division process in a mammalian 
body (c.a. 6 hour / division). These cells differentiate into centroblasts and start the 
process of SHM that introduces base-pair changes into the rearranged V(D)J region of 
IgH and IgL genes (Klein and Dalla-Favera 2008). Both V(D)J regions of IgH and IgL 
encode the immunoglobulin variable region (IgV); therefore some of these base-pair 
mutations lead to a change in the amino-acid sequence and may increase the affinity of 
the antibody against its antigen. Centroblasts then give rise to centrocytes and move to 
the light zone in the GC, where the mutated/modified antibody is selected for improved 
binding to the antigen. Newly generated centrocytes that produce high affinity antibodies 
can escape from undergoing apoptosis, whereas centrocytes with low affinity antibodies 
are removed. A portion of centrocytes undergoes immunoglobulin heavy chain CSR, by 
which B cells can switch their immunoglobulin expression from IgM and IgD to other 
classes that have distinct effector functions such as IgG, IgA and IgE (Chaudhuri et al. 
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2007; Muramatsu et al. 2007). There are 8 different constant gene segments in the mouse 
genome, which encode the constant regions of the different immunoglobulin isotypes. 
CSR recombines between the Cμ sequence to one of the downstream C genes, and then 
the intervening DNA segment is looped-out as a circular DNA. Successful CSR allows 
centrocytes to terminally differentiate towards antigen-secreting cells, plasma cells. Both 
SHM and CSR are initiated by the enzyme called AID encoded by the Activation Induced 
cytidine Deaminase gene. AID can initiate both processes by deamination of cytosine to 
uracil in the target DNA which results in both the DNA mutations and the cleavage of 
DNA (Peled et al. 2008). 
 
Figure 15. A simplified schematic drawing of the 3 main steps of immunoglobulin heavy 
chain modifications. The variable (V), diversity (D), joining (J) and constant (C) gene segments are 
represented as boxes. Yellow stars indicate the DNA mutation introduced by the somatic 
hypermutation. Class switching to the Cε, which encodes the exons of IgE, is shown as an example. 
RAG enzymes are absolutely required for V(D)J recombination, whereas somatic hypermutation and 
class switch recombination are initiated by AID. 
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1.3.3 Regulation of V(D)J recombination in the IgH locus 
1.3.3.1 cis-DNA elements  
 
Recombination of the Ig loci is tightly controlled by different layers of regulatory 
mechanisms that ensure the Ig recombination takes place specifically in the lymphocyte 
lineage, at appropriate developmental stages, and on the specific loci/regions that must be 
recombined. Here I discuss the several different types of regulation occurring during IgH 
recombination. 
The first line of regulation is governed by cis-regulatory DNA elements on the Ig loci, the 
recombination signal sequences (RSSs). RSSs include one pair of conserved heptamer 
and nonamer sequences, spaced by a relatively non-conserved sequence of either 12 or 23 
bp, called 12 RSS and 23 RSS, respectively. Both types of sequences can be recognized 
by RAG proteins, which initiate V(D)J recombination by cleaving the DNA to introduce 
DNA DSBs. VH and JH gene segments are flanked by 23 RSSs, whereas DH segments are 
flanked by 12 RSSs (Fig. 16). V(D)J recombination occurs almost exclusively between 
two signals with spacers of different lengths. This restriction, called the 12/23 rule, is 
mediated at the level of RAG1/2 recognition and DNA cutting (Eastman et al. 1996; van 
Gent et al. 1996), therefore the reassembly of Ig genes takes place in a sequential manner 
(D-J first and V-DJ later) and unidirectionally. 
Figure 16. The 12/23 rules at the immunoglobulin heavy chain. The variable 
(V), diversity (D) and joining (J) segments are indicated as boxes together with 
associated RSSs. 
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1.3.3.2 Tissue- and temporally- restricted expression of required factors  
 
The Second regulatory process is governed by the tissue- and temporally- restricted 
expression of essential factors, RAG1 and RAG2. RAG1/2 are co-expressed in distinct 
specific developmental stages of lymphoid cells: first in early progenitor- to pre-BI cells, 
and later again in small pre-BII and immature stages (Oettinger 2004). In the first stage, 
early progenitor cells such as CLP carry out D-to-J and, at pre-BI cell stage, V-to-DJ 
rearrangement, respectively. Successful assembly of pre-BCR transmits the signal to shut 
down RAG expression. Later on B cells re-express RAG genes at the small pre-BII stage 
to initiate recombination of the IgL locus. In addition to transcriptional regulation, the 
level of RAG2 proteins is controlled by ubiquitylation-mediated degradation coupled 
with cell cycle progression. V(D)J recombination occurs in the G1 phase of the cell cycle 
since in mammalian cells the NHEJ pathway predominates during the G1 and early S 
phases (Jiang et al. 2005). Thus the level of transcription and the stability of RAG 
proteins ensures the initiation of V(D)J recombination only at the specific time and in the 
lymphocyte lineage. 
 
 
1.3.3.2 Accessibility control of the Ig loci  
 
The tissue- and temporally- restricted expression of RAG1/2 are not enough to account 
for the restrictions of V(D)J recombination in lymphocytes. During normal development, 
recombination takes place only in lymphoid cells due to the absence of the RAG proteins 
in other tissues. However, when RAG genes are ectopically expressed in other cell types 
such as fibroblasts, the endogenous Ig loci remain in germline 
configuration/unrearranged, even though artificial recombination substrates that are either 
episomal or integrated into the genome can be recombined (Schatz et al. 1992). 
Furthermore, the temporally regulated order of recombination at Ig loci is strictly 
maintained during normal B cell development as IgL recombination follows successful 
recombination of the IgH locus. With regards to the 12/23 rule, it could potentially 
happen that V(D)J recombination starts rearranging the DH segments to VH segments, 
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however this does not take place during normal B cell development. Therefore an 
additional layer of regulation is clearly required to explain these observations. Pioneer 
studies described a correlation between transcription of unrearranged V, D and J gene 
segments “germline transcription” and the onset of rearrangement at those same sites 
(Yancopoulos and Alt 1985). Analysis of the regulatory elements of the IgH locus 
identified multiple control elements: V segments all contain a promoter and a strong B-
cell specific enhancer, iEμ, is found in the large intron upstream of Cμ (see Fig. 14). 
Furthermore the D and J segments also carry promoters that control expression of the 
germline transcripts. Experiments with transgenic substrates and targeted deletions have 
revealed that the iEμ and promoter elements control the locus accessibility of the 
different regions of the Ig locus during B cell development, accompanied with germline 
transcription. Thus germline transcripts  might be the by-products of local 
open/accessible chromatin conformation (Oettinger 2004). However it may also be that 
the germline transcripts are necessary to open up the chromatin. Recent analysis of 
chromatin modifications and its structural changes have further elucidated the molecular 
mechanisms of the locus accessibility control. Germline transcripts are well associated 
with local histone acetylation and methylation on H3K4, which are the hallmark of open 
conformational chromatin structures (Kwon et al. 2000; Chowdhury and Sen 2001; 
Johnson et al. 2003; Sen and Oltz 2006). In early B cell stage during which DH-JH 
recombination occurs, histones associated with DH and JH segments become acetylated, 
thereby transcriptional machinery can access the locus to start gene expression and at the 
same time the recombinase machinery can also initiate the rearrangement process. On the 
other hand, VH segments as well as the whole IgL genes remain hypoacetylated (i.e. are 
not transcriptionally active), preventing access by the recombinase machinery and 
precocious rearrangement. Activation and hyper acetylation of VH segments is observed 
during the subsequent VH-DJH recombination at the pre-BI cell stage, which is under the 
control of IL-7 signaling via the transcription factors, STAT5a/b (Bertolino et al. 2005). 
Thus regulation by the level of chromatin modifications in the Ig loci ensures an 
additional layer of mechanisms that controls the accessibility of the recombinase 
machinery on the Ig loci (Fig. 17). 
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1.3.3.3 Nuclear positioning and contraction of the Ig loci 
 
In non-B lineage cells, the IgH and IgL loci are positioned at close proximity to the 
nuclear periphery and have a highly condensed form of chromatin with high H3K9 
methylation. In the B cell lineage, during the process of IgH recombination concomitant 
with B cell development, the IgH loci become accessible as evidenced by local increases 
in histone acetylation and coincidental relocation to the center of the nucleus (Kosak et al. 
2002; Bertolino et al. 2005). This deassociation from the nuclear periphery occurs 
coincidentaly with V-(D)J recombination as well as an increased accessibility in the VH 
segments, namely at distal VH segments, thereby it is proposed that this relocalization to 
the center of the nucleus might be  important for the control of distal V segments 
accessibility. At the same time, the IgH locus undergoes a large scale conformational 
change of chromatin, IgH locus contraction. “Contraction” of the IgH locus brings distal 
VH segments closer to the already recombined DJH segments, thereby enabling V(D)J 
recombination of distal VH segments such as VHJ558 family genes (Fuxa et al. 2004; 
Roldan et al. 2005; Sayegh et al. 2005). Once an allele has successfully completed its 
V(D)J recombination, the second allele, which has not proceeded to V-DJ recombination 
yet, reverses the contraction (decontraction) and moves to the pericentromeric 
heterochromatin. This re-localization of the second unrearranged IgH locus is proposed to 
induce the heterochromatinization in the locus by the association with pericentromeric 
heterochromatin, based on the fact that the allelic exclusion in Igk locus utilizes this 
mechanism (Goldmit et al. 2005). Both re-localization and decontraction processes are 
thought to ensure the allelic exclusion as well as preventing further recombination of the 
IgH locus (Fig. 17).  
With the similar degree to the locus accessibility control, all these processes, which 
change the higher order of chromatin structure and the sub-nuclear localization of the IgH 
locus, are closely linked to the modifications of histones that are proposed to have a 
critical impact on them (Luger and Hansen 2005; Hansen 2006). In fact, Ig locus 
contraction is observed at the time which B cells show histone hyper-acetylation on the 
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distal VH segments. However in details of mechanisms, functions of acetylation and 
required factors for Ig locus contraction remain to be explored. 
 
 
Figure 17. Simplified scheme of IgH nuclear positioning and histone modifications (modified from 
(Bergman and Cedar 2004; Sen 2005)). Typical positioning of two alleles of IgH genes in the B cell 
nucleus are drawn in the left side. Patterns of histone acetylation and H3K9me2 in the left, and H3K36me2 
and H3K27me3 in the right are shown. Note that histone acetylation and H3K9me2 modifications in the 
IgH locus have not yet been revealed in the high resolution such as a ChIP-seq or ChIP-on-chip 
experiment, so that the relative enrichments of them were examined by the sequence specific primers in 
particular regions. H3K36me2 and H3K27me3 are examined by ChIP-on-chip experiments (Xu et al. 
2008). Pax5-/- B cells lack IgH contraction, enrich H3K9me2 at distal VH segments, and reduce H3K36me3 
at proximal VH segments whereas levels of acetylation and H3K36me2 are largely unchanged (Fuxa et al. 
2004). 
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1.3.3.4 Factors required for IgH locus contraction 
 
Many factors have been identified to be required for early B cell development, however 
so far only two of them are known to be involved in the process of IgH contraction: Pax5 
and YY1 (Busslinger 2004; Matthias and Rolink 2005; Cobaleda et al. 2007; Nutt and 
Kee 2007). 
Pax5-/- pro-B cells (B220+ c-kit+) exhibit a profound defect of IgH recombination on 
distal VH segments, whereas almost no defect is seen on D-JH or proximal VH 
recombination. Three-dimensional DNA fluorescence in situ hybridization (3D-FISH) 
experiments revealed that Pax5-/- pro-B cells can not contract the IgH locus to facilitate 
the recombination of distal VH segments (Fuxa et al. 2004). Since Pax5 functions both as 
a gene activator and repressor, many genes crucial for B cell development are under 
control of Pax5 proteins. However, none of the genes known to control V(D)J 
recombination were deregulated in the Pax5 mutant cells such as RAG1/2, EBF1 and E2A 
(Fuxa et al. 2004). Recent reports have shed some light on the molecular mechanisms of 
Pax5’s roles in IgH contraction. In the absence of Pax5, distal VH segments are accessible 
and hyper-acetylated, however at the same time an accumulation of the 
inactive/condensed histone mark H3K9 methylation is observced. Ectopic expression of 
Pax5 in non-B cell lineage induces the removal of H3K9 methylation on the IgH locus 
even though normally this locus is highly enriched with H3K9 methylation in non-B cells 
(Johnson et al. 2004). Another report suggested that Pax5 binds to the coding regions of 
human and mouse both distal and proximal, with the higher affinity, VH gene segments in 
vivo and in vitro, and then interacts with the RAG protein complex to enhance the RAG 
mediated cleavage of V gene segments (Zhang et al. 2006).  
 
Ying Yang 1 (YY1), a zinc finger containing transcription factor expressed ubiquitously, 
functions as a transcriptional activator, repressor, transcription-initiator element-binding 
protein, and is also a part of the polycomb Group protein complex depending on the 
promoter context. Loss of YY1 in the B cell lineage shows severe defects in B cell 
development and distal VH recombination without changing the expression of known 
genes important for V(D)J recombination (Liu et al. 2007). 3D-FISH analysis showed 
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that B cells lacking YY1 exhibit a similar degree of IgH locus contraction defect as 
described in Pax5 mutant mice. YY1 was shown to bind to the IgH intronic enhancer 
(iEμ) whose function is known to be crucial for V(D)J recombination (Sakai et al. 1999; 
Perlot et al. 2005). 
So far only a very limited knowledge is available about the IgH locus contraction 
phenomenon so that the molecular mechanisms as well as additional factors involved 
remain largely unexplored. 
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Abstract 
The development of mature B lymphocytes from multipotent progenitors is a tightly 
regulated process whose integrity is ensured at several checkpoints. One of these is the 
recombination of the immunoglobulin heavy chain (IgH) locus leading to the production 
of the mu heavy chain. This site-specific DNA recombination is controlled by multiple 
regulatory components including cis-acting DNA elements, specific expression of the 
required factors, accessibility of the locus, chromosome sub-nuclear positioning and 
locus contraction. Here we show that the histone modifying enzymes, histone deacetylase 
(HDAC) 1 and 2, are essential for early B cell development and IgH recombination. 
Combined loss of both proteins causes a very strong block in early B cell development 
accompanied by severe defects in the recombination of IgH variable (VH) segments. 
Using three-dimensional DNA fluorescence in situ hybridization, we show that this 
defect is due to the lack of IgH locus contraction. Analysis of histone modification 
revealed that pre-BI cells lacking HDAC1 and 2 show histone hyperacetylation as well as 
increased histone lysine 9 methylation. Taken together, we conclude that HDAC1 and 2 
are crucial factors for B cell development and IgH recombination by modulating histone 
modifications which may affect the higher order of chromatin structure. 
 
Introduction 
The development of B lymphocytes from progenitor cells is a tightly controlled, yet 
flexible, process under the control of a number of lineage-specific or ubiquitous 
transcription factors which initiate, maintain and restrict specific sets of gene expression 
patterns required for B cell identity (Matthias and Rolink 2005; Cobaleda et al. 2007; 
Fuxa and Skok 2007). Recent gene targeting studies in mice have identified several 
factors that are essential for B cell development and whose loss leads to a developmental 
block at specific stages thought to be checkpoints for B cell development. During 
development, B cells must undergo the sequential rearrangement of immunoglobulin 
heavy (IgH) and light (IgL) chain gene loci to produce an almost infinite diversity of 
antigen receptors. Only cells harboring productively rearranged antigen receptors are able 
to proliferate and complete their maturation.  
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The murine IgH locus spans approximately 3 Mb and comprises 150 or more variable 
(VH), 12 diversity (DH) and 4 joining (JH) gene segments followed by 8 genes encoding 
the different constant (CH) regions (Jung and Alt 2004; Jung et al. 2006). The first 
recombination event takes place at the pro-B cell stage, before full commitment to the B 
cell lineage (these cells do not yet express the surface marker CD19), and starts with DH 
to JH (DJ) rearrangement. At the subsequent pre-BI developmental stage, the locus 
undergoes VH to DJH rearrangement. While DJH recombination takes place on both 
alleles, VH to DJH recombination occurs on one allele at a time with the second allele not 
being processed once a locus has been successfully rearranged. At a later developmental 
stage, the Ig light chain is similarly rearranged by bringing VL and JL segments together 
in order to ultimately produce a functional Ig molecule. Because of the multiple Ig loci 
involved and the stochastic nature of the process, V(D)J recombination needs to be under 
a sophisticated control mechanism. This includes a multitude of cis-acting DNA elements, 
lineage-specific and temporally-restricted expression of the required factors such as the 
recombinases, control of locus accessibility at the level of chromatin and intranuclear 
locus repositioning and contraction (Kosak et al. 2002; Jung et al. 2006; Sen and Oltz 
2006). 
In non-B lineage cells, the IgH and IgL loci are positioned at close proximity to the 
nuclear periphery and preserved from recombination. In the B cell lineage, during the 
process of IgH recombination concomitant with B cell development, the IgH locus 
becomes accessible as evidenced by local increases in histone acetylation and relocation 
to the center of the nucleus (Kosak et al. 2002). “Contraction” of the IgH locus brings 
distal VH segments closer to the already recombined DJH segments, thereby facilitating 
V(D)J recombination (Fuxa et al. 2004; Roldan et al. 2005; Sayegh et al. 2005). All these 
processes, which change the higher order of chromatin structure and the sub-nuclear 
localization of the IgH locus, are closely linked to the post-translational modifications of 
histones that are proposed to have a critical impact on them (Luger and Hansen 2005; 
Hansen 2006). For example, increased accessibility of the IgH locus is well correlated to 
hyperacetylation of histones and inversely to histone lysine 9 methylation (Kwon et al. 
2000; Chowdhury and Sen 2001; Johnson et al. 2003; Johnson et al. 2004).  
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Histone deacetylases (HDACs) are enzymes that catalyze the deacetylation of acetylated 
lysine residues of histones as well as of an increasing number of other proteins. In 
mammals, there are 18 HDACs identified that can be grouped into three classes (Yang 
and Seto 2008). The class I enzymes HDAC1 and 2 are the closest homologs of yeast 
Rpd3 which is the main HDAC regulating the global level of histone acetylation in yeast 
(Kurdistani et al. 2002). In mammals, HDAC1 and 2 are highly related proteins, 
predominantly localized in the nucleus and expressed in a wide range of tissues and cell 
types. HDAC1 and 2 have been identified as components of three different repressive 
complexes; the Sin3, NuRD and Co-REST complexes which are recruited to various 
genes (Yang and Seto 2008). Gene targeting studies of HDAC1 have demonstrated that 
this protein is essential for early embryogenesis, possibly due to its role in cell 
proliferation (Lagger et al. 2002). Furthermore, HDAC1 null ES cells exhibit a 
proliferation defect, in part caused by upregulation of the cell cycle inhibitor p21 which 
was found to be a direct target of HDAC1 (Lagger et al. 2002; Lagger et al. 2003). In 
contrast, recently published HDAC2 deficient mice are viable during embryogenesis and 
show partial or complete perinatal lethality depending on the allele (Montgomery et al. 
2007; Trivedi et al. 2007; Zimmermann et al. 2007), demonstrating that these two 
proteins are only partly redundant. A conditional knockout study of HDAC1 and 2 in 
cardiomyocytes revealed the importance of these two proteins for myocardial growth, 
morphogenesis, and contractility (Montgomery et al. 2007). In spite of these recent 
studies, the physiological function of HDAC1 and 2 remains largely unexplored and their 
role in the lymphoid system is not known. 
 
Here we have examined the role of HDAC1 and 2 in B cell development. For this we 
have generated mice conditionally targeted at the HDAC1 and 2 gene and eliminated 
these enzymes specifically in the B cell lineage by intercrossing with mb1-cre mice to 
induce the deletion from the pre-BI stage onwards. We find that in the absence of either 
of these two proteins B cell development proceeds normally. In contrast, elimination of 
both enzymes simultaneously leads to a complete absence of B cells from the periphery. 
We show that this is the result of a severe developmental block in the bone marrow that 
comprises two steps. While pre-BII cells exhibit massive apoptosis, pre-BI cells are fully 
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viable. However, these cells show a severe impairment in V(D)J recombination, 
associated with a failure of the IgH locus to contract. Furthermore, we show that these 
cells have elevated acetylation of histone H4, but also aberrant other histone 
modifications such as an increased level of methylated H3K9. These data identify 
HDAC1 and 2 as critical novel regulators of B cell development and suggest that histone 
modifications control IgH recombination by altering the higher order of chromatin 
structure.   
 
 
  56
Results 
Generation of HDAC1 and 2 conditional knockout mice 
To explore the functions of HDAC1 and HDAC2 in B cell development, we generated 
conditional HDAC1 and 2 alleles in which exon 6 of either gene is flanked by loxP sites 
(Supplemental Fig. 1). This exon is identical in the two genes and encodes three amino 
acids which have been shown to be essential for the deacetylase activity of HDAC1 
(Hassig et al. 1998). Flox alleles of HDAC1 and HDAC2 produce normal amounts of 
each protein, and both homozygous mice appear to be indistinguishable from their wild 
type (WT) littermates (data not shown). Before analyzing the function of HDAC1 and 2 
in B lymphocytes, we first generated complete knockout (KO) mice by crossing HDAC1 
or 2 flox mice with mice expressing Cre recombinase under the control of a germline 
specific promoter. The offspring obtained allowed us to derive homozygous knockout 
mice by intercrossing. We analyzed these HDAC1-/- mice and confirmed a previous report 
that HDAC1 inactivation leads to embryonic lethality before E10.5 (Lagger et al. 2002) 
(data not shown). In contrast, HDAC2-/- mice show partial (ca. 50%) perinatal lethality, 
with the rest of the mice being smaller than their WT littermates (Supplemental Fig. 2). 
Thus, the phenotype of our HDAC2-/- strain resembles that of another recently reported 
HDAC2 deficient mouse allele (Trivedi et al. 2007; Zimmermann et al. 2007). 
 
B cell-specific elimination of HDAC1 or 2 does not impair B cell development 
We first examined the expression of HDAC1 and 2 during B cell development using a 
quantitative real time PCR assay and RNA isolated from different stages of B cell 
development. Cell surface markers and developmental events defining each B cell stages 
are drawn in Figure 18A. As shown in Figure 18B both enzymes are expressed 
throughout B cell development, but HDAC1 expression moderately increases during B 
cell maturation; in contrast, HDAC2 shows the highest expression in the pro-B/pre-BI 
fraction and then exhibits a gradual decrease up to the mature B cell stage. To inactivate 
the function of HDAC1 and 2 in the B cell lineage, we used the mb1-cre transgenic 
mouse line (Hobeika et al. 2006) which starts to express cre in pre-BI cells, at the 
beginning of B cell commitment. First, we analyzed the efficiency of flox allele deletion 
by a genotyping PCR. For this, DNA was isolated from mice heterozygous for both the 
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HDAC1 and 2 flox alleles and also carrying the mb1-cre gene (HDAC1/2F/+ + mb1-cre). 
With this assay we did not detect deleted alleles (Δ) of either HDAC1 or 2 in a sorted 
bone marrow progenitor population lacking committed B cells (B220+ CD19-), whereas 
no flox (i.e. unrecombined) alleles of either gene were seen in the B cell-committed pre-
BI cell population (B220+ CD19+ CD43+ CD25-, Fig. 18C). This indicates that the 
recombination of the HDAC1 and 2 loci is highly efficient and takes place already at the 
pre-BI stage. We also analyzed by western blotting the levels of HDAC1 and 2 proteins 
in splenic mature B cells using samples from mice homozygous for the flox allele 
(HDAC1F/F or HDAC2F/F) and carrying mb1-cre. As presented in Figure 18D, both 
proteins were below detection in these mice, and no truncated form of HDAC1 or 2 was 
observed (not shown). Together, these results confirm the successful inactivation of 
HDAC1 and 2 in the B cell lineage. These mice were next analyzed by flow cytometry 
(FACS) to determine the effect of ablating HDAC1 or 2 in B cells. For this, a series of 
antibodies were used to distinguish specific stages of B cell development. HDAC1F/F + 
mb1-cre as well as HDAC2F/F + mb1-cre mice have all the B cell developmental stages 
normally represented in the bone marrow and also normal numbers of B cells in the 
spleen (see Supplemental Fig. 3). Thus, individually HDAC1 and 2 appear to be 
dispensable for normal B cell development. 
 
Ablation of both HDAC1 and 2 blocks early B cell development  
The observations presented above suggest that HDAC1 and 2 might be redundant or 
compensate for each other in B cells; therefore, we set out to eliminate both enzymes 
simultaneously. Mice were generated that are homozygously floxed at both genes and 
also carry the mb1-cre transgene (HDAC1/2F/F + mb1-cre); for the analyses, littermates 
lacking the cre transgene were usually used as controls. As shown in Figure 19A, the 
spleen of mice lacking both HDAC1 and 2 is virtually empty of mature B cells that were 
identified here by expression of the marker B220 in combination with IgM. In the bone 
marrow, where developing B cells are generated, the stages of B cell differentiation were 
detected by staining cells with B220 in combination with c-kit or CD43 (pro-B / pre-BI 
cells), CD19 (committed B cells), CD25 (pre-BII cells) or IgM (immature and mature B 
cells). As is evident from the dot plots presented, absence of HDAC1 and 2 leads to a 
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severe developmental block, as early as the pre-BI stage. Accordingly, the number of 
committed B cells (i.e. positive for CD19) is dramatically reduced, as well as all 
subsequent stages. The absolute numbers, obtained from several similar experiments, are 
presented in Figure 19B and C: B220+ CD19- cells, representing the progenitor 
compartment lacking committed B cells and which have not yet recombined the flox 
allele, are present in normal numbers. In contrast, pre-BI cells are reduced about 5 fold in 
the absence of HDAC1 and 2, and pre-BII cells are reduced more than 100 fold. Thus, 
normal progression through early B cell development strictly requires the presence of 
HDAC1 or 2.  
 
Pre-BI cells lacking HDAC1 and 2 show normal cell cycle and apoptosis 
Work done largely in cancer cell lines with HDAC inhibitors has implicated HDACs in 
the control of cell cycle as well as apoptosis (Yoshida et al. 1987; Minucci and Pelicci 
2006). We therefore examined these aspects in the pre-B cells of HDAC1/2F/F + mb1-cre 
mice by in vivo 5-bromo-2-deoxyuridine (BrdU) incorporation assays. For this, BrdU was 
injected intraperitonealy to label cycling cells and pre-BI cells were purified. Total DNA 
and incorporated BrdU were stained and the cell cycle profile was determined by FACS 
analysis. As shown in Figure 20A, at the pre-BI cell stage, the cell cycle profile of 
HDAC1/2F/F + mb1-cre mice was largely unchanged compared to that of control mice, 
although the G2/M and sub G1 populations were slightly, but significantly, altered (Fig. 
3A). In contrast, in pre-BII cells a cell cycle block was evident (data not shown). Next, 
apoptosis induction of pre-BI or pre-BII cells was measured by staining with AnnexinV 
which can bind to exposed phosphatidylserines of cells undergoing apoptosis. While no 
significant apoptosis was observed in the mutant pre-BI cells, a dramatic apoptosis 
increase was seen in cells of the next developmental stages, the large or small pre-BII 
cells (Fig. 20B). 
 
VH-DJH recombination is severely impaired in pre-BI cells lacking HDAC1 and 2 
Pre-BI cells correspond to the stage at which VH to DJH recombination takes place and 
we therefore considered the possibility that this process might be impaired in the absence 
of HDAC1 and 2. To analyze DNA recombination at the IgH locus we used a semi 
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quantitative PCR assay to amplifiy DNA fragments corresponding to alleles rearranged 
between the proximal VH7183, or the distal VHJ558, and the DJH segments (Fuxa et al. 
2004). As controls, a Cμ fragment, which does not rearrange, or a DH–JH segment, which 
rearranges prior to the deletion of HDAC1 and 2, were amplified (Fig. 21A). Using DNA 
from WT pre-BI cells, we were able to detect fragments from proximal or distal 
recombined alleles, as expected. In contrast, in DNA from mutant cells, distal VHJ558 
rearrangements could not be detected and proximal VH7183 rearrangements were reduced 
about 4 fold, while DH–JH amplification was not affected (Fig. 21B). The strong 
reduction in VH–DJH rearrangements was confirmed by measuring spliced μ mRNA 
transcripts initiating at the VHJ558 or VH7183 locus by RT-PCR and also by staining pre-
BI cells for the presence of intracellular μ protein. In each case a strong reduction of the 
signal was observed, indicating that the HDAC1/2 deficiency in pre-BI cells abrogates 
the distal VH-DJH and also has an impact on proximal VH-DJH recombination (Fig. 21C 
and D). These data suggest that the strong block of early B cell development in the 
absence of HDAC1 and 2 is due, at least in part, to the reduced number of cells harboring 
a successfully recombined IgH locus, which are therefore unable to present the pre-BCR 
on their cell surface for clonal expansion at the pre-BII stage. 
 
Combined loss of HDAC1 and 2 in pre-BI cells does not affect distal VHJ558 
germline transcripts 
Previous work has shown that V(D)J recombination correlates positively with 
accessibility of the Ig VH genes, which can be inferred from the presence of 
corresponding germline transcripts (Yancopoulos and Alt 1985). Distal VHJ558 germline 
transcripts are known to be regulated at the pre-BI cell stage by the transcription factor 
STAT5 under the control of IL-7R signaling, which leads to enhanced accessibility of 
distal VH regions and local histone hyperacetylation (Bertolino et al. 2005). To examine 
whether the defect caused by loss of HDAC1 and 2 may impinge on that process, we 
monitored the expression of distal VH germline transcripts. As shown in Figure 21E, the 
level of VHJ558 germline transcripts is not significantly reduced in mutant pre-BI cells 
compared to wild-type pre-BI cells (Fig. 21E). Thus, loss of HDAC1 and 2 is not crucial 
for the proper expression of VH germline transcripts, suggesting that IL-7R signaling is 
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normal in these mice. Moreover, other germline transcripts such as those originating in 
the Cμ locus are also normal in the absence of HDAC1 and 2. 
 
HDAC1 and 2 are essential for IgH contraction 
IgH recombination first takes place in non committed early B cell progenitors, starting 
with DH to JH recombination. At this stage, the distal VH segments are separated from the 
recombined DJH locus by a large distance, as the locus is extended. During the 
subsequent VH to DJH recombination taking place in committed pre-BI cells, the distal VH 
segments are brought in proximity of the DJ segment, a phenomenon called locus 
contraction (Kosak et al. 2002; Fuxa et al. 2004; Roldan et al. 2005; Sayegh et al. 2005). 
Importantly, mice lacking the transcription factor Pax5 or YY1 exhibit defects in distal 
VH recombination and also in IgH locus contraction (Fuxa et al. 2004; Liu et al. 2007).  
To assess whether lack of distal VH recombination in HDAC1 and 2 deficient pre-BI cells 
is due to impaired locus contraction, we performed three-color three-dimensional DNA 
fluorescence in situ hybridization (3D FISH) with DNA probes located in the distal 
VHJ558 family and in the IgH constant region, together with a γ-satellite probe marking 
pericentromeric heterochromatin (Fuxa et al. 2004; Liu et al. 2007; Hewitt et al. 2008). 
Pre-BI cells were sorted from HDAC1/2F/F + mb1-cre or control mice and used for 3D 
FISH experiments (Fig. 22A). IgH locus contraction was scored by measuring the 
distance separating the distal VH segments from the CH region; in addition, the proportion 
of cells showing mono- or bi-allelic recruitment of the IgH locus to pericentromeric 
heterochromatin was determined. As expected, in WT pre-BI cells the vast majority 
(88%) of the IgH alleles were fully contracted. In contrast, pre-BI cells lacking HDAC1 
and 2 only had 37% of the IgH alleles contracted, with another ca. 47% of the alleles in 
an intermediate configuration (Fig. 22B and Supplemental Table 1A). Furthermore, in 
WT pre-BI cells 37% of the cells showed monoallelic- and almost none biallelic- 
recruitment of the IgH locus to pericentromeric regions, in good agreement with previous 
results (Roldan et al. 2005). Strikingly, in the absence of HDAC1 and 2 pre-BI cells 
exhibited aberrant recruitment of the IgH locus: 48% of the cells have monoallelic and 
14% biallelic recruitment (Figure 22C and Supplemental Table 1B). Taken together, the 
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results of Figure 21 and 22 identify HDAC1 and 2 as novel essential factors for IgH 
contraction and recombination.  
 
Combined loss of HDAC1 and 2 does not affect mRNA accumulation of genes 
essential for early B cell development and IgH recombination  
To investigate the molecular mechanism by which HDAC1 and 2 regulate IgH 
recombination and contraction, we first examined the expression of transcription factors 
critical for early B cell development. E2A, EBF and Ikaros are known to regulate gene 
expression of factors essential for early B cell development (Bain et al. 1994; 
Georgopoulos et al. 1994; Sun 1994; Zhuang et al. 1994; Lin and Grosschedl 1995). As 
shown in Figure 23A, we detected comparable amount of transcripts of all these genes in 
HDAC1/2F/F + mb1-cre pre-BI cells compared to WT pre-BI cells. Pax5 and YY1 are 
transcription factors and Ezh2 is a histone methyltransferase part of the Polycomb 
complex, which have all been reported to be crucial for recombination of distal VH genes 
(Su et al. 2003; Fuxa et al. 2004; Liu et al. 2007). We found unchanged levels of Ezh2 
and YY1 transcripts and a slight, but reproducible, upregulation of Pax5 transcripts (2-4 
fold). In these samples, the mRNA encoding HDAC1 and 2 were also greatly reduced, 
confirming the efficient deletion of both alleles in HDAC1/2F/F + mb1-cre pre-BI cells. 
We next examined the expression of genes involved in the process of IgH recombination 
including Rag-1, Rag-2, terminal deoxynucleotidyl transferase (TdT), DNA-dependent 
protein kinase catalytic subunit (DNA-PKc), Ku70 and Ku80 (Jung and Alt 2004). 
Except for a slight reduction of Rag-2 transcripts (2-4 fold), all other transcripts were as 
abundant in HDAC1 and 2 deficient pre-BI cells as in WT cells (Fig. 23B). Furthermore, 
transcripts from cell surface receptor molecules such as IL-7R, Igα (mb1), Igβ (B29), 
lambda5 and VpreB were also unaffected. We conclude from these data that HDAC1 and 
2 regulate IgH recombination and contraction without significantly altering expression of 
known genes involved in early B cell development and the process of V(D)J 
recombination. 
 
Global histone modifications are altered in pre-BI cells lacking HDAC1 and 2 
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Histone post-translational modifications are known to be important for regulating 
chromatin higher order structure, flexibility and accessibility (Hansen 2006; Sen and Oltz 
2006; Berger 2007), therefore we investigated the possibility that HDAC1 and 2 regulate 
IgH recombination and contraction by modulating histone modifications. Because of the 
limitation on number of HDAC1 and 2 deficient pre-BI cells for experiments such as 
western blot and chromatin immunoprecipitation, we carried out quantitative 
measurements of histone modifications in single cells by FACS analysis. For this we first 
established the conditions for intracellular staining of histone modifications using a B cell 
lymphoma line treated with HDAC inhibitors. As shown in Supplemental Figure 4, 
strong increases in histone H3 and H4 acetylation are detected in cells that have been 
treated with the pan-HDAC inhibitors. Next, mouse pre-BI cells were identified using a 
combination of cell surface markers and, after fixation and permeabilization, stained with 
specific antibodies against different histone modifications. As expected, the total amount 
of histone H3 in WT and HDAC1 and 2 deficient pre-BI cells was not significantly 
different (Fig. 24). In contrast, the level of acetylated histone H4 was greatly elevated in 
mutant pre-BI cells, whereas acetylated H3K9 and H3K14 were unchanged. This 
observation suggests that in pre-BI cells HDAC1 and 2 participate in maintaining global 
histone acetylation, preferentially on histone H4. Histone acetylation, as well as di- and 
tri-methylation of histone H3 lysine 4 (H3K4me2, H3K4me3), are associated with active 
genes within open chromatin, whereas histone H3 lysine 9 methylation is a marker for 
repressed loci associated with a more condensed and tightly packed chromatin (Berger 
2007). As shown in Figure 7, the level of H3K4me2 and H3K4me3 were unchanged in 
HDAC1 and 2 deficient pre-BI cells, whereas a robust enrichment of H3K9me2 and 
H3K9me3 was detected. Taken together, these findings suggest that loss of HDAC1 and 
2 dramatically alters the global pattern of histone modifications in pre-BI cells whose 
chromatin, although being more acetylated, does not appear to be globally open, but 
rather shows hallmarks of a repressive conformation.  
 
 
DISCUSSION 
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We have shown here that HDAC1 and 2 are essential factors for early B cell development 
as well as V(D)J recombination by regulating the contraction and pericentromeric 
recruitment of the IgH locus. In the absence of these two enzymes, B cells are virtually 
absent from the periphery and a severe developmental defect is apparent at the pre-BI and 
pre-BII stage. The number of pre-BII cells is more than 100 fold reduced and the rare 
cells that can be detected are highly apoptotic. In contrast, the number of pre-BI cells is 
reduced about five fold, but these cells cycle normally and do not show apoptosis. 
However, in these cells a strong block in V(D)J recombination can be seen, which 
abrogates rearrangement of distal VH genes and moderately reduces rearrangement of 
proximal VH genes. By 3D FISH analysis we found that in these cells the contraction of 
the IgH locus is impaired, thus providing an explanation for the rearrangement defect. 
Our expression analysis demonstrated that this defect is not due to misregulated 
expression of known genes important for early B cell development, or V(D)J 
recombination and DNA repair. Moreover our results show that combined loss of 
HDAC1 and 2 leads to an increase in global histone H4 acetylation, as anticipated, but 
also to an increase in histone H3K9 methylation which may influence the higher order of 
chromatin structure. Taken these data together, we hypothesize that HDAC1 and 2 
control IgH recombination directly or indirectly by regulating the level of histone 
modifications. This conclusion, however, is paradoxical since many reports have pointed 
out that histone hyperacetylation is positively correlated with IgH recombination (Kwon 
et al. 2000; Chowdhury and Sen 2001; Johnson et al. 2003). In the case of the distal VH 
segments, histone hyperacetylation correlates with the presence of germline transcripts 
and is under the control of IL-7R signaling via STAT5 a/b activation at the pre-BI cell 
stage (Bertolino et al. 2005). We did not detect any significant changes in the level of 
germline transcripts from distal VH segments, which suggests that in the absence of 
HDAC1 and 2 the locus around the distal VH segments is accessible and the IL-7R 
signaling pathway is unaffected. 
 
How do HDAC1 and 2 participate in the process of IgH contraction and pericentromeric 
recruitment? Our global histone modification analysis has shown that combined loss of 
HDAC1 and 2 leads to hyperacetylation of histone H4, as anticipated. Surprisingly 
  64
however, we observed an increase in repressive histone modifications, such as H3K9 di- 
and tri-methylation, whereas no significant alteration was seen in the active modifications 
marks H3K9 and K14 acetylation, and H3K4 di- and tri-methylation. Previous reports 
have shown that in Pax5 deficient mice, which were the first mutant mice found to be 
impaired in IgH locus contraction, there is an accumulation of H3K9 di-methylation in 
distal VH regions, yet the chromatin conformation of distal V regions is accessible, as 
evidenced by their hyperacetylation and the normal presence of germline transcripts 
(Fuxa et al. 2004; Johnson et al. 2004). Interestingly, this phenotype is similar to that of 
the HDAC1 and 2 B cell deficient mutant mice described here. This similarity raises the 
question whether these different factors might all work in the same pathway to regulate 
IgH recombination. According to our expression analysis, Pax5 is still expressed in the 
absence of HDAC1 and 2, yet IgH contraction was abrogated. In this context, HDAC1 
and 2 and Pax5 may function in parallel pathways independently required for IgH 
contraction. However, Pax5 is known to regulate gene expression by both active and 
repressive mechanisms, and it has been reported that Pax5 interacts with Grg4/TLE4, one 
of the four members of the mammalian Groucho copressor family (Eberhard et al. 2000). 
In addition, Drosophila Rpd3, which is the closest homolog of mammalian HDAC1 and 2 
in Drosophila, has been identified as an interaction partner of Drosophila Groucho (Chen 
et al. 1999). Thus, it appears plausible that Pax5 might interact with HDAC1 and 2 and 
that this could contribute to the regulation of IgH locus contraction.  
 
How could histone hyperacetylation negatively affect DNA rearrangement of the IgH 
locus? As mentioned above, a positive correlation between histone hyperacetylation and 
IgH recombination has been well documented. Based on these previous studies, one 
might have expected increased recombination efficiency in the absence of HDAC1 and 2, 
but the opposite was observed. A few possibilities can be considered to help explain this 
paradox. First, excessive histone acetylation of the IgH locus may directly influence its 
contraction and sub-nuclear localization through dynamic alterations of the higher order 
structure of chromatin. In vitro studies using recombinant nucleosomal arrays have 
demonstrated that acetylation of histones can affect chromatin organization (Tse et al. 
1998; Dorigo et al. 2003; Shogren-Knaak et al. 2006). Several reports pointed out that in 
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vitro acetylation of histone H4, especially on lysine 16, could inhibit the formation of 
compact 30-nanometer-like fibers and the ability of chromatin to form cross-fiber 
interactions (Shogren-Knaak et al. 2006; Wang and Hayes 2008). A very recent report 
from Murre and colleagues provided the first complete picture of the 3D structural 
organization of the IgH locus (Jhunjhunwala et al. 2008). In cells undergoing IgH 
contraction the topology of the IgH locus is more condensed as compared to non-
committed B cells (E2A-/- pre-pro-B cells): not only are distal VH and DH segments in 
close proximity, but the entire IgH locus is also within a relatively close distance, 
implying that there might be a long range interchromosomal association within the entire 
IgH locus. Therefore, based on these different in vitro and in vivo results, one could 
imagine that highly acetylated histone H4 in HDAC1 and 2 deficient pre-BI cells might 
alter the higher order of chromatin structure to a more decondensed form, which impairs 
IgH contraction.  
Another possibility is that increased histone acetylation is indirectly important for IgH 
contraction. Our global analysis of histone modifications clearly demonstrated that loss of 
HDAC1 and 2 in pre-BI cells also led to accumulation of repressive marks such as 
histone H3K9 di- and tri-methylation. Interestingly, pre-BI cells lacking Pax5 were 
shown to have a higher level of H3K9 dimethylation at distal VH regions (Johnson et al. 
2004). Thus, it could be that HDAC1 and 2 are important either for the removal of or for 
preventing H3K9 dimethylation, which in turn may prevent contraction of the IgH locus 
through alteration of higher order of chromatin structure. Increased histone H3K9 
methylation at the IgH locus may for example lead to increased recruitment of 
chromodomain-containing factors that bind methylated lysine residues and might prevent 
IgH contraction.  
 
Another possibility might be that HDAC1 and 2 impact IgH recombination indirectly 
through regulating gene expression or even the acetylation of non-histone proteins. Our 
analysis showed that a number of transcription factors that are critical for early B cell 
development, such as Pax-5, E2A or EBF, are well expressed in cells lacking HDAC1 
and 2. Likewise, genes essential for Ig recombination, such as Rag-1 and Rag-2, are also 
normally expressed in mutant cells. Yet it is possible that the expression of other 
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unknown genes essential for IgH contraction and recombination requires HDAC1 and 2. 
Given the complexity of the process, it is likely that many such genes remain to be 
identified. Analysis of the transcriptome of HDAC1 and 2 double deficient pre-BI cells 
may be useful to that end. Finally, it is also possible that some of the phenotypes 
described here are not due to a primary defect at the level of chromatin (i.e. changes in 
histone modifications), but rather reflect the lack of deacetylation of an essential factor 
implicated in contraction and rearrangement of the IgH locus. Given the increasingly 
recognized importance of acetylation for a wide range of cellular processes (Minucci and 
Pelicci 2006) this appears a plausible possibility. While it is not known whether 
acetylation/deacetylation of Rag proteins may be important for their function, this 
scenario appears unlikely since the IgH locus, although not rearranged, is contracted 
normally in Rag-2 deficient pro-B cells (Jhunjhunwala et al. 2008). Yet, another protein 
implicated in this process might be regulated by acetylation.  
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METHODS 
 
Generation of HDAC1 and 2 conditional knockout mice and animal experiment 
Each exon 6 of mouse HDAC1 and 2 was flanked by a single loxP site and a cassette 
expressing the neomycin resistance gene and thymidine kinase gene flanked by two loxP 
sites. E14 ES cells (129/Ola strain) were electroporated with either the targeting vector 
for mouse HDAC1 or 2 and correctly targeted ES clones were identified by PCR, 
sequencing and Southern blot analysis. One targeted ES cell clone for HDAC1 and 2, 
number 149 and 233 respectively, was used for aggregation to generate chimeric mice. 
Chimeric mice were crossed to C57/Bl6 animals to obtain germ line transmission of the 
targeted allele. To delete the neomycin cassette (flox allele) and generate delta allele, 
targeted mice were crossed with either EIIa-Cre mice or Meox-Cre mice. The chimeras 
that contain both Cre and targeted alleles were genotyped and we identified mice having 
recombined delta or flox alleles by PCR and verified by sequencing. For the generation of 
B cell specific KO mouse, we used mb1-cre transgenic mice kindly provided by Dr. 
Michael Reth. 
For all analyses, flox allele littermates of the same sex were used as controls. All 
experiments were done using mixed background (129/Ola and C57/Bl6 mixed strain) 
transgenic mice from 6 to 12 weeks olds. Animal experiments were carried out according 
to regulations effective in the Kanton of Basel-Stadt, Switzerland. The mice were housed 
in groups of one to eight animals at 25°C with a 12:12 h light-dark cycle. They were fed a 
standard laboratory diet containing 0.8% phosphorus and 1.1% calcium (NAFAG 890, 
Kliba, Basel, Switzerland). Food and water was provided ad libitum.  
 
Flow cytometry (FACS) 
Single cell suspensions were prepared from indicated lymphoid tissues. Cell staining was 
done according to standard procedures. FACS analysis was performed on a FACSCalibur 
(BD Biosciences, San Jose, CA) by gating on live cells. Samples were analyzed by using 
CellQuest (Becton Dickinson) or Flow-Jo (Tree star) software. Cell sorting was 
performed on a MoFlo (DakoCytomation). The purity of sorted cells was checked by 
reanalysis. 
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The following mAbs were from BD Biosciences; RA3-6B2 (anti-B220) conjugated to 
allophycocyanin (APC), ACK45 (anti-c-kit) conjugated to phycoerythrin (PE) or 
biotinylated, S7 (anti-CD43) conjugated to fluorescein isothiocyanate (FITC), 1D3 (anti-
CD19) conjugated to APC-Cy7 and 7D4 (anti-CD25) biotinylated. 1B4B1 (anti-IgM) 
conjugated to FITC was from Southern Biotech. 6D5 (anti-CD19) conjugated to PE was 
from Biolegend. Streptavidin conjugated to PE-Cy5.5 was from CALTAG. For the 
Annexin V staining, we followed the manufacturer’s protocol from BD Biosciences. 
  
Quantitative RT-PCR and semi quantitative RT-PCR 
RNA was purified from sorted cell population mentioned in each figure with the RNeasy 
Microkit (Qiagen) according to the manufacturer’s protocol. cDNA was synthesized by 
using the Thermoscript Reverse Transcriptase Kit (Invitrogen). Oligo dT primers 
provided in the kit were used for the first strand synthesis.  
Quantitative PCR was performed on an ABI PRISM 7000 Sequence Detection System 
(Applied Biosystems, Foster City, CA) using a MESA GREEN qPCR MasterMix Plus 
for SYBR® Assay (Eurogentec). The amount of HDAC1 and 2 transcripts was 
normalized by Gapdh. 
For semi quantitative RT-PCR, cDNA was serially diluted 4 fold for PCR reactions. As a 
control reaction for contamination by genomic DNA, we prepared samples without 
reverse transcriptase (-RT). Primers used for these experiments are provided in 
Supplementary Table 3. Primers for semi quantitative RT-PCR were previously reported 
(DeKoter et al. 2002; Fuxa et al. 2004; Delogu et al. 2006; Liu et al. 2007). For the 
amplification of μ transcripts, combinations of a forward primer used for V(D)J 
recombination analysis (VHJ558 and VH7183) and a reverse primer, Cμ transcript, were 
used.  
 
PCR analysis of deleted HDAC1 and 2 alleles and V(D)J recombination 
DNA was extracted from sorted cell populations mentioned in each figure by overnight 
proteinase K digestion, phenol/chloroform extraction and ethanol precipitation. DNA was 
serially diluted at 1:4 ratios and used for each PCR reaction. Primers used for the PCR 
detection of HDAC1 and 2 genotyping and V(D)J recombination are shown in 
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Supplementary Table 2 (Fuxa et al. 2004; Liu et al. 2007). PCR analysis of V(D)J 
recombination was described previously (Fuxa et al. 2004). Combinations of a forward 
primer for different parts of the IgH locus (VHJ558, VH7183 and DH) and a reverse JH3 
primer were used. Amplicons from PCR reactions were separated on 1.5% agarose gel 
and visualized by ethidium bromide. 
 
Western blot analysis of mature B cells 
Naïve mature B cells from spleen were isolated by negative selection with CD43 
microbeads (Miltenyi Biotec) according to the manufacturer’s protocol. Sample 
preparation, SDS-PAGE and blotting were done as described previously (Zhang et al. 
2008). Mouse monoclonal anti-HDAC1 and anti-HDAC2 were described in (Zupkovitz 
et al. 2006). 
 
In vivo BrdU incorporation assay 
Mice were injected intraperitneally with 20 µg of BrdU and sacrificed 30 minutes later. 
Bone marrow single cell suspensions were prepared, stained and sorted with the 
combination of antibodies against the following cell surface molecules; CD19+ CD43+ 
CD25-. BrdU staining using sorted cells was performed according to the manufacturer’s 
protocol of BrdU flow kit (BD bioscience). Analysis was performed on a FACSCalibur 
and analyzed by Flow-Jo software.  
 
Three-dimensional DNA FISH and confocal microscopy 
Cells sorted by flow cytometry were washed in PBS and then were fixed on poly-L-
lysine-coated slides for three-color and three-dimensional DNA-FISH analysis as 
described (Fuxa et al. 2004). Probes were directly labeled by nick translation with 
ChromaTide Alexa Fluor 488-5-dUTP, ChromaTide Alexa Fluor 594-5-dUTP 
(Molecular Probes) or dUTP-indodicarbocyanine (GE Healthcare). The γ-satellite probe 
was prepared from a plasmid containing eight copies of the γ-satellite repeat sequence 
(Hewitt et al. 2008) and was directly labeled with dUTP-fluorescein isothiocyanate 
(Roche; Enzo Biochem) or dUTP-indodicarbocyanine. Cells were analyzed by confocal 
microscopy on a Leica SP5 AOBS system (Acousto-Optical Beam Splitter). Optical 
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sections separated by 0.3 µm were collected, and only cells with signals from both alleles 
(typically 90%) were analyzed. Details of sample sizes and statistical analysis are 
provided in Supplementary Table 1. 
 
Intracellular FACS for histone modifications 
Cells were stained with fluorochrome coupled antibodies; B220-APC, CD19-PE and c-
kit-biotinylated. Streptavidin-PE-Cy5.5 was used for the staining of c-kit-biotinylated 
antibody. After staining, cells were fixed with 3% paraformaldehyde for 15 minutes at 
room temperature, permeabilized with 0.1% saponin, 3% bovine serum albumin (BSA) in 
PBS for 30 minutes at room temperature, and then subjected to the intracellular staining 
with different histone modification antibodies as follows; anti-Histone H3 (ab1791; 
Abcam), anti-acetyl-Histone H3K9 and K14 (06-599; Millipore), anti-acetyl-Histone H4 
(06-866; Millipore), anti-Histone H3 di-methyl lysine 4 (07-030; Millipore), anti-Histone 
H3 tri-methyl lysine 4 (ab8580; Abcam), anti-Histone H3 di- and tri-methyl lysine 9 
antibodies were kindly provided by Dr. Antoine Peters (Peters et al. 2003). After washing 
of cells to remove nonspecific antibody binding, cells were stained with the secondary 
antibody recognizing rabbit IgG coupled to alexa Fluor® 488 (A11034; Invitrogen). 
FACS analysis was performed after extensive washing. The buffer containing 0.1% 
saponin in PBS was used for all staining, washing and FACS analysis after 
permeabilization. 
 
Statistical analysis 
Significance was assessed by analysis of normal distribution, variances and two-tail T 
test.  
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Figure 18  
Ablation of HDAC1 or 2 in B cells. (A) Scheme of early B cell differentiation, depicting the different 
developmental stages and the expression of markers used to discriminate them (marker expression is 
indicated by +, lack of expression by -). Curved arrows indicate relative cellular proliferation activities: 
very high in large pre-BII, intermediate in pro- and pre-BI, low or absent in small pre-BII, immature and 
mature B cells. V(D)J shows the rearrangement status of the different Ig gene alleles during B cell 
differentiation. The kind of immunoglobulin present at the membrane is also indicated at the bottom. (B) 
HDAC1 and 2 transcripts were analyzed by quantitative RT-PCR and normalized to Gapdh expression. B 
cell populations were purified from three wild type mice and RNA was extracted. Pro/pre-BI cells: B220+ 
c-kit+ CD25- IgM-; pre-BII cells: B220+ c-kit- CD25+ IgM-; immature B cells: B220+ IgM+; mature B cells: 
B220High IgM+. (C) PCR detection of recombination at HDAC1 and HDAC2 alleles. Cells were purified 
from a mouse (HDAC1/2F/+ +mb1-Cre) and DNA was extracted from two sorted cell populations: 
B220+CD19- and pre-BI cells (B220+ CD19+ CD43+ CD25-). Specific sets of primers were used to 
discriminate flox, wild type and KO alleles. (D) Western blot analysis of HDAC1 or HDAC2 single KO 
mouse. Protein lysates from splenic mature B cells were detected by anti-HDAC1, HDAC2 and Actin 
antibodies, as indicated.  
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Figure 19 
Early block in B cell development after combined loss of HDAC1 and 2. (A) Flow cytometric analysis of 
HDAC1/2F/F + mb1-Cre mice. Single cell suspensions from bone marrow or spleen were stained with the 
indicated antibody combinations and representative data are shown. Numbers in plots represent the 
percentage of cells in the respective gate or quadrant. (B) Total cell numbers present in different B cell 
populations. The absolute numbers were determined based on FACS analysis and cell counting. Pro-B cells 
were identified as B220+ CD19-, pre-BI cells as B220+ CD19+ CD43+ CD25- and pre-BII cells as B220+ 
CD19+ CD25+. (C) Absolute numbers of B220+ splenic B cells. The histograms represent the mean ± SE 
based on the analysis of at least four mice per genotype. 
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Figure 20 
HDAC1/2 deficient pre-BI cells have a normal cell cycle profile and apoptosis while pre-BII cells are 
highly apoptotic. (A) In vivo BrdU incorporation assay. Pre-BI cells (CD19+ CD43+ CD25-) were sorted and 
after fixation, permeabilization and DNA digestion, their DNA was stained with an anti-BrdU antibody and 
7-AAD. Numbers in plots indicate the percentage of cells in each cell cycle phase. The histogram on the 
right presents the results of cell cycle profiling from four mice (mean ± SE). (B) Analysis of apoptosis by 
annexin V staining. Cells were stained with combinations of cell surface markers (as in Figure 20A for pre-
BI cells and CD19+ CD25+ for pre-BII cells) and annexin V. Data is representative of more than three mice 
of each genotype. 
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Figure 21 
Impaired VH-DJH recombination but normal VH germline transcript expression in the absence of HDAC1 
and 2. (A) Schematic of the IgH locus in germline configuration with relative positions of distal VH (J558) 
and proximal VH (7183) gene families (not drawn to scale). (B) Semi quantitative PCR analysis of V(D)J 
rearrangements. DNA was isolated from pre-BI cells (B220+ CD19+ c-kit+ CD25- IgM-) and used in four 
fold serial dilutions for PCR with specific primers. The Cμ locus was amplified as a loading control. (C) 
RT-PCR detection of spliced Igμ transcripts. RNA was isolated from pre-BI cells (as above), reverse 
transcribed to cDNA and decreasing amounts (4 fold steps) were used for PCR reactions. Equal loading of 
cDNA was shown by the Gapdh transcripts. (D) Intracellular μ staining. Pre-BI cells were identified as 
B220+ CD19+ c-kit+ and intracellular staining was done by an anti-IgM antibody. Gray shadow represents 
staining of control cells and the black line shows staining of HDAC1/2 double deficient cells. Percentages 
of μ positive cells are shown on the right. Data is representative of three mice of each genotype. (E) VH 
germline transcript (GLT) is normally expressed in double KO pre-BI cells. RNA as in Figure 4C was used 
for the detection of VH GLT and Cμ GLT. Gapdh was amplified as a loading control. Two samples are 
presented for each genotype. All PCR experiments shown in Figure 21 are representatives of at least three 
experiments with independent samples. 
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Figure 22 
Impaired IgH locus contraction in HDAC1/2 deficient pre-BI cells. (A) Schematic of the mouse IgH locus, 
indicating the positions of probes used for three-color three-dimensional DNA FISH analysis. The BAC 
probes used were CT7-526A21 for the IgH 5' J558 segment and CT7-34H6 for the 3' IgH constant region 
(green) plus a gamma-satellite probe (white). Cells were FACS-sorted as in Figure 21B and used for the 
experiment. A representative confocal picture is presented; individual alleles from the same cell are shown 
in different z sections. (B) Distances separating the VHJ558 and CH gene segments in pre-BI cells of wild 
type and HDAC1/2 double deficient mice (for percentages, sample sizes and statistic analysis, see 
Supplemental Table 1A). (C) Percentage of cells showing mono- or biallelic pericentromeric recruitment of 
the IgH locus (percentages, sample sizes and statistical analysis, Supplemental Table 1B). 
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Figure 23 
Cells lacking HDAC1 and 2 have a mostly normal expression of genes required for early B cell 
development and V(D)J recombination. RNA from pre-BI cells (as in Fig. 21C) was used to measure gene 
expression by RT-PCR using decreasing amounts (4 fold steps) of cDNA. (A) Transcription factors and 
histone modifiers essential for early B cell development. (B) Genes involved in IgH recombination and cell 
surface or signaling molecules. All PCR experiments in Figre 23 are representative of at least three 
experiments with independent samples.  
 
  78
 
 
 
Figure 24 
Combined loss of HDAC1 and 2 leads to altered global histone modification patterns. Cells were stained 
with B220+ CD19+ c-kit+ and subjected to intracellular staining with an antibody recognizing different 
histone modifications. Gray shadows represent staining of control cells and black lines show staining of 
HDAC1/2 double deficient cells. All data are representatives of more than three independent experiments. 
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Results 
HDAC1 is dispensable for hematopoietic cell development 
To explore the functions of HDAC1 in hematopoietic cell development, we generated 
HDAC1 conditional knock out mice in which exon 6 of the HDAC1 gene is removed 
by Cre recombinase expressed specifically in hematopoietic cells. This exon has been 
shown to be essential for the deacetylase activity of HDAC1 (Hassig et al. 1998). Flox 
alleles of HDAC1 produce normal amounts of protein, and homozygous mice appear 
to be indistinguishable from their wild type (WT) littermates (data not shown). To 
inactivate the function of HDAC1 in hematopoietic cell lineages, we used the Vav-
iCre transgenic mouse line which starts to express the codon-improved Cre (iCre) in 
the entire hematopoietic cell lineage (de Boer et al. 2003). First, we analyzed the 
efficiency of flox allele deletion by southern hybridization analysis. For this, DNA 
was isolated from bone marrow cells, splenocytes and thymocytes of mice 
heterozygous for the HDAC1 flox allele and either positive for Vav-iCre gene or 
negative, and mice homozygous for the HDAC1 flox allele and Vav-iCre gene 
(HDAC1F/+, HDAC1F/+::Vav-iCre, and HDAC1F/F::Vav-iCre, respectively). After 
digestion by the restriction enzyme, DNA was blotted onto the membrane and 
hybridized by the radio-labeled probes which specifically recognize the DNA 
sequences on the HDAC1 genomic locus. With this assay, we did not detect deleted 
alleles (Δ) of HDAC1 in HDAC1F/+ mouse DNA from all 3 cell types, whereas no flox 
(i.e. unrecombined) allele was seen in all 3 cell types of HDAC1F/+::Vav-iCre and 
HDAC1F/F::Vav-iCre mice (Fig. 25A). This result indicates that the recombination of 
the HDAC1 locus is highly efficient and takes place at an early progenitor stage, 
resulting in the deletion of HDAC1 in all hematopoietic lineages. We also analyzed by 
western blotting the level of HDAC1 proteins in same types of cells used in southern 
hybridization. As presented in Figure 25B, HDAC1 proteins were below detection in 
bone marrow, splenic and thymic cells from HDAC1F/F::Vav-iCre mice, and no 
truncated form of HDAC1 protein was observed (data not shown). Interestingly, in the 
absence of HDAC1 protein, the amount of HDAC2 protein was found to be increased. 
Together, these results confirm the successful inactivation of HDAC1 in 
hematopoietic cell lineages and show that loss of HDAC1 leads to an increase in the 
level of HDAC2. These mice were next analyzed by flow cytometry (FACS) to 
determine the effect of ablating HDAC1 on hematopoietic cell development. For this, 
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a series of antibodies recognizing cell surface molecules were used to distinguish 
specific subsets of hematopoietic cell populations in bone marrow, spleen and thymus. 
B220 in combination with IgM were used to detect distinct B cell subpopulations, 
CD4 and CD8 were used for T cells, Mac1 and Gr-1 were used for myeloid cells, and 
TER119 and CD71 were used for erythrocytes. Apparently HDAC1F/F::Vav-iCre mice 
have all hematopoietic cell populations normally represented in the bone marrow, 
spleen and thymus (Fig. 25C), although a slight reduction of Mac1+Gr-1+ cells is 
reproducibly observed in the spleen. Thus, HDAC1 appears to be dispensable for the 
majority of hematopoietic cell development.  
 
Impaired T cell dependent immune response in hematopoietic HDAC1 deficient 
mice 
We next tested the functional implication of HDAC1 for the immune response. To 
check that, we measured the amount of immunoglobulin (Ig) secreted in the mouse 
serum. We collected sera from HDAC1F/+::Vav-iCre and HDAC1F/F::Vav-iCre mice 
and measured different isotypes of Ig by the Enzyme-Linked ImmunoSorbent Assay 
(ELISA) assay. Surprisingly we saw that all of class switched Ig isotypes examined; 
IgG1, IgG2a, IgG2b, IgG3 and IgA were reduced about 2-3 fold in the hematopoietic 
HDAC1 deficient mice, whereas no change was observed in the level of IgM (Fig. 
26A). This result tempted us to consider the possibility that HDAC1 might be 
important for the immune response against exogenous antigens. To investigate this 
possibility, we carried out immunization experiments injecting intraperitneally the T 
cell dependent antigen, dinitrophenylated keyhole limpet haemocyanin (DNP-KLH). 
We collected sera weekly from immunized control and HDAC1 hematopoietic 
deficient mice until 3 weeks post-injection. At 21 day post-injection, mice were 
subjected again to an immunization to boost the immune reaction and sera were 
collected 6 days after the second injection. Thereafter we performed the ELISA 
experiments to measure the relative titers of specific antibodies against DNP (Fig. 
26B). The level of specific IgM recognizing DNP-KLH was largely unchanged, 
whereas the level of IgG in sera of HDAC1 deficient mice was reduced. After the 
boost, this reduction of IgG antibody level was further enhanced. Histological 
analysis of HDAC1 deficient spleen showed an impaired formation of the germinal 
centers (GCs) (Fig. 26C). The defect in the GC formation was also confirmed by 
FACS analysis identifying cells harboring the GC-specific antigen, GL7. Collectively, 
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these data demonstrate that HDAC1 plays important roles to regulate the T-cell 
dependent immune response. Additionally, we observed that spleens from immunized 
HDAC1 deficient mice were enlarged, and this was observed at as early as 5 days post 
immunization. Splenic mass of hematopoietic HDAC1 deficient mice was c.a. 1.5 
times heavier than the littermate control, and the number of splenocytes was as well 
increased c.a. 1.5 fold. Interestingly, the proportion of each hematopoietic cell 
subpopulation in the spleen was largely the same as in unimmunized mice, indicating 
that all populations were equally increased compared to the unimmunized condition 
(Supplementary Fig. 5). To investigate the proliferation rate of hematopoietic cells, 
we injected BrdU into immunized mice and investigated BrdU-incorporated cells (i.e. 
cells having replicated their DNA) in the spleen. To our surprise, the proportion of 
BrdU positive cells in splenic B and T cells of HDAC1 hematopoietic deficient mice 
was largely unchanged compared to WT littermates controls (Supplementary Fig. 5). 
This result suggests that the increased cell number in the peripheral hematopoietic cell 
compartments might be due to enhanced proliferation of progenitor cells such as 
common lymphoid progenitors (see discussion). 
 
B cell intrinsic immune defect in HDAC1 deficient mice 
To identify the cell lineage responsible for the defect observed in the T dependent 
immune response, we next used HDAC1F/F::mb1-Cre mice, which specifically lack 
HDAC1 in the B cell lineage (Hobeika et al. 2006). As shown in Fig. 27A, the steady 
state level of Ig isotypes in mice lacking HDAC1 in B cells are reduced similarly as 
was seen in hematopoietic deficient mice. The DNP-KLH immunization experiments 
using B cell deficient mice showed a reduced titer of specific anti-DNP IgG, whereas 
there was no obvious change in the anti-DNP IgM titer (Fig. 27B). Moreover, we 
have carried out the same experiment using T cell specific HDAC1 inactivated mice, 
HDAC1F/F::lck-Cre. However we did not observe any alteration of the T dependent 
immune response (Grausenburger et al. Manuscript in preparation). These results 
therefore strongly suggest that the impaired T dependent immune reaction described 
here is due to the lack of HDAC1 protein in the B cell lineage. 
 
In vitro class switching and B cell proliferation are not abrogated in the absence 
of HDAC1 
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Next we examined the possibility that the impaired adaptive immune response might 
be due to critical roles of HDAC1 for class switch recombination of the Ig gene. To 
assess that, we detected antibody secretion in vitro by culturing primary B cells under 
conditions allowing them to undergo class switching. Mature B cells were isolated 
from spleens of HDAC1F/+::Vav-iCre and HDAC1F/F::Vav-iCre mice, cultured for 
several days in the presence of bacterial lipopolysaccharide (LPS) with or without 
interleukin-4 (IL-4), and class switched antibody secretion in the medium was 
measured by ELISA. In the presence of LPS and IL-4, B cells undergo class switch 
recombination between the Cμ gene and the Cγ1 gene, which results in the production 
of IgG1 antibodies, whereas in the presence of LPS alone, B cells switch to Cγ3 and 
produce IgG3 antibodies. Surprisingly, as shown in Fig. 28A, the secreted IgG1 as 
well as IgG3 were more abundant in HDAC1-/- mature B cells than in control cells: 
IgG1 4 fold and IgG3 1.5 fold increased. This increased secretion was not due to a 
change in B cell proliferation in response to various mitogenic stimuli (Fig. 28B). 
These results thus suggest that HDAC1 functions as an inhibitory factor for class 
switch recombination, at least, in vitro situation. 
 
Aberrant patterns of gene expression in the absence of HDAC1 
To further investigate the cause of the impaired germinal center formation as well as 
the reduced immune response observed in the absence of HDAC1, we carried out 
microarray analysis using RNA isolated from mature B cells as well as germinal 
center cells of immunized mice. In the absence of HDAC1, the expression of 133 
genes on the microarray was found to be up- or down-regulated more than 2 fold in 
HDAC1 KO mature B cells, whereas 1545 genes were deregulated in HDAC1-/- 
germinal center cells. Furthermore, 57 genes were commonly misregulated (Fig. 29A). 
Many transcription factors critical for GC formation, such as Bcl6, Irf4, Irf8, Pax5, 
Nfkb1, Nfkb2, Prdm1 (encodes Blimp1) and Xbp1, were found to be unaffected (less 
than 1.7 fold changes) by the absence of HDAC1; however, Irf4 was found to be up-
regulated c.a. 2.1 fold. Moreover the essential gene for class switch recombination, 
Aicda encoding the AID protein, was shown to be c.a. 3.5 fold reduced in the HDAC1-
/- GC cells (Fig. 29B). IRF4 plays a critical role in the noncycling centrocytes as well 
as in post–GC plasma cell development (Klein et al. 2006). IRF4 is present in mature 
B cells, absent from highly proliferating GC centroblasts and is then re-expressed in a 
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subpopulation of centrocytes as well as in plasma cells (Falini et al. 2000). Our 
expression analysis implies that in the absense of HDAC1, the Irf4 gene fails to be 
repressed in the GC centroblasts. Next we clustered the expression patterns of 
misregulated genes from the microarray data to identify genes deregulated similary to 
the Irf4 gene. We classified the expression profiles of the 1545 misregulated genes 
into 9 clusters based on relative expression in mature B cells and GC cells; the Irf4 
gene falls into cluster b. This cluster (307 genes) represents the set of genes that are 
highly expressed in WT mature B cells and are repressed in GC cells, but remain 
expressed in HDAC1-/- GC cells (Fig. 29C). This set of genes is particularly 
interesting, because these genes are actively down-regulated when mature B cells 
undergo differentiation into GC cells. Since HDAC1 may repress gene expression by 
modulating histone acetylation, these genes, therefore, might be potential direct 
targets of HDAC1. Cluster a and d contain genes that are also upregulated in HDAC1-
/- GC cells, which therefore may be potential direct targets of HDAC1. Genes 
clustered in a, b and d were further analyzed through the use of Ingenuity Pathways 
Analysis (Ingenuity Systems®, www.ingenuity.com) and significantly relevant 
molecular and cellular functions associated with deregulated genes in each cluster are 
listed in Supplementary Figure 6A. Interestingly, all 3 clusters contain genes 
associated with cell cycle functions in a significantly high proportion. It implies that 
the potential targets of HDAC1 must be down-regulated in GC cells are highly 
represented in the category involved in the cell cycle regulation. In the Fig. 29D, The 
heat maps of transcriptional regulators, cell cycle associated genes and apoptosis/cell 
death associated genes from cluster b are shown. Importantly in cluster b, E2f5 and 
Cdkn1b are found to be highly upregulated in HDAC1-/- GC cells. Both gene products, 
E2F5 and p27 are known to be important for the G1 cell cycle progression. Clusters c 
and e, containing genes failed to be activated in HDAC1-/- GC cells, show namely 
different functions such as lipid metabolism, molecular transport and small molecule 
biochemistry (Supplementary Fig. 6B). These facts indicate that the lack of gene 
repression in HDAC1 deficient GC cells may directly affect cell cycle regulation, 
which may trigger the failure of GC cell differentiation and the inappropriate 
expression of genes implicated in cellular metabolisms. 
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Figure 25. Conditional inactivation of HDAC1 in hematopoietic cell lineages. (A) Southern 
hybridization analysis of HDAC1 genomic alleles. DNA from mice of the indicated genotypes were 
digested with SacI, separated by gel electrophoresis, blotted on a membrane and detected by the 
specific probe. Modified alleles are represented as follows: F, flox allele; Δ, deleted (KO) allele and 
alleles corresponding to each genotype are indicated in the left. (B) Western blot analysis of HDAC1 
KO mice. Protein lysates from cells from the bone marrow, spleen and thymus were detected by 
anti-HDAC1, HDAC2 and Actin antibodies, as indicated. (C) Flow cytometric analysis of 
HDAC1F/F::Vav-iCre mice. Single cell suspensions from bone marrow, spleen or thymus were 
stained with the indicated antibody combinations and representative data are shown. Numbers in 
plots represent the percentage of cells in the respective gate or quadrant. 
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Figure 26. Impaired immune response and germinal center formation in HDAC1 hematopoietic 
deficient mice. (A) Serum immunoglobulin detection by ELISA. Sera were collected from 4 mice of 
each genotype and the concentration of each Ig isotypewas plotted. The median value of each genotype 
is indicated by black bars. (B) DNP-specific IgM and IgG titers. Five Mice of each genotype were 
immunized with DNP-KLH and sera were collected at the indicated days post injection.  At 21 day, a 
second immunization was done. (C) Impaired germinal center formation. Frozen sections of spleens 
were stained with anti-B220-PE labeled antibody and biotinylated-peanut agglutinin (PNA) (Top). 
Streptavidin-FITC was used for the detection of PNA. FACS analysis of germinal center cells (bottom). 
Single cell suspensions from immunized mouse spleen were stained with anti-B220 and anti-GL7 
antibodies. Numbers in plots represent the average percentage of cells and S.E. in the gate (N=3; 
P=0.016).  
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Figure 27. Impaired immune response in HDAC1 B cell deficient mice. (A) Serum 
immunoglobulin detection by ELISA. Sera were collected from 3 mice of each genotype and each 
isotype concentration was plotted. The median value of each genotype was indicated as a black bar. 
(B) DNP-specific IgM and IgG titers. More than 3 mice of each genotype were immunized by DNP-
KLH and sera were collected at listed days post injection. The results from 2 independent experiments 
are shown. 
Experiment 2 
Experiment 1 
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Figure 28. Enhanced secretion of IgG1 and IgG3 and normal proliferation of HDAC1 
inactivated mature B cells in vitro. (A) Secreted immunoglobulin detection by ELISA. The 
supernatants from B cell cultures were collected and IgG1 and IgG3 concentration was measured. 
The median value of each genotype is indicated as black bars. (B) 3H-thymidine incorporation assay 
after 3 days culture in vitro. Mature B cells were cultured with the indicated mitogens and 3H-
labeled thymidine was added in the medium 24h before harvesting. 
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Figure 29. Microarray analysis of mature B cells and GC B cells. RNA was isolated from 
mature B cells and GC B cells from spleens of immunized mice at 10 days post injection (N=3 for 
each genotype). (A) The numbers of misregulated genes (more than 2 folds changes) in HDAC1 
deficient mature B cells and GC B cells are shown. (B) Expression value for Aicda and key TFs in 
mature and GC B cells of each genotype. (C) Clustering of genes misregulated in HDAC1 KO GC B 
cells. All genes misregulated are grouped into 9 types of expression patterns represented in the panel 
(N=3 per genotype and condition). A high expression value is indicated in the upper side of each 
panel and a low expression value is indicated close to the bottom side. Numbers in the bottom-right 
of each panel indicate the number of genes in the corresponding cluster. For example, cluster b 
contains 307 misregulated genes. These genes are highly expressed in mature B cells and 
downregulated in GC cells from control mice, whereas the same genes are highly expressed in mature 
B cells and remain expressed in GC cells from HDAC1 KO mice. 
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Figure 29. Microarray analysis of mature B and GC B cells. RNA was isolated from mature B 
cells and GC B cells from spleens of immunized mice at day 10 post injection (N=3 for each 
genotype). (D) Heat map analysis of particular genes in cluster b. Relative expression values are used, 
which are indicated by the colors in the bottom. The left heat map shows genes defined or predicted to 
be transcriptional regulators. The middle heat map present genes involved in cell cycle regulation. The 
right heat map shows genes involved in apoptosis and cell death processes. 
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Supplementary Figure 5. BrdU incorporation assay using DNP-KLH immunized mice. BrdU were 
injected into immunized mice (2x 1mg / a day) continuously post immunization day 1-4 (A) and 5-9 
(B). BrdU+ cells were stained together with cell surface markers: B220, CD4 and CD8. Percentages 
of BrdU+ cells within each population were plotted. Three mice of each genotype were examined. 
The error bar represents S.E..  
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Supplementary Figure 6. Ingenuity Pathways Analysis revealing significantly relevant molecular 
and cellular functions associated with disregulated genes in the absence of HDAC1. (A) The lists of 
relevant functions and diseases are associated with cluster a, b and d which are highly upregulated in 
HDAC1 KO GC cells. (B) The lists of relevant functions and diseases are associated with cluster c 
and e which are downregulated in HDAC1 KO GC cells. 
genes 
genes 
genes 
genes 
genes 
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DISCUSSION 
3.1 Histone deacetylase 1/2 functions in B cells 
3.1.1 Misregulated genes in HDAC1/2 inactivated pre-BI cells 
 
We have shown here that HDAC1 and 2 are essential factors for early B cell 
development as well as V(D)J recombination by regulating the contraction and 
pericentromeric recruitment of the IgH locus. In the absence of HDAC1 and 2 at the 
pre-BI cell stage, cells show largely normal proliferation and apoptosis but are 
reduced about 4-5 fold in numbers. To find out other potential defects in B cell 
development other than the impairment of V(D)J recombination, we have carried out 
a microarray analysis of pre-BI cells. Pre-BI cells were isolated by FACS sorting 
using the following cell surface molecules; B220+CD19+CD43+CD25-. HDAC1/2F/F 
+mb-1 Cre mice and their littermate control (Flox allele mice without the Cre gene) 
were used for the experiment. The summary of the microarray analysis is shown in 
Appendix 8.4.  
In total, 747 genes are deregulated in the absence of HDAC1/2 (P<0.05 and 2 fold 
change). Ingenuity Pathways Analysis (Ingenuity Systems®, www.ingenuity.com) 
was used to classify the relevant molecular and cellular functions associated with 
deregulated genes and a list is presented in Appendix 8.4. Many deregulated genes are 
classified into the functions such as Cell Death and Cellular Growth and Proliferation 
although HDAC1/2 inactivated pre-BI cells show normal cell viability. This suggests 
that these cells look phenotypically normal, however genes associated with cell death 
and proliferation start to be misregulated. It should be pointed out that this clustering 
of genes based on their function does not separate positive functions or negative 
functions; thus, for example, pro-apoptotic and anti-apoptotic factors are both 
categorized in the Cell Death group. In fact, the best characterized HDAC1 target, p21, 
which is crucial to inhibit the cell cycle, was not misregulated in HDAC1/2 abrogated 
pre-BI cells. This indicates that these cells are likely not yet blocked in the cell cycle 
progression. 
In addition to the genes categorized to the cell viability group, a high proportion of 
deregulated genes is associated with lymphocyte development, as listed in Appendix 
8.4. I summarize below several potential direct targets of HDAC1 and 2 at the pre-BI 
cell stage. Since HDACs are well characterized as corepressors, I mainly discuss 
genes highly upregulated in HDAC1/2 mutant cells. 
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Flt3 
The tyrosine kinase receptor Flt3 (also called flk2 and CD135) is up-regulated during 
early hematopoietic cell differentiation, concomitantly to a reduction of self-renewal 
capacity of the cells (Adolfsson et al. 2001). The earliest Flt3+ population described so 
far is the lymphoid-primed multipotent progenitor (LMPP) and its expression remains 
until cells fully commit to the B lineage (CD19+ pre-BI cells) (Nagasawa 2006; 
Iwasaki and Akashi 2007). Even though these Flt3+ progenitors have a lymphoid 
lineage short-term reconstitution potential, they can also give rise to, at the single-cell 
level, the myeloid lineage (Adolfsson et al. 2001). In vivo, the functions of Flt3 or the 
Flt3 ligand have been further elucidated in studies of gene inactivated mice; in these 
mice a reduction in early B and T cell progenitors as well as common lymphoid 
progenitors (CLPs) is observed (Veiby et al. 1996; McKenna et al. 2000; Sitnicka et al. 
2002). Although Flt3 and its ligand are essential for early B cell progenitors, 
repression of Flt3 in pre-BI cells is crucial for B cell lineage commitment. In the 
absence of Pax5, the key transcription factor for B-cell lineage commitment, B cells 
are blocked at the pro-B cell stage with a high level of Flt3 expression (Holmes et al. 
2006). These Pax5-/- pro-B cells maintain the potency to differentiate into multiple 
hematopoietic lineages (Nutt et al. 1999; Rolink et al. 1999). Furthermore, enforced 
expression of Flt3 in bone marrow stem cells selectively inhibits B cell differentiation 
and biases commitment to the myeloid lineage (Holmes et al. 2006). Repression of 
Flt3 is inversely correlated to the up-regulation of CD19 gene expression, by which 
Pax5 regulates down- and up-regulation by directly binding to the promoters of both 
genes (Holmes et al. 2006). Thus several functions of Flt3 are essential for early 
lymphocyte progenitors and repression of Flt3 in committed B cells, mediated by 
Pax5, has critical roles to specify the cell fate towards B cell lineage. 
 
Tal1 
Stem cell leukemia/T cell acute leukemia 1 (SCL/Tal1) is a member of the basic 
helix-loop-helix (bHLH) transcription factors. During hematopoietic cell 
differentiation, Tal1 is expressed mainly in erythroid cells, megakaryocytes, and 
hematopoietic stem cells (HSCs) and its expression decreases with differentiation in 
all lineages. Tal1 is essential for blood cell development in the yolk sac (Kallianpur et 
al. 1994; Robb et al. 1995; Shivdasani et al. 1995; Elefanty et al. 1998). In the B cell 
lineage, Tal1 expression is the highest in pro-B cells, whereas its expression is more 
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than 5 fold reduced in committed pre-BI cells (Herblot et al. 2002). In addition 
ectopic expression of Tal1 blocks B cell development at the pro-B cell stage and cell 
numbers in later stages from pre-BI (Hardy fraction B) to mature B (Hardy fraction F) 
are decreased. Thus sustained up-regulation of Tal1 in committed B cells inhibits B 
cell development. 
 
Cebpa  
Cebpa encodes the transcription factor C/EBPα belonging to the CCAAT enhancer 
binding protein (C/EBP) family (Ramji and Foka 2002). In the hematopoietic system, 
Cebpa expression is detected in myeloid cells and C/EBPα activates myeloid specific 
genes such as granulocyte colony stimulating factor (G-CSF), macrophage CSF (M-
CSF) and granulocyte–macrophage CSF (GM-CSF) (Hohaus et al. 1995; Smith et al. 
1996; Zhang et al. 1996). In addition, in the absence of C/EBPα cells fail to undergo 
myeloid differentiation and generate mature neutrophils, whereas no defect has been 
shown in B cell development (Zhang et al. 1997). These studies strongly suggest that 
C/EBPα plays a role in myeloid cell development. Interestingly, enforced expression 
of C/EBPα and its homolog, C/EBPβ in differentiated B cells leads to their rapid and 
efficient reprogramming into macrophages. C/EBPs induce this trans-differentiation 
by inhibiting Pax5, which results in the down-regulation of the Pax5 target CD19 and 
up-regulation of Mac-1 and other myeloid markers (Xie et al. 2004). Moreover the 
full reprogramming of terminally differentiated mature B cells into induced 
pluripotent stem cells (iPS cells) requires introducing C/EBPα in addition to the 
“conventional” set of 4 transcription factors, Oct4, Sox2, Klf4, and c-Myc (Hanna et 
al. 2008). Thus C/EBPα, if expressed in the B cell lineage, antagonizes the functions 
of Pax5. 
 
Csf2rb2 
Colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage), 
is the common subunit of GM-CSF, IL-3 and IL-5 receptors, which is critical for 
eosinophil differentiation but not essential for B cell differentiation (Nishinakamura et 
al. 1996). 
 
Mlf1 
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Myeloid leukemia factor 1 (MLF1) was first discovered as the leukemic fusion 
protein generated by some chromosomal translocations (Yoneda-Kato et al. 1996). 
MLF1 expression is preferentially detected in non-committed progenitor cells and 
declines in more lineage-restricted cells during hematopoietic cell development 
(Matsumoto et al. 2000). Enforced Mlf1 expression impairs the development of 
erythroid colonies in normal hematopoietic precursors and differentiation to 
erythrocytes in an erythropoietin-dependent cell line (Williams et al. 1999). Thus 
Mlf1 can have an influence on commitment to the myeloid lineage. 
 
Meis1 
The Meis1 gene locus was first discovered as a common viral integration site in 
myeloid leukemic cells of BXH-2 mice and Meis1 is critical for the MLL protein-
induced leukemogenesis (Moskow et al. 1995; Wong et al. 2007). Though Meis1 is 
clearly crucial for the MLL dependent leukemogenesis, the role of Meis1 in normal 
hematopoiesis remains unclear. Meis1 is expressed in the most primitive HSCs and is 
down-regulated following differentiation (Pineault et al. 2002). Moreover Meis1-
deficient mice show embryonic lethality by E14.5, presenting with extensive 
hemorrhaging due to the lack of megakaryocytes (Hisa et al. 2004). 
 
Ndn 
Necdin is a nuclear protein which promotes neuronal differentiation and survival 
through the regulation of p53 acetylation by facilitating the interaction between Sirt1 
and p53 (Maruyama et al. 1991; Aizawa et al. 1992; Hasegawa and Yoshikawa 2008). 
In mammals, the Ndn gene locus is maternally imprinted and expressed in the wide 
range of tissues except in peripheral blood leukocytes (Jay et al. 1997; MacDonald 
and Wevrick 1997). Loss of necdin show abnormalities and apoptosis of central and 
peripheral neurons (Muscatelli et al. 2000; Ren et al. 2003).  
 
Hmga2 
The High Mobility Group A (HMGA) family of proteins are abundant non-histone 
chromatin associating factors that bind to DNA and alter the chromatin structure. 
HMGA2 is one of two members of the HMGA proteins which have three AT-hook 
domains that bind the minor groove of AT-rich DNA sequences (Reeves et al. 2001). 
HMGA proteins are involved in many essential biological processes, including 
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regulation of gene expression, cell cycle, and differentiation. HMGA proteins are 
often associated with gene active loci and have positive effects on cell proliferation 
(Reeves et al. 2001). Therefore, HMGA2 is abundant in highly proliferating cells, 
undifferentiated progenitor cells and its expression is gradually decreased during 
terminal differentiation (Zhou et al., 1995). A recent paper described that HMGA 
proteins facilitate senescence-associated heterochromatic foci formation in concert 
with the p16 tumor suppressor and stabilize senescence by repressing proliferation-
associated genes (Narita et al. 2006). 
In B lymphocytes, HMGA1 functions as a co-activator of the Ets family TFs required 
for the IgH μ enhancer (iEμ) activity. HMGA1 interacts with the Ets factor PU.1 and 
enhanced transcriptional synergy with Ets-1 on the iEμ (Andreucci et al. 2002; 
McCarthy et al. 2003). Thus it may be interesting to test the binding of HMGA2 on 
the IgH locus, since HMGA proteins are known to regulate the higher order of 
chromatin structure. 
 
Tcf3 
Tcf3 is the HMG box transcription factor 3, which encodes a protein with a DNA 
binding domain and a ß-catenin interaction domain. Through activation of the Wnt 
signaling pathway, β-catenin protein is stabilized and can associate with the Tcf/Lef1 
family of DNA binding proteins to activate downstream target genes. WNT signaling 
is essential for various biological processes, such as progenitor cell survival, cell-fate 
determination, establishment of the dorsal axis and control of asymmetric cell division 
(Staal et al. 2008). In both T and B cells, WNT signaling is crucial for differentiation 
as well as TCRα gene expression mediated by Lef1 and Tcf1 (Okamura et al. 1998; 
Reya et al. 2000; Timm and Grosschedl 2005). In contrast, complete loss of Tcf3 
results in gastrulation defects and impairment in hair stem cells; therefore Tcf3 is 
proposed to function to maintain an undifferentiated state in the absence of Wnt and, 
through Wnt activation, it directs stem cells to the hair lineage (Kim et al. 2000; 
Nguyen et al. 2006). 
. 
 
3.1.2 Developmental defects in HDAC1/2 KO pre-BI cells 
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Three factors shown to be critical for the development of “Hematological System 
Development” are up-regulated in HDAC1/2 deficient pre-BI cells: Flt3, 15.8 fold; 
Tal1, 3.91 fold; Cebpa, 3.62 fold. Importantly these genes are normally detected at 
very low levels in B-lineage committed pre-BI cells and their primary functions are 
found in early progenitor stages and non-B cell lineages. Moreover, enforced 
expression of these genes leads to the blockade of B cell development. Thus, 
HDAC1/2 inactivated pre-BI cells might not fully commit to the B lineage, as 
HDAC1/2 are required to repress genes involved in the maintenance of the multi-
potency and development into non-B cell lineages. Therefore these mutant pre-BI 
cells may not be fully equivalent to the pre-BI cells present in the WT situation. An 
alternative possibility is that loss of HDAC1/2 initiates CD19 gene expression earlier 
than at the “usual” pre-BI cell stage, i.e. in pro-B cells. In pro-B cells, expression of 
the genes identified in the microarray experiment is higher than in pre-BI cells. This 
interpretation is, in theory, also possible, although unlikely; since we know that the 
deletion of HDAC1/2 flox allele in pro-B cells is not as complete as in pre-BI cells. In 
addition, another important gene in the pre-BI cell stage, Pax5, is expressed as highly 
as in WT cells. Thus, we think that the first possibility which HDAC1/2 KO pre-BI 
cells fail to shut down expression of certain genes is more likely. So far we do not 
know whether these deregulated genes are the cause of the developmental blockade 
observed in HDAC1/2 B cell KO mice or affect recombination and contraction of the 
IgH locus. To address this, we need to knock down their expression to see whether 
this rescues some of the phenotype. 
 
3.2 Histone deacetylase 1 functions in the hematopoietic system 
 
We have shown that HDAC1 is largely redundant for normal hematopoiesis but has 
crucial roles in the T cell dependent immune response and GC cell differentiation by 
regulating genes involved in cell cycle regulation. In the absence of HDAC1 in the 
hematopoietic compartments, the amount of IgG is reduced which is in line with 
impaired formation of GCs. This defect is due to HDAC1 B cell-intrinsic functions, as 
was confirmed by the in vivo conditional inactivation of HDAC1 specifically in the B 
cell lineage. Using transcriptome analysis, we found that genes that must be repressed 
during GC cell differentiation are not properly controlled in the absence of HDAC1, 
These genes are enriched for genes involved in cell cycle control and apoptosis. 
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Several genes are highly upregulated in HDAC1 mutant GC cells such as Irf4 or are 
important for the G1 cell cycle progression such as E2f5 and Cdkn1b, encoding p27 
(Fig. 30). Centroblasts in the GC dark zone undergo extremely fast proliferation; the 
time for one cell cycle ranges from 6 to 12 hours (Klein and Dalla-Favera 2008). 
Therefore the transition from resting/non-cycling mature B cells to highly 
proliferating centroblasts requires a dramatic change in gene expression ensuring the 
ability to complete cell cycle as fast as they should be (Klein et al. 2003). 
 
3.2.1 Gene repression by Bcl6 during GC formation 
Bcl6 is a key transcriptional repressor which control groups of genes that function in 
the cell cycle regulation and lymphocyte differentiation upon induction of the GC 
formation. Mice lacking Bcl6 contain normal proportions of B cell subpopulations, 
however show defects in T cell dependent immune responses, which is due to the 
failure of mature B cells to proliferate and form GCs (Ye et al. 1997). Basal serum 
levels of Ig isotypes as well as the antigen-specific antibody production induced by 
the T cell dependent response are modestly reduced in Bcl6 mutant mice. 
Interestingly the reduction of antigen-specific Ig isotypes ranges from a modest effect 
on IgM to more severe effects on all IgGs, which is similar to defects observed in 
HDAC1 mutant mice. This phenotypic similarity implies the possibility that Bcl6 and 
HDAC1 might work together to repress genes involved in the formation of GCs and 
in T-dependent antibody responses. Several reports demonstrated protein-protein 
interaction between HDAC1 and Bcl6, which contributes to sequence-specific 
transcriptional repression via the Bcl6 DNA binding activity (Dhordain et al. 1998; 
Bereshchenko et al. 2002). In addition, acetylation of Bcl6 inactivates its repressive 
activity by dissociating it from HDACs (Bereshchenko et al. 2002). Taken together, 
the loss of HDAC1 may alleviate the Bcl6 gene repressive activity in a two steps 
mechanism: Bcl6 itself is hyper-aectylated and looses its co-represssor partner, 
HDAC1. Several genes have been identified as repressed targets of Bcl6, which may 
account for severe defects in proliferation and GC formation of Bcl6 mutant mice 
(discussed in the next topic) (Shaffer et al. 2000; Phan et al. 2005).  
 
3.2.2 Upregulated genes in HDAC1 mutant GC cells 
 
Cdkn1b is one of the potential direct targets of Bcl6, whose expression was detected 
to inversely correlate to the presence of Bcl6 (Shaffer et al. 2000). Cdkn1b encodes a 
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cyclin dependent kinase (Cdk) inhibitor protein, p27kip1, which inhibits the catalytic 
activity of Cdk4 and arrests the cell cycle at the G1 phase (Polyak et al. 1994). 
Therefore highly proliferative centroblasts express no detectable level of p27kip1 
(Quintanilla-Martinez et al. 1998). Our microarray analysis identified that Cdkn1b 
expression in WT mice is highly abundant in resting/non-cycling mature B cells and 
reduced in vigorously dividing GC cells. In sharp contrast, in HDAC1 inactivated GC 
cells Cdkn1b expression remains as high as in mature B cells. This upregulation of 
Cdkn1b may inhibit progression through the cell cycle, which results in the failure of 
proliferation and subsequent B cell terminal differentiation. In addition to known Bcl6 
target genes, the E2F transcription factor 5, E2f5 was also identified as a gene that is 
expressed at low level in WT GC cells (33 fold reduction in WT GC cells compared 
to WT mature B cells) but 13 fold higher expression in HDAC1 mutant GC cells 
(only 2.4 fold reduction in KO GC cells compared to KO mature B cells). E2F5 
belongs to the transcriptional repressor group of the E2F family and inactivates genes 
required for the cell cycle progression whereas E2F1, 2 and 3a function as 
transcriptional activators to enhance expression of these genes and promote the G1 
 
Active 
Figure 30. Model of the G1-S transition of 
the cell cycle in the absence of HDAC1 in 
mature B cells and GC cells. Arrows next 
to each protein represent up/down-
regulation of the mRNA taken from the 
microarray experiment. One arrow 
indicates 1.5-3 fold changes in HDAC1 
KO cells. Two arrows in p27, 3 arrows in 
E2F5 indicate 3.8 fold and 13 fold 
changes, respectively. 
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phase of the cell cycle (McClellan and Slack 2007; Sun et al. 2007). Both E2F4 and 
E2F5 are expressed throughout the cell cycle as well as in quiescent (G0) cells (Sardet 
et al. 1995; Moberg et al. 1996). E2F5 associates with tumor suppressor gene 
products; pRb2/p130 or pRb/p107, which facilitate the translocation of E2F5 into the 
nucleus and the binding to various promoter regions. This E2F5-p107/p130 complex 
recruits chromatin remodelers and modifiers such as SWI/SNF and HDAC1/2 to 
repress gene expression in G0 cells (Ferreira et al. 1998; Stiegler et al. 1998; Iavarone 
and Massague 1999). HDAC1 mutant GC cells contain abundant E2F5 which may 
inhibit the transition from the G0/G1 phase of the cell cycle to the S phase by 
repressing genes essential for the G1/S transition (Fig. 30). 
 
3.2.3 Phenotypic difference between in vivo and in vitro activation of mature B 
cells 
 
Surprisingly, HDAC1 inactivated mature B cells show largely normal proliferation 
and higher production of IgG1 and IgG3 antibodies in vitro under different mitogenic 
conditions. In vitro mature B cells divide c.a. 5-7 times within 96 hours in LPS 
containing culture medium (T.Y. unpublished data); thus, one cell cycle takes c.a. 14- 
19 hours. This relatively slow cell cycle progression compared to centroblasts in vivo 
may account for one possible explanation for this difference between in vivo and in 
vitro. Alternatively, loss of HDAC1 may affect gene expression of cell surface and 
signaling molecules involved in B cell activation, so that mutant GC cells fail to 
receive appropriate signals for the clonal expansion after the immunization in vivo. 
We also found that in vitro mature B cells lacking HDAC1 secrete more class 
switched antibodies (IgG1 and IgG3) in the medium. This result suggests that there 
may be an inhibitory effect of HDAC1 on class switch recombination, at least, in vitro. 
There is ample literature describing the positive correlation between histone 
acetylation and class switch recombination (Nambu et al. 2003; Li et al. 2004; 
Odegard et al. 2005). In general, histone acetylation is found in opened/accessible 
conformation of chromatin loci in the genome. It may well be that loss of HDAC1 
leads to increased histone acetylation in the IgH locus, which will result in increased 
accessibility for the recombination machinery such as AID protein. HDAC1 also 
might regulate negatively expression of genes involved in class switch recombination 
and the DNA double strand repair pathway by deacetylating their promoter regions. 
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3.2.4 An increased number of splenocytes accompanied with the induction of 
the dependent immune response 
 
The number of splenocytes in HDAC1 hematopoietic cell KO mice are increased 
about 1.5 fold in immunized mice. This is observed as early as 5 days post injection of 
DNP-KLH. In HDAC1 mutant spleens, B, T and NK cell numbers are all increased 
proportionally about 1.5 fold, whereas the number of Mac1+Gr-1+ (myeloid) cells 
stays the same as in unimmunized mice. In addition, the percentages of BrdU positive 
cells in the B and T cell compartments are largely similar to the WT control. Based on 
these observations, we could have the hypothesis explaining the increase of the 
peripheral B and T cell numbers without changing their intrinsic proliferation/survival 
activity. A number of early progenitor populations such as common lymphoid 
progenitors may be increased in association with the enhanced proliferation/survival 
upon immunization. If this is the case in HDAC1 hematopoietic KO mice, peripheral 
B and T cells will appear to be increased without changing their proliferation since 
early progenitor cells are increased. It is worth to note that loss of Mi-2β, a chromatin 
remodeler in part of the Nucleosome Remodeling Deacetylase (NuRD) complex, in 
hematopoietic lineages results in an increase of hematopoietic stem cell proliferation 
and an accumulation of lympho myeloid primed progenitors (LMPP) and erythrocyte 
progenitors whereas myeloid progenitors are reduced (Yoshida et al. 2008) (Fig. 31). 
HDAC1 is responsible for the catalytic activity of the NuRD complex to remove 
acetyl groups from proteins. Therefore our observation of HDAC1 KO mice in 
hematopoietic lineages might be explained, at least in part, by similar mechanisms as 
reported in Mi-2β mutant mice. Thus HDAC1 is potentially an important factor for 
the fate decision of hematopoietic lineages. Additional studies addressing the roles of 
HDAC1 in the early stages of cell lineage choice will yield more complete picture of 
epigenetic regulation for hematopoietic cell development.  
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Figure 31. The effects of Mi-2β ΚΟ in hematopoietic cells (modified from (Yoshida et al. 2008)). In 
the absence of Mi-2 β, long term-hematopoietic stem cells (LT-HSC) proliferate more and 
accumulate down-stream subpopulations. Accumulated subpopulations are indicated by red arrows. 
Developmental blockades are depicted with red crosses. Subpopulations which were not explained 
are shown as N.D. 
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4. Material and Methods 
 
Generation of HDAC1 and 2 conditional knockout mice and animal experiment 
Each exon 6 of mouse HDAC1 and 2 was flanked by a single loxP site and a cassette 
expressing the neomycin resistance gene and thymidine kinase gene flanked by two 
loxP sites. E14 ES cells (129/Ola strain) were electroporated with either the targeting 
vector for mouse HDAC1 or 2 and correctly targeted ES clones were identified by 
PCR, sequencing and Southern blot analysis. One targeted ES cell clone for HDAC1 
and 2, number 149 and 233 respectively, was used for aggregation to generate 
chimeric mice. Chimeric mice were crossed to C57/Bl6 animals to obtain germ line 
transmission of the targeted allele. To delete the neomycin cassette (flox allele) and 
generate delta allele, targeted mice were crossed with either EIIa-Cre mice or Meox-
Cre mice. The chimeras that contain both Cre and targeted alleles were genotyped 
and we identified mice having recombined delta or flox alleles by PCR and verified 
by sequencing. For the generation of hematopoietic and B cell specific KO mice, we 
used Vav-iCre and mb1-Cre transgenic mice kindly provided by Dr. Dimitris Kioussis 
and Dr. Michael Reth, respectively. 
For all analyses, flox allele littermates of the same sex were used as controls. All 
experiments were done using mixed background (129/Ola and C57/Bl6 mixed strain) 
transgenic mice from 6 to 12 weeks olds. Animal experiments were carried out 
according to regulations effective in the Kanton of Basel-Stadt, Switzerland. The mice 
were housed in groups of one to eight animals at 25°C with a 12:12 h light-dark cycle. 
They were fed a standard laboratory diet containing 0.8% phosphorus and 1.1% 
calcium (NAFAG 890, Kliba, Basel, Switzerland). Food and water was provided ad 
libitum.  
 
Southern hybridization analysis 
DNA was purified from bone marrow cells, splenocytes and thymocytes from 
indicated genotypes and digested by Sac I enzyme. After inactivation of restriction 
enzymes and purification, DNA was electropholated and blotted onto the membrane. 
The probe indicated in Supplementary Figure 1 was prepared by PCR, radio-labeled 
and incubated for over night at 65 °C. Hybridized DNA was visualized after 3 times 
intensive washing. 
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Western blot analysis 
Bone marrow cells, splenocytes and thymocytes were isolated from indicated 
genotype of mice. Sample preparation, SDS-PAGE and blotting were done as 
described previously (Zhang et al., 2008). Mouse monoclonal anti-HDAC1 and anti-
HDAC2 were kindly provided by Dr. Christian Seiser and described in (Zupkovitz et 
al., 2006). 
 
Quantitative RT-PCR and semi quantitative RT-PCR 
RNA was purified from sorted cell population mentioned in each figure with the 
RNeasy Microkit (Qiagen) according to the manufacturer’s protocol. cDNA was 
synthesized by using the Thermoscript Reverse Transcriptase Kit (Invitrogen). Oligo 
dT primers provided in the kit were used for the first strand synthesis.  
Quantitative PCR was performed on an ABI PRISM 7000 Sequence Detection 
System (Applied Biosystems, Foster City, CA) using a MESA GREEN qPCR 
MasterMix Plus for SYBR® Assay (Eurogentec). The amount of HDAC1 and 2 
transcripts was normalized by Gapdh. 
For semi quantitative RT-PCR, cDNA was serially diluted 4 fold for PCR reactions. 
As a control reaction for contamination by genomic DNA, we prepared samples 
without reverse transcriptase (-RT). Primers used for these experiments are provided 
in Supplementary Table 3. Primers for semi quantitative RT-PCR were previously 
reported (DeKoter et al. 2002; Fuxa et al. 2004; Delogu et al. 2006; Liu et al. 2007). 
For the amplification of μ transcripts, combinations of a forward primer used for 
V(D)J recombination analysis (VHJ558 and VH7183) and a reverse primer, Cμ 
transcript, were used.  
 
Flow cytometry (FACS) 
Single cell suspensions were prepared from indicated lymphoid tissues. Cell staining 
was done according to standard procedures. FACS analysis was performed on a 
FACSCalibur (BD Biosciences, San Jose, CA) by gating on live cells. Samples were 
analyzed by using CellQuest (Becton Dickinson) or Flow-Jo (Tree star) software. Cell 
sorting was performed on a MoFlo (DakoCytomation). The purity of sorted cells was 
checked by reanalysis. 
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The following mAbs were from BD Biosciences; RA3-6B2 (anti-B220) conjugated to 
allophycocyanin (APC), ACK45 (anti-c-kit) conjugated to phycoerythrin (PE) or 
biotinylated, S7 (anti-CD43) conjugated to fluorescein isothiocyanate (FITC), 1D3 
(anti-CD19) conjugated to APC-Cy7 and 7D4 (anti-CD25) biotinylated. 1B4B1 (anti-
IgM) conjugated to FITC was from Southern Biotech. 6D5 (anti-CD19) conjugated to 
PE was from Biolegend. Streptavidin conjugated to PE-Cy5.5 was from CALTAG. 
For the Annexin V staining, we followed the manufacturer’s protocol from BD 
Biosciences. 
 
PCR analysis of deleted HDAC1 and 2 alleles and V(D)J recombination 
DNA was extracted from sorted cell populations mentioned in each figure by 
overnight proteinase K digestion, phenol/chloroform extraction and ethanol 
precipitation. DNA was serially diluted at 1:4 ratios and used for each PCR reaction. 
Primers used for the PCR detection of HDAC1 and 2 genotyping and V(D)J 
recombination are shown in Supplementary Table 2 (Fuxa et al. 2004; Liu et al. 2007). 
PCR analysis of V(D)J recombination was described previously (Fuxa et al. 2004). 
Combinations of a forward primer for different parts of the IgH locus (VHJ558, 
VH7183 and DH) and a reverse JH3 primer were used. Amplicons from PCR reactions 
were separated on 1.5% agarose gel and visualized by ethidium bromide. 
 
In vivo BrdU incorporation assay 
Mice were injected intraperitneally with 20 µg of BrdU and sacrificed 30 minutes 
later. Bone marrow single cell suspensions were prepared, stained and sorted with the 
combination of antibodies against the following cell surface molecules; CD19+ CD43+ 
CD25-. BrdU staining using sorted cells was performed according to the 
manufacturer’s protocol of BrdU flow kit (BD bioscience). Analysis was performed 
on a FACSCalibur and analyzed by Flow-Jo software.  
 
Three-dimensional DNA FISH and confocal microscopy 
Cells sorted by flow cytometry were washed in PBS and then were fixed on poly-L-
lysine-coated slides for three-color and three-dimensional DNA-FISH analysis as 
described (Fuxa et al. 2004). Probes were directly labeled by nick translation with 
ChromaTide Alexa Fluor 488-5-dUTP, ChromaTide Alexa Fluor 594-5-dUTP 
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(Molecular Probes) or dUTP-indodicarbocyanine (GE Healthcare). The γ-satellite 
probe was prepared from a plasmid containing eight copies of the γ-satellite repeat 
sequence (Hewitt et al. 2008) and was directly labeled with dUTP-fluorescein 
isothiocyanate (Roche; Enzo Biochem) or dUTP-indodicarbocyanine. Cells were 
analyzed by confocal microscopy on a Leica SP5 AOBS system (Acousto-Optical 
Beam Splitter). Optical sections separated by 0.3 µm were collected, and only cells 
with signals from both alleles (typically 90%) were analyzed. Details of sample sizes 
and statistical analysis are provided in Supplementary Table 1. 
 
Intracellular FACS for histone modifications 
Cells were stained with fluorochrome coupled antibodies; B220-APC, CD19-PE and 
c-kit-biotinylated. Streptavidin-PE-Cy5.5 was used for the staining of c-kit-
biotinylated antibody. After staining, cells were fixed with 3% paraformaldehyde for 
15 minutes at room temperature, permeabilized with 0.1% saponin, 3% bovine serum 
albumin (BSA) in PBS for 30 minutes at room temperature, and then subjected to the 
intracellular staining with different histone modification antibodies as follows; anti-
Histone H3 (ab1791; Abcam), anti-acetyl-Histone H3K9 and K14 (06-599; Millipore), 
anti-acetyl-Histone H4 (06-866; Millipore), anti-Histone H3 di-methyl lysine 4 (07-
030; Millipore), anti-Histone H3 tri-methyl lysine 4 (ab8580; Abcam), anti-Histone 
H3 di- and tri-methyl lysine 9 antibodies were kindly provided by Dr. Antoine Peters 
(Peters et al. 2003). After washing of cells to remove nonspecific antibody binding, 
cells were stained with the secondary antibody recognizing rabbit IgG coupled to 
alexa Fluor® 488 (A11034; Invitrogen). FACS analysis was performed after 
extensive washing. The buffer containing 0.1% saponin in PBS was used for all 
staining, washing and FACS analysis after permeabilization. 
  
 
 
Immunization 
Mice were injected intraperitoneally with 100 μg of DNP-KLH. Sera were collected 
from tail bleeding at indicated dates in each figure. The second immunization was 
done by same way but using 50 μg of DNP-KLH at 21 days post first-injection. 
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ELISA 
DNP-BSA (5 mg/ml in PBS) was coated into 96 well microplates over night at 4 °C. 
The coated plate was washed three times with PBS-/0.05% Tween-20 and blocked 
with 10 mg/ml BSA in PBS-/0.05% Tween-20 for 1 hour at 37 °C. After 3 times 
washing with PBS-/0.05% Tween-20, serial diluted sera were added in the plate and 
incubated for 2 hours at 37 °C. The plate was washed three times with PBS-/0.05% 
Tween-20 and secondary antibodies coupled with alkaline phosphatases were added. 
After 1 hour incubation at 37 °C, washing 3 times with PBS-/0.05% Tween-20 and 
then substrates were added into the plate. The absorbance at 405 nm was read and 
relative titers were calculated.  
 
RNA preparation and hybridization to Affymetrix Microarrays 
Cells were FACS sorted according to the stage specific cell surface markers and RNA 
was purified with RNeasy Micro Kit from Qiagen. Total RNA (~50 ng) from each 
sample was reverse transcribed and labeled using the Affymetrix 2-cycles labeling kit 
according to manufacture’s protocol. Mouse 430v2 GeneChips (Affymetrix, Santa 
Clara, CA) were used for the hybridization. Data were analyzed using Expressionist 
(Genedata AG). The normalized data were subjected to a Student t-test (P < 0.05) and 
were required to have a median fold change of more than 2. 
 
Statistical analysis 
Significance was assessed by analysis of normal distribution, variances and two-tail T 
test. 
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8. Appendix 
8.1 HDAC2 inactivation in hematopoietic lineages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 HDAC2 inactivation in hematopoietic cell lineages by iCre 
recombinase (Vav-iCre transgene). (A) Southern hybridization analysis of HDAC2 
genomic alleles. Wild type and modified alleles of HDAC2 are shown. The structure 
of HDAC2 gene is depicted at the top. Modified alleles are represented as follows: T, 
targeted allele; F, flox allele; Δ, deleted (KO) allele. Black and gray boxes represent 
the coding exons, white rectangular boxes show the neomycin gene cassette, white 
triangles symbolize the loxP sequence and S represents SacI restriction sites.  DNA 
from indicated genotypes of mice were digested by SacI, blotted on a membrane and 
detected by the specific probe indicated. (B) Western blot analysis of HDAC2 KO 
mice. Protein lysates from cells in bone marrow, spleen and thymus were detected by 
anti-HDAC1, HDAC2 and Actin antibodies, as indicated.   
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(C) Flow cytometric analysis of HDAC2F/F::Vav-iCre mice. Single cell suspensions 
from bone marrow, spleen or thymus were stained with the indicated antibody 
combinations and representative data are shown. Numbers in plots represent the 
percentage of cells in the respective gate or quadrant. 
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8.2 Combined inactivation of HDAC1 and 2 in hematopoietic lineages 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Combined inactivation of HDAC1/2 in hematopoietic cell lineages 
leads to the embryonic lethality due to anemia. (A) Pictures of embryos from control 
(without the iCre gene) and HDAC2F/F::Vav-iCre at indicated embryonic days. The 
Vav-iCre gene starts to be active around E13.5 in the fetal liver. Therefore 
HDAC2F/F::Vav-iCre embryos appear to be pale around E15.5. (B) A total number of 
fetal liver cells at E15.5. (N = 3 per each genotype) (C) FACS staining of fetal liver 
erythrocytes. TER119 and CD71 antibodies are used to distinguish different 
developmental stages of erythrocytes. Red windows indicated in the FACS profiling 
represent the different developmental stages (earlier progenitors; I – mature cells; IV). 
The bottom graph shows the absolute number of each stage of erythrocytes (N = 3). 
HDAC1/2 DKO embryos show the accumulation of stage I cells whereas much less 
cells in the stages II and III. 
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8.3 Phenotype of the intermediate genotype of HDAC1/2 B cell KO mice 
         A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 Phenotypic deferences in the intermediate genotype of HDAC1/2 B 
cell KO mice (A) FACS analysis of the intermediate genotype mice. Single cell 
suspensions from bone marrow and spleen were stained with the indicated antibody 
combinations and representative data are shown. Numbers in plots represent the 
percentage of cells in the respective gate or quadrant. 
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Figure 8.3. (B) Cell numbers of B cell subpopulations in each genotype. The 
numbers are calculated based on cell surface marker combinations and lymphocyte 
gated cells (50,000, N = 2). (C) VDJ recombination assay using different genotype of 
pre-BI cells. DNA was isolated from pre-BI cells (B220+CD19+CD43+CD25-). VDJ 
recombination assay by PCR was done as described in material and methods. The 
order of V segments PCR (top to bottom) follows the sequential order in the IgH 
locus (VH7183 is the most proximal and VHJ558 is the most distal from DJ segments). 
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8.4 The summary of the microarray analysis of HDAC1/2 deficient pre-BI cells 
A. Significantly relevant molecular and cellular functions associated with disregulated 
genes (total 800 genes P<0.05 and more than 2 fold change). Top 6 categories are 
listed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B. The list of genes found in the category of “Cell Death” (150 genes) 
 
Molecule Name Entrez Gene ID Fold 
Change 
 
Edg3 13610 27.93 endothelial differentiation, sphingolipid G-protein-coupled receptor, 3 
Ndn 17984 25.44 necdin 
Gstm5 14867 20.52 glutathione S-transferase, mu 5 
Hmga2 15364 18.73 high mobility group AT-hook 2 
Flt3 14255 15.80 FMS-like tyrosine kinase 3 
Agrn 11603 14.96 agrin 
Ptk2 14083 12.37 PTK2 protein tyrosine kinase 2 
Tmepai 65112 10.17 transmembrane, prostate androgen induced RNA 
Tmem158 72309 9.82 transmembrane protein 158 
Tcf3 21415 9.50 transcription factor 3 
Itsn1 16443 7.63 intersectin 1 (SH3 domain protein 1A) 
Fgfr1 14182 7.62 fibroblast growth factor receptor 1 
Ptger3 19218 7.48 prostaglandin E receptor 3 (subtype EP3) 
Ctsl 13039 6.76 cathepsin L 
Jundm2 81703 6.13 Jun dimerization protein 2 
Ppap2a 19012 5.98 phosphatidic acid phosphatase 2a 
Maged1 94275 5.73 melanoma antigen, family D, 1 
Cadm1 54725 5.39 cell adhesion molecule 1 
Kif1b 16561 5.37 kinesin family member 1B 
Lta 16992 5.26 lymphotoxin A 
Runx2 12393 5.26 runt related transcription factor 2 
P2rx7 18439 5.25 purinergic receptor P2X, ligand-gated ion channel, 7 
App 11820 5.22 amyloid beta (A4) precursor protein 
Trip10 106628 5.14 thyroid hormone receptor interactor 10 
Itgb5 16419 4.99 integrin beta 5 
Tgfbi 21810 4.90 transforming growth factor, beta induced 
Timp2 21858 4.76 tissue inhibitor of metalloproteinase 2 
Rras 20130 4.68 Harvey rat sarcoma oncogene, subgroup R 
Ppp1r9a 243725 4.60 protein phosphatase 1, regulatory (inhibitor) subunit 9A 
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Fcgr3 14131 4.41 Fc receptor, IgG, low affinity III 
Laptm4b 114128 4.35 lysosomal-associated protein transmembrane 4B 
3222402P14Rik 235542 4.22 RIKEN cDNA 3222402P14 gene 
Bag3 29810 4.05 Bcl2-associated athanogene 3 
S100a4 20198 4.02 S100 calcium binding protein A4 
Tnfrsf22 79202 3.95 tumor necrosis factor receptor superfamily, member 22 
Tal1 21349 3.91 T-cell acute lymphocytic leukemia 1 
Csf2rb2 984|12983 3.84 colony stimulating factor 2 receptor, beta 2, low-affinity  
(granulocyte-macrophage) 
LOC100045055 : Rbp1 19659 3.71 retinol binding protein 1, cellular : similar to cellular retinol binding protein I 
Nek6 59126 3.66 NIMA (never in mitosis gene a)-related expressed kinase 6 
Cebpa 12606 3.62 CCAAT/enhancer binding protein (C/EBP), alpha 
Ldlr 16835 3.59 low density lipoprotein receptor 
Nrtn 18188 3.55 neurturin 
Pla2g4a 18783 3.54 phospholipase A2, group IVA (cytosolic, calcium-dependent) 
Klrd1 16643 3.54 killer cell lectin-like receptor, subfamily D, member 1 
Dmc1 13404 3.50 DMC1 dosage suppressor of mck1 homolog, meiosis-specific  
homologous recombination (yeast)disrupted meiotic cDNA 1 
Ccnd1 12443 3.36 cyclin D1 
Ppm2c 381511 3.32 protein phosphatase 2C, magnesium dependent, catalytic subunit 
Apbb2 11787 3.29 amyloid beta (A4) precursor protein-binding, family B, member 2 
Gsr 14782 3.28 glutathione reductase 1 
Fbln1 14114 3.26 fibulin 1 
Endog 13804 3.25 endonuclease G 
Ern1 78943 3.14 Endoplasmic reticulum (ER) to nucleus signalling 1 
Pak1 18479 3.13 p21 (CDKN1A)-activated kinase 1 
LOC100047069 : Rxra 20181 3.13 retinoid X receptor alpha : similar to retinoid X receptor-alpha 
Pvrl2 19294 3.13 poliovirus receptor-related 2 
Pea15a 18611 3.12 phosphoprotein enriched in astrocytes 15A 
1200009F10Rik 67454 3.01 RIKEN cDNA 1200009F10 gene 
Abcc1 17250 2.89 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 
Lair1 52855 2.76 leukocyte-associated Ig-like receptor 1 
Ms4a6c 23856 2.75 membrane-spanning 4-domains, subfamily A, member 6C 
Trf 22041 2.73 transferrin 
Igfbp4 16010 2.69 insulin-like growth factor binding protein 4 
Plekhf1 72287 2.67 pleckstrin homology domain containing, family F 
 (with FYVE domain) member 1 
Acvr1 11477 2.66 activin A receptor, type 1 
Smox 228608 2.65 spermine oxidase 
Vcl 22330 2.59 vinculin 
Kit 16590 2.37 kit oncogene 
Ptprf 19268 2.37 protein tyrosine phosphatase, receptor type, F 
Gabbr1 54393 2.36 gamma-aminobutyric acid (GABA-B) receptor, 1 
Sod2 20656 2.32 superoxide dismutase 2, mitochondrial 
Ece1 230857 2.30 endothelin converting enzyme 1 
Lgals3 16854 2.29 lectin, galactose binding, soluble 3 
Cdkn1c 12577 2.28 cyclin-dependent kinase inhibitor 1C (P57) 
Meis1 17268 2.24 myeloid ecotropic viral integration site 1 
Fosl2 : LOC634417 14284 2.19 fos-like antigen 2 : similar to fos-like antigen 2 
Ms4a2 14126 2.16 membrane-spanning 4-domains, subfamily A, member 2 
Gas6 14456 2.14 growth arrest specific 6 
Prkra 23992 2.08 protein kinase, interferon inducible double stranded  
RNA dependent activator 
Adk 11534 1.99 adenosine kinase 
Ripk3 56532 1.95 receptor-interacting serine-threonine kinase 3 
Smpd2 20598 1.94 sphingomyelin phosphodiesterase 2, neutral 
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Mfn1 67414 1.89 mitofusin 1 
Ccbl1 70266 1.76 cysteine conjugate-beta lyase 1 
Sdc4 20971 -1.87 syndecan 4 
 Cd40 21939 -1.94 CD40 antigen 
Birc2 11797 -2.06 baculoviral IAP repeat-containing 2 
Akt2 11652 -2.07 thymoma viral proto-oncogene 2 
Cd79b 15985 -2.11 CD79B antigen 
Pqbp1 54633 -2.11 polyglutamine binding protein 1 
Gmeb1 56809 -2.13 glucocorticoid modulatory element binding protein 1 
Smug1 71726 -2.15 single-strand selective monofunctional uracil DNA glycosylase 
Herpud1 64209 -2.17 homocysteine-inducible, endoplasmic reticulum stress-inducible,  
ubiquitin-like domain member 1 
Trp53inp1 60599 -2.21 transformation related protein 53 inducible nuclear protein 1 
Nme3 79059 -2.22 expressed in non-metastatic cells 3 
Irf5 27056 -2.27 interferon regulatory factor 5 
Traf2 22030 -2.28 Tnf receptor-associated factor 2 
Gab2 14389 -2.29 Growth factor receptor bound protein 2-associated protein 2 
Eme1 268465 -2.30 essential meiotic endonuclease 1 homolog 1 (S. pombe) 
Birc3 11796 -2.31 baculoviral IAP repeat-containing 3 
Pik3cg 30955 -2.33 phosphoinositide-3-kinase, catalytic, gamma polypeptide 
Ercc1 13870 -2.34 excision repair cross-complementing rodent repair deficiency,  
complementation group 1 
Dgka 13139 -2.39 diacylglycerol kinase, alpha 
Cd1d1 480|12479 -2.43 CD1d1 antigen 
Akap13 75547 -2.43 A kinase (PRKA) anchor protein 13 
Traf3ip3 103213 -2.56 TRAF3 interacting protein 3 
Icam2 15896 -2.57 intercellular adhesion molecule 2 
Zfp36 22695 -2.63 zinc finger protein 36 
Tnfaip3 21929 -2.64 tumor necrosis factor, alpha-induced protein 3 
Gfi1 14581 -2.70 growth factor independent 1 
Ndufs1 227197 -2.71 NADH dehydrogenase (ubiquinone) Fe-S protein 1 
Dnajb6 23950 -2.74 DnaJ (Hsp40) homolog, subfamily B, member 6 
Wapal 218914 -2.77 wings apart-like homolog (Drosophila) 
Phlda1 21664 -2.81 pleckstrin homology-like domain, family A, member 1 
Itpr2 16439 -2.86 inositol 1,4,5-triphosphate receptor 2 
Tnfsf10 22035 -2.89 tumor necrosis factor (ligand) superfamily, member 10 
Cerk : LOC676420 223753 -2.89 ceramide kinase : similar to Ceramide kinase (Acylsphingosine kinase) 
 (mCERK) 
Dnase1 13419 -2.90 deoxyribonuclease I 
Lck 16818 -2.94 lymphocyte protein tyrosine kinase 
Snn 20621 -2.96 stannin 
Hdac5 15184 -2.96 histone deacetylase 5 
2010001M09Rik 69816 -3.03 RIKEN cDNA 2010001M09 gene 
Ets1 23871 -3.06 E26 avian leukemia oncogene 1, 5' domain 
Sh2d2a 27371 -3.09 SH2 domain protein 2A 
Lef1 16842 -3.12 lymphoid enhancer binding factor 1 
Apbb1 11785 -3.13 amyloid beta (A4) precursor protein-binding, family B, member 1 
Ppp1r16b 228852 -3.13 protein phosphatase 1, regulatory (inhibitor) subunit 16B 
Egr3 13655 -3.14 early growth response 3 
Ptk2b 19229 -3.18 PTK2 protein tyrosine kinase 2 beta 
Tnfrsf13b 57916 -3.30 tumor necrosis factor receptor superfamily, member 13b 
Ptprcap 19265 -3.35 protein tyrosine phosphatase, receptor type,  
C polypeptide-associated protein 
 Cd5 12507 -3.44 CD5 antigen 
Rrm2b 382985 -3.90 ribonucleotide reductase M2 B (TP53 inducible) 
Dpp4 13482 -4.01 dipeptidylpeptidase 4 
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Igh : Igh-6 : Igh-V7183 : 
Igh-VS107 : Ighg : Ighv14-
2 : 
16017 -4.12 immunoglobulin heavy chain 6 (heavy chain of IgM) :  
immunoglobulin heavy chain (V7183 family) :  
immunoglobulin heavy chain (S107 family) :  
immunoglobulin heavy chain complex :  
Immunoglobulin heavy chain (gamma polypeptide) :  
expressed sequence AI324046 :  
similar to Ig heavy chain V region M315 precursor :  
immunoglobulin heavy variable V14-2 :  
similar to Ig alpha-chain precursor (V139-D-J1) 
Ube1l 74153 -4.13 ubiquitin-activating enzyme E1-like 
Pecam1 18613 -4.18 platelet/endothelial cell adhesion molecule 1 
Irs1 16367 -4.28 insulin receptor substrate 1 
Cdc25b 12531 -4.61 cell division cycle 25 homolog B (S. pombe) 
Msh5 17687 -5.03 mutS homolog 5 (E. coli) 
Cd22 12483 -5.15 CD22 antigen 
Heyl 56198 -5.24 hairy/enhancer-of-split related with YRPW motif-like 
Lig4 319583 -6.22 ligase IV, DNA, ATP-dependent 
Blk 12143 -6.34 B lymphoid kinase 
Mbd4 17193 -6.44 methyl-CpG binding domain protein 4 
Slamf7 75345 -7.06 SLAM family member 7 
Cyfip2 76884 -10.38 cytoplasmic FMR1 interacting protein 2 
Hdac2 15182 -11.16 histone deacetylase 2 
Ikzf3 22780 -11.76 IKAROS family zinc finger 3 
Rasgrp1 19419 -13.21 RAS guanyl releasing protein 1 
Ms4a1 12482 -96.58 membrane-spanning 4-domains, subfamily A, member 1 
 
C. The list of genes found in the category of “Immune and Lymphatic System 
Development and Function” (35 genes) 
 
Molecule Name Entrez Gene 
ID 
Fold 
Change 
 
Flt3 14255 15.80 FMS-like tyrosine kinase 3 
Runx2 12393 5.26 runt related transcription factor 2 
App 11820 5.22 amyloid beta (A4) precursor protein 
Fcgr3 14131 4.41 Fc receptor, IgG, low affinity III 
Tal1 21349 3.91 T-cell acute lymphocytic leukemia 1 
Csf2rb2 12984|12983 3.84 colony stimulating factor 2 receptor, beta 2, low-affinity (granulocyte-macrophage) 
Cebpa 12606 3.62 CCAAT/enhancer binding protein (C/EBP), alpha 
Ccnd1 12443 3.36 cyclin D1 
Mlf1 17349 3.32 myeloid leukemia factor 1 
Lair1 52855 2.76 leukocyte-associated Ig-like receptor 1 
Kit 16590 2.37 kit oncogene 
Meis1 17268 2.24 myeloid ecotropic viral integration site 1 
Cd79b 15985 -2.11 CD79B antigen 
Traf2 22030 -2.28 Tnf receptor-associated factor 2 
Pik3cg 30955 -2.33 phosphoinositide-3-kinase, catalytic, gamma polypeptide 
Cd1d1 12480|12479 -2.43 CD1d1 antigen 
Zfp36 22695 -2.63 zinc finger protein 36 
Gfi1 14581 -2.70 growth factor independent 1 
Tec 21682 -2.70 cytoplasmic tyrosine kinase, Dscr28C related (Drosophila) 
Hivep2 15273 -2.88 human immunodeficiency virus type I enhancer binding protein 2 
Tnfsf10 22035 -2.89 tumor necrosis factor (ligand) superfamily, member 10 
Lck 16818 -2.94 lymphocyte protein tyrosine kinase 
Hdac5 15184 -2.96 histone deacetylase 5 
Ets1 23871 -3.06 E26 avian leukemia oncogene 1, 5' domain 
Lef1 16842 -3.12 lymphoid enhancer binding factor 1 
Egr3 13655 -3.14 early growth response 3 
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Tnfrsf13b 57916 -3.30 tumor necrosis factor receptor superfamily, member 13b 
Igh : Igh-6 : Igh-
V7183 : Igh-VS107 : 
Ighg : Ighv14-2 :  
16017 -4.12 immunoglobulin heavy chain 6 (heavy chain of IgM) :  
immunoglobulin heavy chain (V7183 family) :  
immunoglobulin heavy chain (S107 family) :  
immunoglobulin heavy chain complex :  
Immunoglobulin heavy chain (gamma polypeptide) :  
expressed sequence AI324046 :  
similar to Ig heavy chain V region M315 precursor :  
immunoglobulin heavy variable V14-2 :  
similar to Ig alpha-chain precursor (V139-D-J1) 
Irs1 16367 -4.28 insulin receptor substrate 1 
Cd22 12483 -5.15 CD22 antigen 
Lig4 319583 -6.22 ligase IV, DNA, ATP-dependent 
Blk 12143 -6.34 B lymphoid kinase 
Il33 77125 -12.94 interleukin 33 
Rasgrp1 19419 -13.21 RAS guanyl releasing protein 1 
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The list of genes found in HDAC1 KO GC cells (Cluster b). 
 
A. The lists of TFs and transcriptional regulator found in the cluster b. 
 
Molecule Name Entrez 
GeneID 
WTmB WTGC KOmB KOGC KOGC 
/WTGC 
E2f5 13559 29985.9 916.7 27856.3 11709.7 12.77 E2F transcription factor 5 
MGI:1916782 74318 966.4 231.8 1386.7 823.0 3.55 homeobox only domain 
Hhex 15242 2578.7 908.7 2775.1 3065.9 3.37 hematopoietically expressed homeobox 
Aff1 17355 2070.3 844.7 1897.4 2527.7 2.99 AF4/FMR2 family, member 1 
Mef2c 17260 932.4 39.2 1127.1 116.5 2.97 Myocyte enhancer factor 2C, mRNA 
Tsc22d1 21807 373.6 128.6 290.2 369.0 2.87 TSC22 domain family, member 1 
Mib2 76580 343.7 156.0 383.5 441.9 2.83 mindbomb homolog 2 (Drosophila) 
MGI:2385920 64451 150.9 93.2 217.6 242.2 2.60 disco interacting protein 2 homolog (Drosophila) 
Notch1 18128 710.6 291.3 783.5 753.9 2.59 Notch gene homolog 1 (Drosophila) 
Jarid1b 75605 700.8 298.9 751.7 726.7 2.43 jumonji, AT rich interactive domain 1B (Rbp2 like) 
Zfp238 30928 2120.2 983.3 2274.1 2350.6 2.39 zinc finger protein 238 
Pcgf4 12151 886.2 292.8 1076.4 691.8 2.36 polycomb group ring finger 4 
Smarca2 67155 627.6 160.2 571.6 365.7 2.28 SWI/SNF related, matrix associated, actin dependent  
regulator of chromatin, subfamily a, member 2 
Tcf12 21406 113.8 34.6 93.0 76.8 2.22 transcription factor 12 
Sub1 20024 118.7 51.2 108.2 113.7 2.22 SUB1 homolog (S. cerevisia 
D130016B08Rik 319524 65.8 20.7 47.9 45.9 2.22 RIKEN cDNA D130016B08 gene 
Trim24 21848 1341.2 495.0 1262.9 1068.7 2.16 tripartite motif protein 24 
Irf4 16364 2027.3 1011.8 1770.1 2171.7 2.15 interferon regulatory factor 4 
Foxo3 56484 229.0 32.3 198.1 68.4 2.12 Forkhead box O3a (Foxo3a), mRNA 
 
 
B. The lists of genes associated with the cell cycle regulation in the cluster b. 
Molecule Name Entrez 
GeneID 
WTmB WTGC KOmB KOGC KOGC 
/WTGC 
Cdkn1b 12576 810.0 213.6 639.5 819.4 3.84 cyclin-dependent kinase inhibitor 1B (P27) 
Erbb3 13867 39.4 25.6 81.9 97.1 3.79 v-erb-b2 erythroblastic leukemia viral oncogene  
homolog 3 (avian) 
Errfi1 74155 130.0 49.1 171.7 181.5 3.70 ERBB receptor feedback inhibitor 1 
Dpp4 13482 1575.6 458.7 1681.5 1480.7 3.23 dipeptidylpeptidase 4 
Ski 20481 261.6 58.6 232.5 188.8 3.22 Sloan-Kettering viral oncogene homolog 
Vav3 57257 386.4 102.8 358.6 285.6 2.78 vav 3 oncogene 
Zbtb10 229055 188.9 43.4 147.2 108.7 2.51 zinc finger and BTB domain containing 10 
Ches1 71375 2275.5 945.8 2464.9 2341.9 2.48 checkpoint supressor 1 
Rps6ka2 20112 31.8 16.7 38.4 41.1 2.46 ribosomal protein S6 kinase, polypeptide 2 
Socs5 56468 1036.7 512.5 1012.0 1240.3 2.42 suppressor of cytokine signaling 5 
Ikbkb 16150 1234.8 197.6 1343.7 454.6 2.30 inhibitor of kappaB kinase beta 
Pvr 52118 24.3 11.5 40.6 26.4 2.30 poliovirus receptor 
Mphosph9 269702 250.6 85.8 286.6 194.5 2.27 M-phase phosphoprotein 9 
Ppp3ca 19055 1292.6 519.1 1474.1 1167.9 2.25 protein phosphatase 3, catalytic subunit,  
alpha isoform 
Myh9 17886 2332.0 1015.2 2191.2 2269.1 2.24 myosin, heavy polypeptide 9, non-muscle 
Ceacam1 26365 601.4 286.2 365.2 618.1 2.16 CEA-related cell adhesion molecule 1 
D4Ertd767e, 
Nasp 
50927, 
52413 
131.8 30.3 140.9 63.2 2.08 nuclear autoantigenic sperm protein (histone-binding),  
DNA segment, Chr 4, ERATO Doi 767, expressed 
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C. The lists of genes associated with apoptosis in the cluster b. 
 
Molecule 
Name 
Entrez 
GeneID 
WTmB WTGC KOmB KOGC KOGC 
/WTGC 
Afp 11576 245.3 52.7 335.2 304.4 5.77 alpha fetoprotein 
Il6st 16195 205.7 43.2 276.9 199.9 4.62 interleukin 6 signal transducer 
Trps1 83925 371.8 71.2 508.3 321.6 4.52 trichorhinophalangeal syndrome I (human) 
Unc5cl 76589 259.0 96.2 531.1 415.2 4.31 unc-5 homolog C (C. elegans)-like 
Rtn4 68585 529.3 48.4 545.2 191.5 3.96 RTN4 (Rtn4) mRNA, complete cds, alternatively spliced 
Serpine2 20720 133.9 53.8 186.1 192.6 3.58 serine (or cysteine) peptidase inhibitor, clade E, member 2 
Pdk1 228026 174.9 44.2 165.6 136.4 3.09 pyruvate dehydrogenase kinase, isoenzyme 1 
Gabbr1 54393 221.7 69.1 289.1 211.7 3.06 gamma-aminobutyric acid (GABA-B) receptor, 1 
Fbxo32 67731 552.9 245.0 597.0 744.6 3.04 F-box only protein 32 
Prkra 23992 103.4 29.8 108.6 84.8 2.85 protein kinase, interferon inducible double stranded RNA  
dependent activator 
Zmynd11 66505 1867.2 634.6 1927.0 1792.3 2.82 zinc finger, MYND domain containing 11 
Bnip3 12176 463.2 151.6 509.0 414.6 2.73 BCL2/adenovirus E1B 19kDa-interacting protein 1, NIP3 
Ndst1 15531 1544.7 486.9 1640.6 1300.1 2.67 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 
Hck 15162 439.5 143.4 376.0 348.3 2.43 Hemopoietic cell kinase (Hck), mRNA 
Itga4 16401 1851.5 547.3 1678.9 1263.6 2.31 integrin alpha 4 
Abcg1 11307 1427.7 642.5 1436.3 1427.2 2.22 ATP-binding cassette, sub-family G (WHITE), member 1 
Gng2 14702 134.5 74.7 165.5 165.9 2.22 guanine nucleotide binding protein (G protein),  
gamma 2 subunit 
Sh3kbp1 58194 163.9 29.9 148.5 62.1 2.08 SH3-domain kinase binding protein 1 (Sh3kbp1), mRNA 
  705.2 243.1 663.4 500.2 2.06 gb:BG695418 /DB_XREF=gi:13955314 
/DB_XREF=NISC_iv17b11.w2  
Hsh2d 209488 751.1 368.3 836.2 749.0 2.03 Hematopoietic SH2 domain containing, mRNA  
(cDNA clone MGC:106069 IMAGE:5316178) 
Rps6ka5 73086 243.6 81.5 247.1 163.5 2.01 ribosomal protein S6 kinase, polypeptide 5 
Dag1 13138 631.0 408.7 712.9 819.3 2.00 dystroglycan 1 
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8.5 Abbreviations 
 
 
3D-FISH three-dimensional DNA fluorescence 
in situ hybridization 
iPS cell induced pluripotent stem cell 
AID activation induced cytidine deaminase KO knock out 
BCR B cell receptor LMPP lymphoid-primed multipotent progenitor 
BrdU 5-bromo-2-deoxyuridine LPS  lipopolysaccharides 
Cdk cyclin-dependent protein kinase LSK Lin− Sca-1+ c-kithi population 
CLP common lymphoid progenitor LT-HSC long-term HSC  
CMP common myeloid progenitor MEF mouse embryonic fibroblast   
CoREST corepressor for REST (RE1 silencing 
transcription factor 1) 
MEF2 myocyte enhancer factor-2 
CSR class switch recombination MEP megakaryocyte-erythrocyte progenitor 
DNP-KLH dinitrophenylated keyhole limpet 
haemocyanin 
MPP multipotential progenitor 
DSB DNA double-strand break NHEJ non-homologous end joining pathway 
ELISA enzyme-linked immunosorbent assay NuRD nucleosomal remodeling and deacetylation 
ELP early lymphoid progenitor PIC preinitiation complex 
ES cell embryonic stem cell PRC Polycomb repressive complex 
ETP early T lineage progenitor Rb Retinoblastoma 
FACS fluorescence-activated cell sorting / 
flow cytometry 
RNAP RNA polymerase 
GC germinal center Rpd3 reduced potassium dependency 3 
GMP granulocyte-macrophage progenitor RSS recombination signal sequence 
GTF general transcription factor  SAHA suberoylanilide hydroxamic acid 
HAT histone acetyltransferase SHM somatic hyper-mutation 
HDAC histone deacetylase  Sir2 silent information regulator 2 
HDACi HDAC inibitor SIRT sirtuin 
HP1 heterochromatin protein 1 ST-HSC short-term HSC 
HSC Hematopoietic stem cell TAF TBP-associated factor 
IgH immunoglobulin heavy chain TBP TATA-binding protein 
IgL immunoglobulin light chain TF  transcription factor 
IL interleukin TSA trichostatin A 
 
 
 
 
 
 
